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QUILL ON SCALPEL
PLUME ET SCALPEL

Current Management of
Choledocholithiasis
Roger G. Keith, MD, FACS, FRCSC, FRCS
Chairman, Department o f Surgery, Royal University Hospital, Saskatoon, Sask. Coeditor,
Canadian Journal of Surgery

A

bdominal surgeons have been
the recognized experts in man
agement of disease of the biliary
tract, but technologic advances
have now opened a welcome door
for radiologists and gastroenterolo
gists to participate in the manage
ment of stone disease. Currently,
interventional endoscopists see far
more bile duct disease than a sur
geon would have seen during a
comparable period of the “operative
era.” In Europe and especially in
the United States, the interventional
endoscopist is rarely a surgeon.
Such is not the case in Canada. A
substantial number of general sur
geons in Canadian medical centres
have expertise in endoscopic biliary
intervention. The working relation
ship between surgeons, gastroen
terologists and interventional radi
ologists has developed favourably in
most teaching centres in this coun
try.
During the decades before the
advent of laparoscopic cholecystec
tomy, exploration of the common
bile duct was frequently performed
in association with cholecystecto
my. This was standard treatment
for common bile duct stones. With
the introduction of endoscopic ret
rograde cholangiopancreatography
(ERCP) in the early 1970s and the
subsequent development of inter
ventional techniques, preoperative
endoscopic stone removal became

popular. Experienced surgical and
medical endoscopists were able to
remove the majority of common
duct stones with ever-decreasing
morbidity and mortality. Neverthe
less, during the early 1980s, the
majority of general surgeons still
favoured open exploration of the
common bile duct, and this became
the accepted choice for patients
with the gallbladder in situ and with
documented common bile duct cal
culi. In the mid-1980s, authorita
tive “ERCPists”1'2 recommended
clearance of the common bile duct
by endoscopic sphincterotomy (ES)
before cholecystectomy and limiting
the open operation to cholecystec
tomy with operative cholangiogra
phy to confirm a stone-free biliary
tract. In the hands of such experts,
this protocol reduced overall mor
bidity and mortality compared with
those reported in surgical series.3-5
Endoscopists noted that the com
mon bile duct remained cleared of
stones after ES, and occasionally
stones cleared from the gallbladder
as well. Inconsistency of gallbladder
clearance, disturbance of function
and stasis all preclude ES as total
treatment for cholelithiasis and
choledocholithiasis.6
Interventional endoscopy for the
management of retained common
bile duct stones after cholecystecto
my had the same effect on reopera
tive biliary surgery as H2 receptor

blockers have had on peptic ulcer
surgery. Residents training in gen
eral surgery have limited exposure
to reoperative biliary procedures.
Trainees will require increasing ex
perience with endoscopic interven
tional procedures.
In this issue (pages 75 to 80),
Girard and Morin from the Univer
sity de Montreal report a Canadian
experience with open cholecystecto
my, which will serve as a cited
publication by virtue of case num
bers and the excellence of outcome
immediately predating the shift to
laparoscopic cholecystectomy. Pur
suant to management strategy for
choledocholithiasis, Girard and
Morin documented a death rate for
open duct exploration of 1.6%. This
is superior to the rate reported in
most other large surgical series and
is comparable to the 1% death rate
recognized for ERCP with ES. Simi
larly, the death rate of 0.3% for
open cholecystectomy alone in Gi
rard and Morin’s series will likely be
comparable to that from laparo
scopic cholecystectomy after accru
al of data from single centres to
more than 9000 cases. In Girard
and Morin’s series, only 24 bile
duct injuries were reported in the
cholecystectomy group, of which 7
were considered major — an inci
dence of 0.07%. This represents a
high-water mark for safe open cho
lecystectomy.
CJS, VOL. 36, NO. 1, FEBRUARY 1993
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Except for the incidence of bile
duct injury, laparoscopic cholecys
tectomy dramatically reduces peri
operative morbidity, shortens hospi
tal stay and hastens return to work.
Early reports of bile duct injury
during laparoscopic cholecystecto
my by well-trained surgeons was
0.2%.7 Recent data and longer term
follow-up suggest that the inci
dence may be 10- to 20-fold great
er. The time of recognition and the
site of injury associated with laparo
scopic cholecystectomy render the
consequences more threatening
than injuries associated with open
cholecystectomy.
Additional manipulations of the
bile duct for stone extraction dur
ing laparoscopic cholecystectomy
include transcystic duct retrieval or
lithotripsy, cystic duct or direct
laparoscopic choledochoscopy, and
laparoscopic choledochotomy and
exploration. As biliary surgical
techniques, these are not new meth
ods; however, recent advances are
through the minimal access ap
proach. These methods are in the
development stage and must be crit
ically evaluated over the longer
term for the incidence of retained
common duct stones and increase in
the frequency of bile duct injury.
Roy, McAlister and Passi (pages
81 to 84) from London, Ont., pres
ent their preliminary experience
with perioperative ERCP in associa
tion with laparoscopic cholecystec
tomy. Endoscopists have achieved
ERCP success rates of 85% to 95%.
Therefore, the London group fa
vours selective laparoscopic cholan
giography. This approach demands
that the following be recognized: (a)
liberal use preoperatively of ERCP
and possible ES, based on indica
tions outlined by Roy, McAlister

8
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and Passi in their Table II; (b) safe
and effective laparoscopic clearance
of common duct stones after posi
tive laparoscopic cholangiography;
and (c) effective postoperative clear
ance of common duct stones by
ERCP and ES. Postoperative diag
nostic ERCP will be indicated for all
suspected biliary complications of
laparoscopic cholecystectomy.
Deaths recorded after ERCP have
been due to pancreatitis or sepsis.
There is virtually no evidence of
iatrogenic bile duct stricture or
transection after ERCP. Clearance
rates of common duct stones ap
proaching 100% will be achieved by
experienced endoscopists through
ERCP and ES. Recently, CarrLocke8 reported a 1.5% incidence of
residual stones utilizing selective
preoperative ERCP and intraopera
tive cholangiography in 600 con
secutive cases. None of these pa
tients had indications for preopera
tive ERCP or intraoperative cholan
giography. All presented within 6
months of laparoscopic cholecystec
tomy with non-life-threatening
symptoms.
Laparoscopic cholecystectomy is
now accepted as the treatment of
choice for cholelithiasis. To pre
clude a moratorium on this tech
nique, surgeons must reduce the
incidence of bile duct injury close to
that reported for open cholecystec
tomy by Girard and Morin. Choledocholithiasis suspected preoperative
ly should be diagnosed and treated
by ERCP before laparoscopic chole
cystectomy is carried out. Current
data indicate that this combination
would achieve the lowest mortality,
morbidity, length of hospital stay
and “sick time.” Common bile duct
stones that are demonstrated by
selective laparoscopic cholangiogra

phy should be considered for post
operative ERCP and stone extrac
tion, until laparoscopic bile duct
surgery proves to be as effective as
postoperative ERCP and to create
no iatrogenic bile duct injury. The
natural history of residual common
duct stones will select postcholecys
tectomy patients for efficacious
stone extraction by ERCP with
morbidity and mortality far lower
than those reported for primary or
secondary open exploration of the
common bile duct.
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QUILL ON SCALPEL

Transurethral Resection of the Prostate:
Still the Gold Standard?
Ernest W. Ramsey, MB, ChB, FRCS, FRCSC
Member, Editorial Board, Canadian Journal of Surgery. Professor, University o f Manitoba,
Section o f Urology, Health Sciences Centre, Winnipeg, Man.

n this issue of the Journal (pages
37 to 40), Estey, Mador and
McPhee report on a 3-year experi
ence with transurethral resection of
the prostate (TURP) in a teaching
hospital where 75% of the primary
resectionists were senior residents.
Their results confirm those of other
reports that TURP for most pa
tients is a fairly safe procedure with
a low death rate and a relatively low
complication rate.1 Mortality was
related to age, impaired renal func
tion and higher American Society of
Anaesthesiologists class. The article
does not address the success of the
procedure in relation to improve
ment in symptoms or long-term
complications such as urethral
strictures and the reoperation rate.
TURP has been used to treat benign
prostatic hyperplasia (BPH) for over
50 years and has largely replaced
open prostatectomy, which is re
served for large glands. Microscopic
BPH seems to be an inevitable
consequence of aging.2 It is more
difficult to determine the incidence
of clinical BPH because not all men
with symptoms seek or undergo
treatment. The incidence of clinical
BPH appears to range from about
10% of men in the 40- to 50-year
age group to about 40% of men
over 70 years of age.3 The probabil
ity of a 40-year-old man undergoing
TURP in the United States during
his lifetime is 29%. This translates
into over 400 000 such procedures
each year.4 In Canada in 1991, over
38 000 such resections were per
formed.

I

Despite the frequency with which
TURP is performed, it is only re
cently that efforts have been made
to assess the short- and long-term
outcomes.5 At the same time, the
management of patients with BPH
has been thrown into turmoil by
recent advances, which have seen
the successful use of medication to
treat this disease as well as the
introduction of a variety of new
techniques that may permit treat
ment with less morbidity. A recent
editorial in the New England Jour
nal o f Medicine was entitled “ Is the
prostate pill finally here?”6 This
editorial was in reaction to publica
tion of the results of a study of
finasteride, a 5a-reductase inhibi
tor. Finasteride prevents the con
version of testosterone to dihy
drotestosterone, the active andro
gen in the prostate, causing a de
crease in the size of the prostate
and improving symptoms and urine
flow rates. This drug is now ap
proved for use in Canada. Alphaadrenergic blocking agents have
also been studied in BPH. These do
not decrease prostate size but cause
relaxation of the smooth muscle in
the gland, again improving symp
toms and voiding. Terazosin, an
a-l-adrenergic blocking agent cur
rently approved in Canada for the
treatment of hypertension, is under
going investigation for use in BPH,
as are a variety of other treatment
options. These include transureth
ral incision of the prostate, balloon
dilatation, prostatic stenting, tran
surethral microwave thermotherapy

and the use of lasers to perform
transurethral prostatectomy.
Although the morbidity associat
ed with these treatments appears
lower than that for TURP, the
effectiveness of some of them, such
as thermotherapy, requires further
evaluation before they are offered
as an alternative treatment. It has
become obvious that there is a
major placebo effect in the treat
ment of this disease. This effect
must be considered in the assess
ment of new treatments. Also, not
all patients with symptoms require
treatment, and observation (watch
ful waiting) is an option even with
the advent of less morbid treat
ments. Although TURP remains the
most effective way to relieve ob
struction, the decreased morbidity
associated with newer options may
make them attractive. The relative
costs of the new treatments also
need to be assessed.
How is the urologist and the
patient to choose from this plethora
of treatments? The decision will
relate partly to the severity of the
problem. Medical treatment for ex
ample, has been assessed for pa
tients with symptoms of BPH and is
not currently indicated for the treat
ment of patients with acute or
chronic urinary retention. An inter
esting and possibly helpful ap
proach is that taken by the Founda
tion for Informed Medical Decision
Making, in New Hampshire. This
group has produced an interactive
videodisc program that allows the
patient to review treatment options
CJS, VOL. 36, NO. 1, FEBRUARY 1993
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along with their harms and benefits
and to watch interviews with pa
tients who have chosen particular
options. In this way the patient can
play an active role in decision mak
ing. However, to be effective, the
information supplied to the patient
must be comprehensive and accu
rate. This will require prospective,
controlled studies of all new treat
ment options.
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QUILL ON SCALPEL

Blood Use in Resuscitation After Trauma
James P. Waddell, MD, FRCSC
Department of Surgery, St. Michael’s Hospital, Toronto, Ont. Member, Editorial Board,
Canadian Journal of Surgery

n this issue (pages 21 to 27),
Hamilton lucidly outlines the use
and abuse of blood transfusion in
the trauma patient.
In a comprehensive review of the
current literature he describes clear
ly the indications for blood transfu
sion, the risks associated with such
transfusion and the alternatives to
banked blood.
Of particular interest is the em
phasis on the initial priorities in
resuscitating the trauma patient,
the different categories of transfu

I

sion (emergency versus urgent) and
a comprehensive discussion of the
complications of blood transfusion.
Surgeons involved in the care of
trauma patients know how essential
rapid access to a reliable source of
banked blood is — both in resusci
tation and during surgical treat
ment of the patient. Too often
blood is given at inappropriate
times, for inappropriate reasons and
in inappropriate amounts. Careful
reading of Hamilton’s article will
help the surgeon rationalize the use

of blood and blood products in the
trauma patient, ensuring that safe
transfusion practice complements
safe surgical practice during resus
citation and surgical control of on
going hemorrhage.
All surgeons and residents in
volved in the care of trauma pa
tients should be familiar with the
principles outlined by Hamilton and
should modify their treatment prior
ities if necessary to reflect current
practice in the use of blood in
resuscitating the trauma patient. ■

QUILL ON SCALPEL

T h e Journal Expands Its Role
Jonathan L. Meakins, MD, FRCSC;* Roger G. Keith, MD, FRCSCf
*Coeditor, Canadian Journal of Surgery. Chairman, Department o f Surgery, McGill University,
Royal Victoria Hospital, Montreal, Que.
fCoeditor, Canadian Journal of Surgery. Chairman, Department o f Surgery, University o f
Saskatchewan, Royal University Hospital, Saskatoon, Sask.

he crisis imposed on the Cana
dian Journal o f Surgery (CJS)
and the previous coeditors by the
staged withdrawal of financial sup
port of the Royal College of Physi
cians and Surgeons of Canada has
given the Journal an opportunity to
expand its role and better serve its
surgical community, now made up
of the Canadian Society for Vascu
lar Surgery, the Canadian Ortho
paedic Association, the Canadian
Association of General Surgeons,
the Canadian Society of Cardiovas
cular and Thoracic Surgeons and
the Canadian Society of Surgical
Oncology, with support from the
Royal College. These sponsoring

T

societies have begun to publish ab
stracts and representative portions
of their annual meetings in the CJS.
It is the intention of the coeditors
that the involvement of these socie
ties shall expand to include many of
their innovative and key manu
scripts. It is planned that within the
next year the journal will carry a
review article solicited from each
society, starting in this issue
(pages 29 to 32) with an overview
of the Royal College’s Maintenance
of Competence Program.
With this issue a new section
“Sponsors’ News” (pages 96 to 99)
is being initiated. Its purpose is to
provide a forum of communication

on a bimonthly basis for the Cana
dian surgical community. This issue
carries the initial offering, which, in
time, we expect to expand signifi
cantly. Although each society’s
input is focussed on its members,
there is much information that with
diffusion will benefit the entire Ca
nadian surgical community. The
participating societies incorporate
Canadian cardiac, general, orthope
dic, thoracic and vascular surgeons
together with surgical oncologists.
Although this represents the major
ity of Canadian surgery, we look
forward to the other surgical spe
cialties participating and publishing
their work in the CJS. u

SESAP VII Question / Question SESAP VII
Item 360

Which of the following statements about pulmonary function after nonthoracic operation is TRUE?
(A) The site of incision has only a minor effect on postoperative pulmonary function.
(B) Patients with significant chronic obstructive pulmonary disease (COPD) have a 60% incidence of
pulmonary complications despite preoperative treatment with bronchodilation, antibiotics, and
physiotherapy.
(C) The lower limit of FEVi below which a patient should not be given general anesthesia has not been
clearly defined.
(D) The changes in lung volume seen after an upper abdominal midline incision can be reversed by
intercostal nerve blockade.
(E) The decrease in vital capacity is directly related to the anesthetic agent used.
For the critique of Item 360 see page 52.
(Reproduced by permission from SESAP '92-’93 Syllabus; Surgical Education and Self-Assessment Program
No. 7. For enrolment in the Surgical Education and Self-Assessment No. 7, please apply to the American College
of Surgeons, 55 E Erie St., Chicago, IL 60611.)
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NON-NARCOTIC

NARCOTIC EFFICACY
WITHOUT NARCOTIC DRAWBACKS
Now, Toradol offers a real alternative to narcotics
for the management of pain - an analgesic that
provides the strength of narcotics without the
associated drawbacks.

CLASSIFICATION
Toradol belongs to the non-steroidal anti
inflammatory drug (NSAID) family. However, unlike
conventional NSAIDs, it is a potent analgesic agent
with minimal anti-inflammatory and antipyretic
activity. And it’s the only non-narcotic analgesic
available in both IM injection and tablet form .'2

EFFICACY
One Toradol 30 mg IM injection has been proven to
be as effective as morphine 12 mg IM and meperidine
100 mg IM,410 while one Toradol 10 mg tablet has
been shown to be more effective than 2 tablets of
acetaminophen + codeine #3*:,7',M2
COMPARABLE PEAK
PAIN RELIEF

LONGER DURATION
OF ANALGESIA

Analgesic efficacy of Toradol 30 mg
IM administered 24-72 hours
postsurgery in 5 single dose studies.
Adapted from reference 10.

Analgesic efficacy of
TORADOL 30 mg IM vs.
morphine 12 mg IM and
meperidine 100 mg IM.'“

□ TORADOL 30 mg IM
□ Morphinel2 mg IM
□ MeperidinelOO mg IM

1

2
3
4
5
HOURS FROM ADMINISTRATION
Measure of pain relief: 0 = none, 1 = poor, 2 = fair, 3 = good, 4 = very good.

EQ UIVALENTS SUPERIOR PEAK
ONSET OF ■ PAIN RELIEF
ACTION

LONGER DURATION
OF ANALGESIA

Randomized, double-blind,
single dose study in patients
following oral surgery.
Adapted from reference 17.
1

2

3
4
5
HOURS FROM ADMINISTRATION
Measure of pain relief: 0 = none. 1 = poor, 2 = fair, 3 = good, 4 - very good.

Analgesic efficacy of
TORADOL 10 mg Tablet
vs. 2 Tablets of
acetaminophen +
codeine #3'7

□ TORADOL 10 mg oral

D ’ Acefaminophen 600 mg -r
codeine 60 mg oral
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TOLERABILITY

CLINICAL APPLICATIONS

Because Toradol is peripherallyacting, its tolerability profile is superior
to morphine, meperidine, and codeine
containing analgesics, producing less
nausea, vomiting, drowsiness171821 and
constipation.2 Furthermore, Toradol has
no reported incidence of respiratory
dep ression,"12 and no potential for
narcotic addiction or abuse.3

Toradol has been proven effective in
managing a wide range of pain following
general, orthopedic, gynecological49
and oral surgery1718 as well as pain in the
Emergency Room setting.2922 27
And Toradol is well-suited for the post
operative pain of day-stay surgery, with
faster patient recovery,13 and no need for
monitoring of narcotic-related side-effects
which can delay discharge.32
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COST-EFFECTIVE
Importantly, Toradol’s proven efficacy
and tolerability help make it cost-effective
for Canadian hospitals.13 Earlier hospital
discharge and a lower incidence of
complications result in considerable cost
savings - in one well-controlled study,
Toradol IM and tablets saved an average
of approximately $75.00 per patient
compared to meperidine IM followed by
acetaminophen + codeine #3.13
This study also demonstrated that
patients on Toradol were easier to care
for and had greater independence,
requiring significantly less nursing time
and effort.13

General Surgery'

Orthopedic Surgery'

Gynecological Surgery'

Oral Surgery

For a better alternative to narcotics in
pain management, consider Toradol IM
and tablets. The non-narcotic analgesic
that is a step ahead of narcotics.

NON-NARCOTIC

I_______________ I

lOmg TABLETS &30m glM INJECTIONS

(KETOROLAC TROMETHAMINE)

NARCOTIC EFFICACY WITHOUT NARCOTIC DRAWBACKS

aT0RAD0L3 |
ketorolac tromethamine
tablets/comprim6s
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Forearm-Plate Removal
To the editors. I am an orthopedic
surgeon and practise in a communi
ty hospital. I read with interest the
article “ Complications of forearmplate removal” by Bednar and
Grandwilewski in the August 1992
issue (pages 428 to 431) of the
Journal. The authors state that an
incidence of infectious and neuro
logic complications of approximate
ly 10% each may be expected with
elective forearm implant removal.
Personally, I think that a 10% infec
tion rate with elective upper ex
tremity surgery is unacceptable,
and I would suggest the authors
review their aseptic technique.
George K. Aitken, MD, FRCSC
Brampton Orthopedic Associates
Brampton, ON
L6V 1B4

probably identified minor, early
postoperative cellulitis that might
otherwise go unreported. To my
knowledge, in the 5 years I have
been practising on the Orthopedic
and Trauma Service of the Hamil
ton General Hospital there has been
no problem with infection rates
generally reported on the service;
this close attention to infectious
complications may define part of
our elevated incidence. Although
these minor acute cellulitides are
generally not a major clinical prob
lem, their appearance does increase
the reported frequency of complica
tions, although perhaps they do not
carry any great clinical significance.
Drew A. Bednar, MD, FRCSC, FAAOS
Assistant clinical professor
Department of Orthopedic Surgery
McMaster University
Hamilton. Ont.

Dr. Bednar Responds
To the editors. I am happy to
review Dr. Aitken’s letter and con
cur with his comment on the sur
prisingly high infection rate we
noted in our review of elective fore
arm-plate removal.
Frankly, we were surprised and
appalled at the finding, much as we
would expect any surgeon to be on
discovering such a high complica
tion rate in his own case review.
Nevertheless, we stand by the im
portance of the review and encour
age all practising orthopedic sur
geons to pay thorough attention to
aseptic techniques in all of the
surgeries they undertake.
The clinical review of this series
was most aggressively directed to
the definition of complications and
16
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Retroperitoneal
Lymphadenectomy
To the editors. I read with interest
the report by Morin and colleagues
regarding vascular injury and repair
associated with retroperitoneal
lymph node dissection (RPLND) in
patients with testicular cancer (Can
J Surg 1992; 35: 253-256). In 78
patients who underwent RPLND,
17 (22%) required vascular repair
intraoperatively. Of particular inter
est were five renal artery injuries,
three of which resulted in nephrec
tomy. The 6.4% renal injury rate
and 3.8% nephrectomy rate are
noteworthy.
In a review of complications of
testicular cancer therapy, we noted

six lost renal units in 148 patients
who underwent RPLND, for a renal
loss rate of 4.1%.1 In our series,
only one nephrectomy was per
formed at the time of RPLND be
cause of inadvertent injury. Howev
er, three patients required nephrec
tomy within 1 year of operation
because of nonfunction or hydrone
phrosis, and two patients required
nephrectomy because of renovascu
lar hypertension. We have now doc
umented five cases of renovascular
hypertension after RPLND (unpub
lished data). Hypertension in three
of the cases was due to renal artery
injury, in one to cortical necrosis
and in one to hydronephrosis from
utereral injury. Interestingly, in
three of the five cases, hypertension
did not develop until more than 10
years after the testicular cancer
surgery.
We emphasize the importance of
monitoring these patients on a
long-term basis for the possibility of
delayed renovascular hypertension,
which could have resulted from
unrecognized surgical insult. In ad
dition, because of the possibility of
hypertension as a result of vascular
toxicity from cisplatin-based chemo
therapy also commonly used to
treat this patient population, blood
pressure screening takes on added
importance.2 The two patients re
ported by Morin and colleagues
who had renovascular repair and
did not require immediate nephrec
tomy would be interesting to study
in the long term for the possibility
of renovascular hypertension. Long
term follow-up of their entire co
hort with respect to hypertension
may also lead to delayed morbidity
as our experience has shown.1-2 We
agree with Morin and colleagues

CORRESPONDENCE

that surgery for the patient with
advanced retroperitoneal testicular
cancer should encompass a multi
specialty approach.
Despite these precautions, mor
bidity does occur, and the patients
require long-term follow-up.

Judd W. Moul, MD
Attending urologic-oncologist
Walter Reed Army Medical Center
Washington, DC.
Assistant professor of surgery
Uniformed Services University of the Health
Sciences
Bethesda, Md
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The Need for General
Surgeons

1
1

i
i

>

To the editors. The article by
Blanchard (Can J Surg 1992; 35:
531-535) and the editorials by Duff
(page 466) and Taylor (pages 467
and 468) are of interest to me and
to all rural general surgeons, active
or retired.
Time, the Golden Hour — is it
forgotten? Weather and its com
plexities — are they not a factor?
Economics — are the patient and
his or her loved ones considered? It
appears that the tertiary centres
supported by the surgeon-scientist
will be valid by the 21st century.
Is this the way to go? Personally
I, and active and retired rural sur
geons, disagree that all patients
should go to a tertiary centre and
be supervised by surgeon-scientists.

Each rural medical centre has its
own particular problems. For this
reason, regionalization is not the
answer.
The seaport of Prince Rupert,
BC, is an excellent example, yet
there are active surgeons who feel
that Terrace, BC, should be a re
gional centre. Personally, I do not
agree. Each year half a million
people use the “Inside Passage”
or are off shore, whether they
are on cruise ships, American or
Canadian ferries, commercial fish
ing or pleasure boats and local or
off-shore freighters. Medically and
surgically the Prince Rupert Re
gional Hospital supports five native
villages, Oona River and the Queen
Charlotte Islands.
In the second paragraph I men
tioned time, weather and econom
ics. It takes time to bring a patient
to hospital whether for trauma,
abdominal surgery, heart attack or
pregnancy. The weather and its
complexities at times make it diffi
cult to get the patient to a tertiary
hospital. Economically it is cheaper
for the British Columbia govern
ment, since an air ambulance is
costly, for a patient to be looked
after in his or her own area whenev
er possible. The loved ones cannot
afford the air fare, $600 to go to
Vancouver, the nearest tertiary fa
cility.
Trainee surgeons should have an
opportunity early in their training
to practise under the supervision of
a general surgeon in a rural com
munity hospital. The provincial
government should provide an ade
quate allowance for new surgeons
until they can support themselves
financially. All physicians should
take the Advanced Trauma Life
Support course. General surgeons
will have to make decisions, wheth
er to operate now or later, or to
transfer. If they can read, there are
books. If they are in doubt, they
can phone the resident on call at

the tertiary hospital for the specific
specialty.
There is an absolute need for true
general surgeons now and into the
21st century.
J.E. Schinbein, BA, MD, FRCSC, FACS
1137 Prince Rupert Blvd.
Prince Rupert, BC
V8J 2Y8

Training the General
Surgeon
To the editors. The recent article
by Blanchard in the October 1992
issue (pages 531 to 535) and the
editorials from Drs. Duff (page
466), Taylor (pages 467 and 468)
and Deschenes (page 469) point out
the need for general surgical train
ing programs to be responsive to
the changing needs of society.
However, we must also recognize
the present constraints on our pro
grams and the resources available
for training and be realistic as to
what newly trained general sur
geons may be willing to undertake.
Above all, we must not compromise
the quality of our programs or the
care of patients in the interests of
cost containment, ease of access or
short-term political gains.
General surgery training current
ly takes 5 years. The increase from
4 years was introduced for two
reasons. The first reason was to add
flexibility to training to allow for
the production of community sur
geons, academic teachers or surgi
cal scientists and to form a basis for
the training of subspecialists in vas
cular, thoracic and colorectal sur
gery and in critical care. The second
reason was to recognize the in
creasing scope of general surgery,
which has grown to include the
technical skills of endoscopy, head
and neck surgery and laparoscopic
surgery, the cognitive areas of critiCJS, VOL. 36. NO. 1, FEBRUARY 1993
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cal appraisal, research methodology
and medical ethics and jurispru
dence, and the treatment of the old,
the sick and immune deficient. Pro
grams also need to inculcate atti
tudes of humanity, communication
skills, cost consciousness and the
need for maintenance of compe
tence.
All of these added requirements
make for a very crowded 5-year
program. If we are proposing to add
extra exposure to plastics, urology,
obstetrics and gynecology and or
thopedics, what should we drop
from the present training?

My nonsurgical colleagues in
community hospitals claim that any
“ well-trained general surgeon”
should be able to repair an extensor
tendon, do a cesarean section or pin
a hip. Will newly trained general
surgeons be willing to offer these
services, mainly at night and on
weekends? Will they still wish to
offer them if “capping” dictates
that such services are offered with
out pay? What will lawyers and
judges have to say if things go
wrong? Finally, and most impor
tantly, would it not be wise to seek
the views of the relevant specialty

committees on what areas general
surgeons could undertake safely
without 6 or 7 years of training?
The old-fashioned surgeon who
did everything is a popular cult-fig
ure. However, the scope and com
plexity of modern surgery has made
him (few, if any, were women) a
virtual anachronism. Let us be care
ful not to turn the clock back 30
years in the name of progress.

drawing on the wall of the 12th century
BC Tomb of Ipuy. In that drawing, a
dislocated shoulder is seen being re
duced using a method exactly like
Kocher’s, 3000 years before he de
scribed it. The Egyptian Orthopaedic
Association, with understandable pride,
uses the same drawing as its logo.
LeVay presents a massive amount of
historical information in a clever and
readable way. He reviews first the peri
od from the Stone Age to the end of the
16th century, ranging with an eclectic
pen through the lore of ancient Egypt,
India, China, Japan and the well-record
ed Hellenic and Roman periods. The
section ends in early medieval Europe.
It is a fascinating story of pragmatism
and of intelligent innovation. The text
is both well illustrated and well refer
enced.

Andry (1658-1747), Dean of the Facul
ty of Physics at the University of Paris,
combined the Greek words “orthos”
(straight) and “paidion” (a child) into
“orthopedie.” Other, current and older
terms, like Andry’s, were used original
ly as book titles. The Paedotrophia of
Scevole de Sainte-Marthe and Callipaedia of the Abbe Claude Quillet were
soon dropped. Nineteenth century ef
forts — “orthomorphy” , “orthosomatics” and “orthopraxy” thankfully also
lost out to “orthopaedic surgery.”
Major developments in orthopedic
surgery and traumatology are described
in 18 separate chapters, each devoted to
the contributions of a nation. To create
a text that is a pleasure to read and not
a catalogue, the author has described
the work of great surgical pioneers in
the form of brief biographical sketches
and the diseases, such as poliomyelitis
that have had a significant effect on
orthopedic practice. Landmark papers
are referred to and in some instances,
their face pages are reproduced. Indeed,
the whole of this section is a treasure-

Christopher Heughan, MB, BChir, FRCSC
Division of Surgery
Memorial University of Newfoundland
St. John’s, NF
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The following books are also re
viewed in this issue: Sabiston Re
view of Surgery (page 32); Surgi
cal Revascularization of the Heart:
the Internal Thoracic Arteries
(page 71); The Principles of Trau
ma Surgery (page 71).

HISTORY OF ORTHOPAEDICS.
David LeVay. 693 pp. Illust. The Par
thenon Publishing Group, Park Ridge,
NJ. 1990. $125. ISBN 0 -8 5 0 7 0 -1 4 5 8

The hard, mineral nature of bone has
preserved evidence of human bone and
joint disease since the New Stone Age.
Dinosaur fossils have also shown how
long vertebrates have suffered from
degenerative arthritis.
In this book, David LeVay reviews
the history of human musculoskeletal
disorders and their treatment from the
time of the building of the Pyramids of
Giza in the 5th dynasty to the present.
The great antiquity of what is now
orthopedic surgery was established by a
18
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The second and largest section of the
book concerns development of the arts
and science used in the management of
musculoskeletal disorders. A good ac
count is given of finding the term under
which the many aspects of this field of
interest could be collected. Nicolas

continued on page 32
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Statistics show they could both end up driving it
People who buy a Mercedes-Benz
expect to keep it longer than other
cars. And for good reason.

car’s underbody and exterior.
Little wonder that 97% of all

driver a new Mercedes, and drive it
yourself until he’s ready.

Mercedes-Benz cars registered over

For additional information on

Galvanized steel is used for body

the last 15 years are still in

Mercedes-Benz call 1-800-387-4632.

parts that are prone to corrosion.

operation* (that’s more than any

Ten kilograms of weather-resistant

luxury car make sold throughout

sealant and as many as eight

that time period).

coatings and finishes protect the

So buy your budding young

'Based on registration data for cars sold continuously for years 1977-1991. ©1992 Mercedes-Benz Canada Inc., Toronto, Ont., Member o f the Daimler-Benz Group.
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REVIEW ARTICLE
ARTICLE DE REVUE

T h e Use of Blood in Resuscitation
of the Trauma Patient
Stewart M. Hamilton, MD, FRCSC, FACS
The ability to transfuse blood (a form of tissue transplantation) with relatively few
immediate and long-term complications has led to increased survival in victims of
injury who require massive amounts of blood. The primary deficit in hypovolemic
shock secondary to trauma is in oxygen transport to the hypoperfused tissues;
therefore, blood transfusion has an essential role in therapy during resuscitation
and definitive treatment. The major immediate complications to be avoided are
hypothermia and acidosis, which are the main causes of the coagulopathy associated
with massive transfusion. The most worrisome long-term complication is the
transmission of disease, of which hepatitis C is the most frequent. With improved
screening techniques and heightened donor awareness, the risk of disease
transmission is less than 2%. Until synthetic oxygen-carrying solutions are
available, the transfusion of red blood cells, when appropriately indicated, will
remain an important component in the resuscitation of the trauma patient.

La capacite a transfuser du sang (une forme de greffe tissulaire) avec relativement
peu de complications immediates ou retardees, a contribue a l’augmentation de la
survie des blesses qui necessitent des quantites massives de sang. Le deficit primaire
en cas de choc hypovolemique consecutif a un traumatisme, est relie au transport
d’oxygene vers les tissus hypoperfuses; en consequence, la transfusion sanguine
joue un role therapeutique essentiel durant la reanimation et au cours du traitement
definitif. Les complications majeures immediates qui doivent etre evitees sont
l’hypothermie et l’acidose, les principales causes de la coagulopathie reliee aux
transfusions massives. La complication tardive la plus inquietante est la
transmission de maladies, l’hepatite C etant la plus frequente. Avec les techniques de
depistages ameliorees et des donneurs mieux informes, le risque de transmission est
inferieur a 2 %. En attendant la venue des solutions de transporteurs d’oxygene de
synthese, la transfusion d’hematies pour les indications appropriees va demeurer
une composante importante de la reanimation des patients traumatises.

hroughout history blood has
been synonymous with life. In
ancient times it was considered to
be the basis of the soul and to carry
with it the physical and mental

T

qualities of its owner. The Romans
drank the blood of recently slain
gladiators to acquire their strength.
These attitudes toward blood con
tinued well into the Renaissance,
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when in 1492, Pope Innocent VIII
received blood from three young
boys in an unsuccessful attempt to
rejuvenate him. Following Harvey’s
description of the circulation, oth
ers, among them Sir Christopher
Wren, began to work on the intra
venous injection of fluids into the
circulation. In 1667, the first re
corded transfusion of an animal’s
blood into a human was made by
Jean Baptiste Denis. His work met
with some success and led to the
first description of a transfusion
reaction, including diaphoresis,
tachycardia, pain at the injection
site and black urine. The patient
survived but 2 months later re
ceived another transfusion and died
the next day. This led to a charge
of murder against Denis, of which
he was acquitted, and to a ban on
all transfusions by the Faculty of
Medicine in Paris.1’2
It was not until early in the 19th
century that man-to-man transfu
sion was initiated by an obstetri
cian, James Blundell, for acute he
morrhage. He performed 10 such
transfusions, of which 4 were suc
cessful.1 The success rate of trans
fusion therapy did not improve sig
nificantly until the major blood
groups (ABO) were described in
1901 by Landsteiner. During the
late 1930s progress was made to
develop blood banking, and during
the Spanish Civil War, mobile trans
fusion services came into being
largely because of work by Bethune. The Barcelona Blood Trans
fusion Service used more than 9000
L of blood during its existence. In
CJS, VOL. 36, NO. 1, F E B R U A R Y 1993
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1939 the Rhesus factor system was
described, further facilitating blood
transfusion and lowering the inci
dence of transfusion reactions.2-3
Blood transfusion is a form of
tissue transplantation, with atten
dant risks that must be weighed
against the perceived benefits. Our
ability to store blood in large quan
tities for immediate use has permit
ted tremendous advances in the
fields of surgery and critical care,
particularly cardiac, transplant and
trauma surgery.
Twenty years ago, survival after
transfusion of more than 20 units
of blood was reported to be 7%.4
With improved triage, retrieval, re
suscitation techniques, surgical
care, anesthetic care and postopera
tive intensive care, the survival in
one series today is over 50%. Addi
tionally, the majority of these survi
vors returned to gainful employ
ment.5 Clearly, the ability to trans
fuse blood, a solution that for the
most part remains in the vascular
compartment as a volume expander,
that carries oxygen and has some
buffering capacity, is an important
weapon in the management of the
injury victim. In fact, if we could be
certain that there were no risks of
disease transmission, allergic reac
tions or transfusion reactions, it
would be the ideal fluid.

Initial Priorities
The initial treatment of the trau
matized patient is challenging and
in most cases rewarding. Primary
objectives are to ensure an adequate
airway, oxygenation and ventila
tion, with spinal control. Assess
ment of the circulatory status re
quires an estimate of the bloodvolume deficit and of ongoing loss
es. This will determine the rapidity
with which blood will be used. The
response or lack of it, to the initial
fluid bolus of 2000 mL of crystal22
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loid, aids in this assessment. Imme
diate surgical control of ongoing
losses must be considered in all
hypotensive patients. It is essential
to remember that most complica
tions of hemostasis are related to
the length of time that the patient
is in hypovolemic shock and to the
degree of hypothermia present.6-8
Reversing hypotension and hypo
thermia are the top priorities of
management once oxygenation and
ventilation are assured.
In the trauma patient with hypo
volemia who does not require imme
diate surgical control, the options
for the type of fluid to be adminis
tered are many. That the initial
fluid resuscitation should be a bal
anced electrolyte solution is not
controversial, although the adminis
tration of hypertonic saline solu
tions, particularly in the prehospital
setting, has its proponents. Intrave
nous access should be through two
large-bore (12 to 14 gauge) short
catheters inserted into an uninjured
upper extremity. A second option is
to access the femoral vein percutaneously using a large-bore line (8.5
French). A third option would be by
a saphenous vein cutdown at the
medial malleolus. Resistance to flow
is proportional to diameter and to
length; therefore, for rapid largevolume resuscitation, short, large
lines must be placed.
Hemorrhagic shock can be classi
fied into four categories. Loss of up
to 1000 mL (15% of blood volume)
(class 1) results in minimal clinical
symptoms. In uncomplicated cases
tachycardia develops, but blood
pressure, respiratory rate, capillary
refill and pulse pressure are un
changed. In class 2 hemorrhagic
shock (a loss of 15% to 30% of
blood volume [1001 to 1500 mL]),
symptoms include tachycardia
(more than 100 beats/min), tachyp
nea, a decrease in pulse pressure
(mainly due to a rise in the diastolic
pressure secondary to catechola

mine stimulation), anxiety and de
layed capillary refill. In class 3
hemorrhagic shock (a loss of 30%
to 40% of blood volume [1501 to
2000 mL]), the signs are more
dramatic and consist of cold clam
my skin, diaphoresis, marked tachy
cardia and tachypnea, significant
changes in mental status and a
measurable fall in systolic blood
pressure. With this degree of blood
loss transfusion is required. In class
4 shock (loss of more than 40% of
blood volume [more than 2000
mL]), there is an immediate threat
to life. Marked tachypnea and
tachycardia and a very narrow pulse
pressure, or unrecordable diastolic
pressure, indicate this magnitude of
bleeding. End-organ function is
markedly impaired as manifested
mainly by oliguria progressing to
anuria. Patients in this situation
require immediate blood therapy
and surgical intervention.3

Oxygen Transport
By definition a patient who is in
shock suffers from a generalized
state of circulatory inadequacy.
Specifically, in hemorrhagic shock,
cellular hypoperfusion exists be
cause of a primary deficit in circu
lating blood volume resulting in
inadequate oxygen delivery. It fol
lows that the major objective of
treatment is to restore cellular per
fusion. This requires the restoration
of oxygen delivery which can be
defined by the equation: oxygen
delivery = oxygen content X cardi
ac output, which equals percent
oxygen saturation X (hemoglobin X
1.34) X cardiac output.
Oxygen saturation can be opti
mized by ensuring that an adequate
airway and an adequate minute ven
tilation exist, either spontaneously
or with intervention. Cardiac output
is determined by preload, contractil
ity and afterload. It is unusual for
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intrinsic cardiac disease to exist in
the majority of injury victims. How
ever, with increasing numbers of
elderly people involved in motor
vehicle accidents, intrinsic cardiac
disease must be considered. In the
younger patient population, the
component most commonly in
volved in causing a decrease in
cardiac output is inadequate pre
load. This is corrected by the ad
ministration of fluids or blood, or
both. Obstructive causes of shock
in the form of pericardial tampon
ade or tension pneumothorax, must
be diagnosed and treated. It is rare
for increased afterload to be of
concern, and if it is, it can be
rectified by volume infusion and
augmented cardiac performance.
The ability of the blood to oxy
genate tissues is determined by the
intrinsic ability of the hemoglobin
molecule to carry oxygen. This rela
tionship between oxygen and hemo
globin is further defined by the
hemoglobin-oxygen dissociation
curve. The association of hemoglo
bin and oxygen is influenced by
many factors, but with respect to
the quantity of oxygen carried and
in a young patient without intrinsic
lung or cardiac disease, the hemo
globin concentration is the major
determinant of oxygen delivery.

easily from hemoglobin, a “shift to
the right” of the hemoglobin-oxy
gen dissociation curve, resulting in
improved oxygen delivery. Other
conditions that assist oxygen deliv
ery are not commonly found in the
acute situation of hemorrhagic
shock associated with trauma.9
Manipulation of the hemo
globin-oxygen dissociation curve
can be valuable in assisting oxygen
delivery when resuscitating a pa
tient with extensive blood loss (Fig.
1). Most importantly, a “shift to the
left,” in which an increased affinity
of hemoglobin for oxygen occurs,
must be prevented. All stored red
cells become depleted in 2,3-DPG,
although functionally this reverses
with transfusion. In the traumatized
patient it is treatment of the associ
ated hypothermia and avoidance of
an alkalotic state, by overadminis
tration of sodium bicarbonate, that
can prevent this leftward shift. Mild
elevation of temperature is prefera
ble to hypothermia, and a moderate
acidosis with pH ranging between

7.25 and 7.35 is preferable to alka
losis.3 In summary, although ade
quate preload to maximize cardiac
output and restoration of hemoglo
bin to maintain oxygen-carrying ca
pacity are the first goals of resusci
tation, attention to the effects on
the hemoglobin-oxygen dissociation
curve, particularly with respect to
hypothermia, will assist in achiev
ing the overall objective: restoring
cellular perfusion.

Indications for Blood
Transfusion

Emerqency Transfusion
In certain situations, consider
ation must be given to immediate
transfusion. This decision is made
on clinical grounds after a rapid
initial assessment reveals a patient
in a state of profound hypoperfu
sion, unresponsive to volume load
ing. As venous access is being es
tablished, blood must be sent for

Oxygen unloading

Hemoglobin-Oxygen Dissociation
The primary function of the red
cell is to carry oxygen to the tissues
and to carry carbon dioxide away
from them, both functions being
performed by the hemoglobin mole
cule. In the terminal vascular bed,
the ability of the hemoglobin to
unload oxygen is modified by three
intracellular factors: the hydrogen
ion concentration, the carbon diox
ide tension and the level of
2,3-diphosphoglycerate (2,3-DPG).
An increase in concentration of
each or any of these substances
allows oxygen to dissociate more

FIG. 1. Hemoglobin-oxygen dissociation curve. Relationship of hemoglobin to
oxygen as function of saturation versus partial pressure of oxygen. Increased
acidosis, decreased 2,3-diphosphoglycerate (DPG) and decreased temperature all
shift curve to left, interfering with the unloading of oxygen in terminal vascular
bed.
CJS, VOL. 36. NO. 1. FEBRUARY 1993
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typing and crossmatching. It is im
perative that this be done before the
administration of blood products.
After the blood has been typed and
crossmatched, the trauma team has
three options: (a) use of type-specif
ic blood, (b) use of type 0, Rh-negative blood and (c) autotransfusion.
In most situations, the time taken
to establish lines and infuse a
2000-mL bolus of crystalloid is
long enough for type-specific blood
to be made available. It is axiomatic
that the typing of the patient be
done by the blood bank giving the
blood. This process should take no
longer than 5 minutes, so the need
for “universal donor” blood is mini
mal, and if it is used, it should be
used only until type-specific blood
is available.10 That this is possible is
borne out by military experience:
even in situations of mass casual
ties, the number of units of type 0,
Rh-negative blood transfused is less
than 5%.n
If type 0, Rh-negative blood is to
be transfused, it should be as
packed cells and not as whole
blood. Because of the presence of
anti-A and anti-B antibodies in the
plasma of universal donor whole
blood, the risk of a subsequent
transfusion reaction is greatly en
hanced. The lack of available low
titre anti-A and anti-B whole blood
precludes it as a solution whose
supply can be relied upon. It should
be necessary to transfuse only 1 or
2 units of type 0, Rh-negative
packed red cells before type-specific
blood is ready. By switching to
type-specific blood early in the
transfusion, reactions can be mini
mized.10 If the situation dictates
that a large volume of universal
donor blood be used, then type 0,
Rh-negative blood should continue
to be given, to prevent a reaction,
until the patient is stable and can
manufacture red blood cells.
Potentially, autologous blood
transfusion is the safest alternative
24
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to type-specific blood in emergency
situations. There is no risk of a
transfusion reaction or of the trans
mission of disease. The ability to
predict the potential benefit of
using an autotransfusion device is
difficult and very subjective. Age,
presence of shock and mechanism
of injury are not predictors of auto
transfusion efficacy. Some very gen
eral indicators that may assist in
determining that autotransfusion
could be beneficial are an initial
hematocrit of less than 35% and the
requirement for more than 2000
mL of crystalloid solution for resus
citation.12
Blood that is confined to the
thorax is usually clean, as is blood
from the abdominal cavity, provided
the gastrointestinal tract is not
open. Devices for collection and
subsequent administration of blood
from the chest are readily available
and are not expensive. Red blood
cell-saver techniques used intraoperatively for retrieval of intraperitoneal blood require more
set-up in equipment, personnel and
disposal costs. They require a larger
priming volume and have slower,
less powerful suction. To be of
benefit at least 3.5 units of packed
cells should be transfused.13 The
major drawbacks to autotransfused
blood are the potential for contami
nation, microemboli from platelet
plugs and fractured red blood cells,
and anticoagulant administration to
a bleeding patient. However, it must
be remembered that the patient’s
own blood comes closest to the
“ideal fluid” in all trauma situations
and therefore it is perhaps best to
err on the side of having liberal
indications for setting up the auto
transfusion system.
Urgent Blood Transfusion

The decision to transfuse a pa
tient who is responding to resusci
tation must be based on a complete

assessment of the clinical situation.
Blood is a scarce resource, and its
administration is not without com
plications. Young adults without
cardiac disease can tolerate hemato
crit levels of 25%, and it is appropri
ate in many situations to allow the
patient’s own bone marrow to re
solve the anemia. However, the de
cision to withold blood must be
based on which organ systems are
injured and the trend in the pa
tient’s hemodynamic status. If there
are signs of circulatory inadequacy
such as a persistent tachycardia,
ongoing lactic acidosis, a fall in
blood pressure of more than 20%
that is refractory to crystalloid ther
apy and an estimated blood loss of
greater than 20% with some ongo
ing losses, blood should be trans
fused to correct the primary prob
lem or to stabilize the situation
until surgical control is obtained.
Associated injury to the brain de
mands close attention to maintain
ing oxygen delivery and an ade
quate cerebral perfusion pressure.
In acute lung injury, the manage
ment of ventilation to minimize ba
rotrauma may necessitate lower ox
ygen saturations. In these situa
tions oxygen transport must be
maintained by optimizing the hemo
globin concentration.14
Complications of Blood
T ransfusion
The complications of blood trans
fusion can be broadly classified into
the general complications of all
fluid resuscitation and complica
tions that are specific to blood
transfusion. The most important of
the general complications are hypo
thermia and coagulopathy. The spe
cific complications pertaining to
blood transfusion that can occur
immediately include an allergic
reaction (4% of recipients), a febrile
reaction (2% of recipients), bacterial
sepsis (0.01% of recipients) and he-
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molytic transfusion reaction (0.03%
of recipients).3 The long-term risks
of transfusion are most often asso
ciated with the complications of
transmissible disease and im
munosuppression.
Hypothermia

Hypothermia is defined as a core
body temperature of less than
35°C. With progression to moder
ate hypothermia (32°C to 28°C)
and then severe hypothermia (less
than 28 °C) the metabolic abnormal
ities progressively worsen to a state
of coma and cardiac standstill. In
most, if not all, victims of injury, it
can be assumed that they are or will
become hypothermic during their
resuscitation. This condition leads
to a number of physiologic derange
ments that will hinder the return to
a well-perfused state. Among these
derangements are depressed hepatic
metabolism (i.e., synthesis of acutephase reactants, metabolism of ci
trate), a worsening of metabolic
acidosis (due to hypoperfusion of
cold extremities and increased ener
gy consumption due to shivering),
impaired platelet function (de
creased aggregation caused by di
minished production of thrombox
ane B2) and a shift of the oxygenhemoglobin dissociation curve to
the left (increasing its affinity for
oxygen). The management of hypo
thermia is first preventive and sec
ond therapeutic, by warming fluids
and inspired gases and by using
external heating devices. The spe
cific heat-transfer problem that
needs to be addressed in resuscitat
ing with blood is how to rapidly
infuse at temperatures of 35 °C a
solution that is stored at 4°C and
has a high viscosity. Whether
packed red blood cells or additive
red cells are used, the temperature
gradient to be overcome is the
same. An ideal fluid warmer is one
that has a minimum flow rate of

150 mL/min, has a low priming
volume and low pressure drop, is
compatible with blood and is safe,
compact and inexpensive.
There are a number of fluidwarming devices on the market, and
new technology has facilitated the
development of the ideal fluid
warmer. In a comparison of avail
able devices, the single-channel
counter-current heat exchanger was
found to have the most optimal
flow characteristics, although the
multichannel counter-current heat
exchanger also worked well.15 With
these systems now readily available
at moderate cost, the prevention
and treatment of hypothermia in
the injury victim has been greatly
facilitated.
In certain patients who undergo
massive transfusion after traumatic
injury, diffuse pathologic bleeding
develops. There is now abundant
evidence that this “medical” bleed
ing develops because of the pa
tient’s generalized state of hypoper
fusion, usually associated with hy
pothermia and acidosis. This is im
portant to recognize, because the
treatment of this problem is to
warm the patient and to reverse the
state of circulatory inadequacy not
to administer massive volumes of
blood components for their clotting
factors.
Coagulopathy

The coagulopathy of massive
transfusion has been attributed to
the “washout” of platelets and clot
ting factors, and to their deteriora
tion in stored blood. Clinical hemo
stasis requires about one-third nor
mal levels of clotting factors, most
notably the labile Factors V and
VIII. Even after one blood volume
exchange this amount is retained,
and although levels are depressed,
stored blood also preserves some of
these factors. Factor VIII is an
acute-phase reactant that is rapidly

produced in response to injury.
Studies done on patients undergo
ing multiple plasma exchange indi
cate that the factor most danger
ously depleted is fibrinogen, which
can affect coagulation. However,
fibrinogen does not deteriorate in
stored packed red cells, so unless
many units of washed cells are
used, depletion of fibrinogen should
not occur. Based on these data,
there is little evidence to support
the prophylactic use of plasma or
cryoprecipitate, which are rich in
clotting factors.616 These compo
nents should be used only when the
patient’s state of hypothermia and
hypoperfusion has been reversed (as
measured by end organ function)
and there are documented abnor
malities in the coagulation profile.17
Platelets are the other major
component that deteriorate in stor
age and have been implicated in
non-surgical bleeding problems.
The thrombocytopenia associated
with massive transfusion reaches its
nadir 2 days after injury and usually
returns to normal by day 4.18 In
studies comparing groups of pa
tients who received platelet transfu
sion with those who did not, no
difference was found in platelet
count or in bleeding problems.19 In
a patient with normal bone marrow
function it is very difficult to push
the platelet count to a level below
50 X 109/L . Platelet function is an
important aspect of thrombocyto
penia-induced coagulopathy and
must be taken into consideration
with respect to platelet transfusion.
As has been discussed, hypothermia
induces changes in platelet aggre
gation, as do a multitude of medica
tions. In the situation of a non
bleeding patient with normally func
tioning platelets, platelet transfu
sion need not be given prophylactically unless the count falls below
20 X 109/L . In the bleeding patient
with normal function, platelet trans
fusion is generally indicated for a
CJS, VOL. 36. NO. 1. FEBRUARY 1993
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count below 50 X 109/L . In both
situations aggressive steps must be
taken to rewarm and reperfuse the
patient.
Transmission o f Disease

Potentially the most frightening
complication of blood transfusion is
the transmission of disease that
manifests itself weeks to years later.
As the number of persons infected
with the human immunodeficiency
virus (HIV) increases, the need for
vigilant screening of the donor pool
also increases. Although HIV trans
mission through blood transfusion
has declined, cases are still reported
to occur when screening programs
are in place. The development of
more sensitive screening and aware
ness among donors should help to
diminish the risk of HIV in blood
recipients.20 Despite the public’s
preoccupation with HIV transmis
sion, the most commonly transmit
ted viral disease remains non-A,
non-B hepatitis, now known as hep
atitis C.
This disease, recognized as
non-A, non-B hepatitis since 1974,
has now been studied thoroughly
and its clinical course well estab
lished. It is now understood that it
has an even greater tendency than
hepatitis B to produce chronic liver
disease. Persistent alanine amino
transferase (ALT) elevation develops
in more than 50% of cases, and in
up to half of these an indolent form
of chronic active hepatitis will de
velop subsequently with an in
creased risk of cirrhosis and prima
ry hepatocellular carcinoma.21
Identification of the complete
hepatitis C virus (HCV) nucleic acid
sequence has permitted the develop
ment of an HCV antibody im
munoassay. The prevalence of anti
bodies to the virus varies world
wide. The ability to screen for the
virus and surrogate testing for ALT
and the antibody to hepatitis B core
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antigen since 1986, have dropped
the risk of hepatitis C transmission
from 10% to 5% at a cost of about
5% of the donor population. Addi
tional donor awareness about HIV
and the ability to screen for anti
body to HIV have resulted in a
further drop, so that the risk today
of post-transfusion HCV is less than

2%.21
Immunosuppression

In recent years increased atten
tion has been given to the possibi
lity of a persistent form of im
munosuppression in blood transfu
sion recipients. Initial evidence sug
gests that this effect might be dose
related. This has potentially impor
tant ramifications for the trauma
patient who receives massive trans
fusions, particularly because sepsis
is the major non-neurologic cause
of death associated with trauma and
thermal injury, carrying with it an
overall mortality of more than
60%.15'22 Much of the evidence sug
gesting this immunosuppressive ef
fect in humans comes from patients
with cancer and renal transplant
recipients.623-25 It is difficult to
study this phenomenon in the trau
ma patient because of the im
munosuppressive effects of soft tis
sue trauma and hemorrhage, both
of which are usually present.
Most of the laboratory evidence
for suppression of the immune sys
tem after blood loss comes from
small-animal models. Within this
context, hemorrhage has been
found to depress the proliferation of
blood lymphocytes and to reduce
the production of certain cytokines
(interleukin-2). These effects persist
despite resuscitation and can last up
to 3 days.26-28 Within the humoral
immune system, hemorrhage has
been found to depress the ability of
the B cell to react to known anti
gens.29-30 Additionally, impaired
phagocytosis may be associated

with the increased production of
other cytokines (tumour necrosis
factor and interleukin-1) or the re
lease of endotoxin by bacteria tran
slocating from the gastrointestinal
tract.29 The net result is to leave the
victim of blood loss more suscepti
ble to sepsis for an undetermined
time after injury.29-31-32
Because of these findings it will
be very difficult to determine if the
transfusion of blood into the trau
matized patient has an immunosup
pressive effect attributable to the
blood alone. To date, studies in
cancer patients and renal transplant
recipients do provide some circum
stantial evidence for this.23-25 How
ever, after hemorrhage and soft
tissue trauma all efforts should be
directed toward restoring homeosta
sis, and if blood transfusion is indi
cated, it should be given. To deny
blood therapy because of a sup
posed depressive effect on the im
mune system would be incorrect on
the basis of the evidence that exists
today.

C on clu sion s

Work on blood substitutes con
tinues, but recent medical history is
littered with hopeful solutions that
proved to be unsatisfactory. The
best hope appears to be purified
polymerized hemoglobin. In a re
cently published study, sheep toler
ated a 95% exchange transfusion
without evidence of clinical distress
and with stable hemodynamics. The
final hematocrit in this group was
24 ± 0.5%.33 Many of the problems
associated with stroma-free hemo
globin (i.e., physiologic P50, oncotic
pressure, depletion of plasma pro
teins) are gradually being over
come.34 The prospects for having a
synthetic oxygen-carrying solution
that is disease free for use as a
partial or total substitute for red
blood cells appears closer now then

BLOOD USE IN TRAUMA RESUSCITATION

ever before. Until it is available at
reasonable cost, however, blood re
mains the closest to being an ideal
fluid. Although blood must be used
in selected situations, because it is a
limited resource and because of the
potential long-term complications of
blood transfusion, it remains the
fluid of choice for resuscitation in
the critically injured patient with
signs of tissue hypoperfusion.

References
1. H utchin P: History of blood transfusion:
a tercentennial look. Surgery 1968; 64:
685-700
2. W introbe MM: Blood, Pure and Elo
quent, McGraw, New York, 1980
3. B aker RJ: Blood component therapy
in management of acute trauma. In
N ajarian JS, Delaney JP (eds): Trauma
and Critical Care Surgery, Yr Bk Med
Pubs, Chicago, 1987; 219-229

10.

11.

12.

13.

14.

15.

16.

4. W ilson RF, Mammen E, W alt AJ: Eight
years of experience with massive blood
transfusion. J Trauma 1971; 11: 275—
285

17.

5. W udel JH, Morris JA jr , Y ales K et al:
Massive transfusion: outcome in blunt
trauma patients. J Trauma 1991; 31: 17

18.

6. C ollins JA: Recent developments in the
area of massive transfusion. World J
Surg 1987; 11: 75-81

19.

7. F errara A, Mac A rthur JD, W richt HK
et al: Hypothermia and acidosis worsen
coagulopathy in the patient requiring
massive transfusion. Am J Surg 1990;
160:515-518
8. V aleri CF, F eincold H, C assidy G et al:
Hypothermia-induced reversible platelet
dysfunction. Ann Surg 1987; 205: 175181
9. B unn HF: Pathophysiology of the ane
mias. In B raunwald E et al (eds): Harri

20.

21.

son’s Principles o f Internal Medicine,
McGraw-Hill, New York, 1987: 1491 —
1493
P etz LD, S wisher SN (eds): Clinical
Practice o f Transfusion Medicine, 2nd
ed, Churchill Livingstone, New York,
1989: 218
M onahan WP, L evan DR, C amp FR jr :
Military blood banking. Blood transfu
sion aboard a Naval hospital ship receiv
ing multiple casualties in a combat zone,
a controlled medical environment.
Transfusion 1977; 17: 473-478
Jurkovich GJ, M oore EE, M edina G:
Autotransfusion in trauma. A pragmatic
analysis. Am J Surg 1984; 148: 782785
P opovsky MA, D evine PA, T asw ell HF:
Intraoperative autologous transfusion.
Mayo Clinic Proc 1985; 60 (2): 125134
Consensus Conference. Perioperative
red blood cell transfusion. JAMA 1988;
260:2700-2703
F lancbaum L, T rooskin SZ, P edersen
H: Evaluation of blood-warming devices
with the apparent thermal clearance.
Ann Emerg Med 1989; 18: 355-359
Domen RE, K ennedy MS, Jones LL et al:
Hemostatic imbalances produced by
plasma exchange. Transfusion 1984:
24: 336-339
Martin DJ, L ucas CE, L edcerwood AM
et al: Fresh frozen plasma supplement
to massive red blood cell transfusion.
Ann Surg 1985; 202: 5 05-511
Harrican C, L ucas CE, L edcerwood AM
et al: Serial changes in primary hemo
stasis after massive transfusion. Surgery
1985; 98: 836-844
R eed RL 2d, C iavarella D, H eimbach
DM et al: Prophylactic platelet adminis
tration during massive transfusion. A
prospective, randomized, double-blind
clinical study. Ann Surg 1986; 203: 4048
W ard JW, H olmberg SD, A llen JR et
al: Transmission of human immunodefi
ciency virus (HIV) by blood transfusions
screened as negative for HIV antibody.
N Engl J Med 1988; 318: 473-478
W illiams AE, Dodd RY: The .serology of
hepatitis C virus in relation to post
transfusion hepatitis. Ann Clin Lab Sci

1990; 20 (3): 192-199
22. Baker CC, O ppenheimer L, S tephens B

23.

24.

25.

26.

et al: Epidemiology of trauma death. Am
JS u rg 1980; 140: 144-150
B urrows L, T artter P: Effect of blood
transfusions on colonic malignancy re
currence rate [C]. Lancet 1982; 2: 662
Idem: Blood transfusions and colorectal
cancer recurrence: a possible relation
ship. Transfusion 1983; 23: 419
O pelz G, T erasaki PI: Improvement in
kidney graft survival with increasing
numbers of blood transfusions. N Engl J
Med 1978; 299: 799-803
A braham E, Chang YH: C ellular and
hum oral basis of h em o rrh ag e induced
depression o f lym phocyte function. Crit

Care Med 1986; 14: 81-86
27. Abraham E, F reitas AA: Hemorrhage

28.

29.

30.

31.

32.

33.

produces abnormalities in lymphocyte
function and lymphokine generation. J
Immunol 1989; 142: 899-906
S tephan RN, Conrad PJ, J aneway CA
et al: Decreased interleukin-2 produc
tion following simple hemorrhage. Surg
Forum 1986; 37: 73-75
C haudry IH, A y ala A, E rtel W et al:
Hemorrhage and resuscitation: immuno
logical aspects [Ej. Am J Physiol 1990;
259 (4 Pt 2): R663-678
Ayala A, P errin MM, E rtel W et al:
The effects of hemorrhage in Kupffer
cell antigen presentation and those pro
cesses associated with it (abstr). FASEB
J 1990; 4: A1020
L ivingston DH, Malangoni MA: Inter
feron-gamma restores immune compe
tence after hemorrhagic shock. J Surg
Res 1988; 45: 37-43
Idem: An experimental study of suscep
tibility to infection after hemorrhagic
shock. Surg Gynecol Obstet 1989; 168:
138-142
Vlahakes GJ, L ee R, J acobs EE jr et al:
Hemodynamic effects and oxygen trans
port properties of a new blood substitute
in a model of massive blood replace
ment. J Thorac Cardiovasc Surg 1990;
1 0 0 :3 7 9 -3 8 8

34. Mullins R, W ehry M, H udgins R et al:
Plasma albumin repletion after transfu
sion with polymerized hemoglobin. J
Surg Res 1990; 49: 441-446

CJS, VOL. 36, NO. 1, FEBRUARY 1993

27

Mobiflex®
(Tenoxicam Tablets) 20 mg
PHARMACOLOGICAL CLASSIFICATION
Anti-inflammatory, Analgesic Agent
ACTIONS AND CLINICAL PHARMACOLOGY
Non-steroidal anti-inflammatory agent (NSAID) with analgesic and
antipyretic properties. Mechanism of action not completely known.
Tenoxicam inhibits prostaglandin biosynthesis both in vitro and in vivo
(protects mice against arachidonic acid induced toxicity). In vitro tests of
leucocyte peroxidase also suggest tenoxicam may act as a scavenger for
active oxygen at site of inflammation. Effects probably explain in part,
activity in treatment of painful inflammatory and degenerative diseases
of musculoskeletal system. Does not act by pituitary adrenal stimulation.
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Symptomatic treatment of rheumatoid arthritis, osteoarthritis,
ankylosing spondylitis and extra-articular inflammations eg. tendinitis,
bursitis, and periarthritis of shoulders or hips.
CONTRAINDICATIONS
Should not be administered to: patients with active peptic ulcer or
active inflammatory diseases of gastrointestinal tract; patients who have
shown hypersensitivity to the drug; patients in whom acute asthmatic
attacks, urticaria, rhinitis or other allergic manifestations are precipi
tated by ASA or other NSAID’s. Fatal anaphylactoid reactions have
occured in such individuals.
Before anesthesia or surgery, should not be given to elderly patients,
those at risk of renal failure, or those with increased risk of bleeding,
because of increased risk of acute renal failure and possibility of
impaired hemostasis.
WARNINGS
Peptic ulceration, perforation and gastrointestinal bleeding,
sometimes severe and occasionally fatal reported during therapy with
NSAID's including Mobiflex®. Caution should be exercised when a
NSAID such as Mobiflex® used in patients with history suggestive of pep
tic ulcer, melena, or any gastrointestinal disease. Physician must weigh
benefits of treatment against possible hazards.
Patients taking any NSAID including this drug should be instructed to
contact a physician immediately if they experience symptoms or signs
suggestive of peptic ulceration or gastrointestinal bleeding which can
occur without warning symptoms or signs at any time.
Elderly, frail and debilitated patients appear to be at higher risk from a
variety of adverse reactions from NSAID’s. Mobiflex® should be used
with special caution in these patients.
Use in Pregnancy and Lactation - Safety of Mobiflex® during pregnancy
and lactation not established. Use not recommended.
No teratogenic effects observed in animal reproductive studies. Rats
receiving tenoxicam during pregnancy showed delayed delivery.
Tenoxicam readily passes into the milk of lactating rats.
Use in Children - Not recommended for use in patients under 16 years
as dose and indications not established.
PRECAUTIONS
Gastro-intestinal system: If peptic ulceration or gastrointestinal
bleeding occur during treatment drug should be immediately withdrawn.
No definitive evidence that concomitant administration of histamine
H2-receptor antagonists and/or antacids will either prevent occurrence
of gastrointestinal side effects or allow continuation of therapy when and
if these adverse reactions appear.
Renal function: As with other NSAID’s, long-term administration of
tenoxicam to animals has resulted in renal papillary necrosis and other
abnormal renal pathology. In humans, acute interstitial nephritis with
hematuria, proteinuria, and occasionally nephrotic syndrome reported.
A second form of renal toxicity seen in patients with prerenal con
ditions leading to reduction in renal blood flow or blood volume, where
renal prostaglandins have supportive role in maintenance of renal per
fusion. In these patients, administration of a NSAID may cause dosedependent reduction in prostaglandin formation and precipitate overt
renal decompensation. Those with impaired renal function, heart failure,
liver dysfunction, those taking diuretics, and the elderly at greatest risk.
Discontinuation of NSAID therapy usually followed by recovery to pre
treatment state.
Reversible elevation of BUN and serum creatinine reported with
Mobiflex®. Thought to result from inhibition of renal prostaglandin
synthesis resulting in changes in medullary and deep cortical blood flow
with attendant effect on renal function. Patients with impaired renal func
tion or on diuretics, elderly patients and those with congestive heart
failure or liver ascites, more at risk. During long-term therapy, kidney
function should be monitored periodically.
Hepatic Function - As with other NSAID's, borderline elevations of one
or more liver tests may occur. Abnormalities may progress, remain
essentially unchanged, or be transient with continued therapy. A patient
with symptoms and/or signs suggesting liver dysfunction, or in whom
abnormal liver test has occured, should be evaluated for evidence of
development of more severe hepatic reactions. Severe hepatic reactions
including jaundice and fatal hepatitis reported with this drug as with
other NSAID’s. Although rare, if abnormal liver tests persist or worsen,
if clinical signs and symptoms consistent with liver disease develop, or
if systemic manifestations occur (e.g. eosinophilia, rash, etc.), discon
tinue drug.
During long-term therapy, liver function tests should be monitored
periodically.
Fluid and Electrolyte Balance - Fluid retention and edema observed in
patients treated with Mobiflex®. As with many other NSAID’s, possibility
of precipitating congestive heart-failure in elderly patients or those with

compromised cardiac function should be borne in mind. Use with
caution in patients with heart failure, hypertension or other conditions
predisposing to fluid retention.
With NSAID treatment, there is potential risk of hyperkalemia
particularly in patients with conditions such as diabetes mellitus or renal
failure; elderly patients; and patients receiving concomitant therapy with
B-adrenergic blockers, angiotensin converting enzyme inhibitors or
some diuretics. Serum electrolytes should be monitored periodically
during long-term therapy, especially in patients at risk.
Hematology - Drugs inhibiting prostaglandin biosynthesis interfere with
platelet function to some degree; therefore, patients who may be
adversely affected by such action should be carefully observed when
Mobiflex® administered.
Blood dyscrasias associated with use of NSAID’s rare, but could be
with severe consequences.
Infection - In common with other NSAID’s Mobiflex® may mask usual
signs of infection.
Ophthalmology - Blurred and/or diminished vision reported with use of
Mobiflex® and other NSAID's. If such symptoms develop drug should be
discontinued and ophthalmologic examination performed; ophthalmic
examination should be carried out at periodic intervals in any patient
receiving drug for extended period.
Hypersensitivity Reactions - As with other NSAID’s, allergic reactions
may occur. Manifestations include urticaria, bronchospasm and
anaphylaxis, and in rare instances, severe skin reactions e.g. StevensJohnson syndrome and Lyell Syndrome.
Drug Interactions: ASA or Other NSAID’s - Plasma concentrations of
tenoxicam reduced to approx. 80% of normal concentrations when
single doses administered in conjunction with ASA (2,600 to 3,900
mg/day). At steady state, simultaneous administration of ASA does not
appear to have significant effect on plasma concentration of tenoxicam.
Use in conjunction with ASA or another NSAID not recommended since
data not available demonstrating that combination produces greater
improvement than that achieved with either drug alone, and potential for
adverse reactions increased.
Protein-Bound Drugs - As with other NSAID’s, Mobiflex® is highly
protein-bound, and therefore, might be expected to displace other
protein-bound drugs, such as anticoagulants, oral hypoglycemics
(sulfonylureas), phenytoin, and sulfonamides.
Short term pharmacodynamic studies demonstrated that tenoxicam
does not potentiate anticoagulant effect of coumarin-type anti
coagulants nor hypoglycemic effect of sulfonylurea drugs. However,
when a NSAID such as Mobiflex® administered concomitantly with
anticoagulants, oral hypoglycemics, or other highly protein bound
drugs, patients should be monitored and dosage adjustments made, if
necessary.
Oiuretics/Antihypertensives - As with other NSAIDs, Mobiflex® can
attenuate blood pressure lowering effect of hydrocholorathiazide and
peak excretion rates of NA+ and C1- in patients with hypertension. Close
monitoring of patients advisable. Excretion of electrolytes not
significantly affected when tenoxicam (2-day loading dose of 40 mg dai
ly, followed by 20 mg daily) administered to normotensive patients
receiving furosemide therapy (40 mg daily). Some NSAID’s reported to
reduce antihypertensive effects of certain beta-blockers. Interaction
between Mobiflex® and beta-blockers not studied.
Digoxin - In elderly patients, with normal plasma creatinine levels,
plasma digoxin levels not altered by concomitant administration of
Mobiflex® (30 mg daily).
Antacids - Administration of 15 ml of aluminum hydroxide or aluminum
and magnesium hydroxide antacid just prior to single 20 mg oral dose of
Mobiflex® did not affect bioavailability.
Cholestyramine - Average half-life of tenoxicam, after single 20 mg
intravenous dose, reduced from 67.4 hrs. to 31.9 hrs. following
administration of cholestyramine (4 g in 200 ml water p.o.t.i.d.).
Apparent drug clearance of tenoxicam increased by 105%.
Lithium - NSAID’s reported to increase steady state plasma lithium con
centrations. Recommended these concentrations be monitored when
initiating, adjusting and discontinuing Mobiflex® treatment.
Methotrexate - Co-administration of some NSAID’s and methotrexate
associated with reduced renal tubular secretion of methotrexate, higher
plasma concentrations, and severe methotrexate toxicity. Therefore,
caution should be exercised when NSAID’s, such as Mobiflex®,
administered concurrently with methotrexate. Interaction between
Mobiflex® and methotrexate not studied.
ADVERSE REACTIONS
Most common adverse reactions encountered with NSAID’s are
gastrointestinal, of which peptic ulcer, with or without bleeding, is most
severe. Fatalities have occurred, particularly in the elderly. In approx.
12,000 patients administered Mobiflex® (tenoxicam) 10-40mg/day,
(approx, four/fifths receiving 20 mg/day), incidence of peptic ulceration
and of gastrointestinal bleeding (including hematemesis and melena)
was 0.1-0.6%.
Approx, incidences of other adverse effects listed by systems are:
Gastrointestinal: (10.4-23.0%) - Dyspepsia (0.1-9.7%), nausea
(2.0-67%), constipation (0.5-2.9%), abdominal pain (07-3.3%), diar
rhea (0.5-2.3%), flatulence (0.04-1.9%), vomiting (0.2-1.1%), ulcerative
stomatitis (0.1-07% ), gastritis (0.1-0.8%), esophagitis (0.2%),
abdominal discomfort (1.4-2.2%), pyrosis (1.3-1.9%), epigastric dis
comfort (0.2-0.4% ), epigastric pain (1.8-2.5% ), hyperacidity
(0.02-0.4%), anorexia (0.05-0.4%), indigestion (0.1-0.2%), meteorism
(0.2-0.4%), gastric pressure (0.5-1.0%), mouth dryness (0.1-0.3%).
Glossitis, stomatitis, dysphagia, reflux esophagitis each reported in less
than 0.1%.
Dermatologic: (1.6-39%) - Rash (0.2-14%), pruritis (0.3-13%),

sweating (0.06-0.3%), exanthema (0.2-0.3%), itching (0.05-0.4%).
Photosensitivity reaction, seborrhea, urticaria, eczema, nail disorder
each reported in 0.1% or less of patients. One case of angioedema
reported.
Central Nervous System: (2.0-9.1%) - Headache (0.9-4.3%), dizziness
(0.8-3.3%), malaise (0.04-0.8%), parasthesia (0.02-0.5%), somnolence
(0.1-07%), vertigo (0.2-0.4%), confusion (0.2%), fatigue (0.1 -0.9%),
depression (0.6%), insomnia (0.1-0.2%). Leg cramps, nervousness,
fever, and paresis each reported in 0.1%.
Cardiovascular: Hypertension (0.02-0.3%), palpitations (0.02-0.2%),
flushing (0.02-0.03%), purpura (0.02-0.2%). Tachycardia reported in
less than 0.1%.
Hematologic: Anemia (0.04-0.3%), leukopenia (0.04-0.4%). Thrombo
cytopenia reported in 0.1% or less.
Renal: Haematuria (0.02-0.2%), edema (0.2-1.3%), micturition
frequency (0.02-0.3%), polyuria (0.03-0.1%). Dysuria, cystitis,
increased BUN, increased creatinine, and albuminuria each reported in
less than 0.1% of patients. Isolated cases of abnormal renal function and
one case of renal failure reported.
Hepatic: (0.06-0.4%) - Abnormal hepatic function (0.3%). Jaundice,
increased SG0T, SGPT, gamma GT and bilirubin each reported in less
than 0.1%. Hepatitis, hepatic coma and hepatic failure each reported
once.
Respiratory: (0.02-0.65%) - Dyspnea (0.2%), bronchospasm (0.1%).
Eyes, Ears, Nose, Throat: - Vision abnormal (0.02-0.3%). Diplopia,
conjunctivitis, tinnitus, deafness, epistaxis, abnormal lacrimation each
reported in 0.1% or less.
SYMPTOMS AND TREATMENT OVERDOSE
Cases of overdoses not reported. In event of overdosage with Mobiflex®,
supportive and symptomatic therapy indicated.
DOSAGE AND ADMINISTRATION
Single daily dose of 20 mg Mobiflex® (tenoxicam) should be taken orally
at the same time each day. Higher doses should be avoided as they do
not usually achieve significantly greater therapeutic effect, but may be
associated with higher risk of adverse events.
In some patients a 10 mg (1/2 tablet) daily dose may be sufficient.
Smallest effective dose should be prescribed.
Use In elderly - Mobiflex® should be used with special caution in elderly
patients since they may be less able to tolerate side effects than younger
patients. Also more likely to be receiving concomitant medication or
have impaired hepatic, renal or cardiovascular function.
AVAILABILITY
Yellow film coated, oblong 20 mg tabs, single scored on one side,
imprinted ’ROCHE’. Available in white opaque density polyethylene
bottles of 100 tabs.
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T h e Maintenance of Competence
(MOCOMP) Program: Motivating
Specialists to Appraise the Quality
of Their Continuing Medical
Education Activities
I. John T. Parboosingh, MB, ChB, FRCOG, FRCSC;* S. Tunde Gondocz, MScf
The goal of the Maintenance of Competence (MOCOMP) Pilot Project is to develop a
comprehensive CME strategy that will motivate specialists to continuously update
their clinical practice. In its 1st year the pilot program has taken several significant
steps. A credit system has been implemented to facilitate recognition of CME of the
highest educational quality and to encourage specialists to compare their CME
efforts with those of their colleagues. The self-directed CME curriculum currently
followed by the typical MOCOMP Program member has been described. A diary has
been implemented for specialists to record CME activities and their potential impact
on practice. The MOCOMP Program is the first attempt to motivate self-directed
continuing medical education (CME) through the use of a diary and the first attempt
to use this instrument to encourage critical appraisal of personal CME habits.

Le but du projet pilote de maintien des competences (MOCOMP) est de developper
une strategic globale de FMC qui va inciter le specialiste a continuellement remettre
a jour sa pratique clinique. Dans sa premiere annee d’application, le programme
pilote a franchi plusieurs etapes importantes. Un systeme de credits a ete instaure
en vue de faciliter la reconnaissance d’une FMC des plus hauts standards de qualite
et d’encourager les specialistes a comparer leurs efforts de FMC a ceux de leurs
collegues. On decrit ici le programme courant de FMC auto-geree suivi par un
participant type au programme MOCOMP. Un journal a ete develope pour permettre
aux specialistes de consigner leurs activites de FMC et d’enregistrer Timpact
qu’elles peuvent avoir sur leur pratique. Le programme MOCOMP constitue la
premiere tentative pour promouvoir la formation medicale continue (FMC)
auto-geree par Tutilisation d’un journal; c’est aussi la premiere utilisation de cet
instrument pour encourager une evaluation critique des habitudes personnelles de
FMC.
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Canada, Ottawa, Ont.
fResearch associate, MOCOMP Pilot Project, Royal College o f Physicians and Surgeons o f
Canada, Ottawa
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ost programs of maintenance
of competence (MOCOMP) op
erate through legislation, which
mandates continuing medical educa
tion (CME) or re-certification by
examination. Nineteen specialty
boards in the United States have
introduced time-limited certifica
tion, and mandatory CME is in
place in many states. The Royal
Australian College of Obstetricians
and Gynaecologists has linked man
datory CME to licensure since
1988.
The MOCOMP Program of the
Royal College of Physicians and
Surgeons of Canada will achieve its
objectives by encouraging special
ists to apply the principles of total
quality management to their CME
efforts. This involves examining the
resources used, the outcome of
their CME efforts and the process
whereby these outcomes are
achieved.
CME resources are the time com
mitted and the CME methods used
(e.g., reading, conferences, rounds).
Data on the CME resources used by
members of the MOCOMP Pilot
Project (MOCOMP Bulletin January
1993) show that teaching and re
search (Type III CME activities)
account for more than 50% of the
time spent undertaking CME. Al-
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though scholarly activities certainly
contribute to MOCOMP, the rela
tionship is not always easily de
scribed. Furthermore, this CME ac
tivity is more likely to be driven by
the needs of students and research
programs than by the needs of
patients. The data suggest a need to
define and record the outcomes of
CME efforts, namely the clinical
problems in current practices that
have been reviewed and updated.
The model of a self-directed CME
curriculum (Fig. 1) describes the

process whereby MOCOMP Pro
gram members use CME resources
to achieve the outcomes that have
impact on their clinical practice.
Physicians obtain information on
a daily basis from a multitude of
sources. Some professional activi
ties (e.g., rounds, journal reading)
are used primarily to scan for new
information that may enhance clini
cal practice, whereas others (e.g.,
consultations, teaching, research)
are undertaken primarily for other
purposes. Both are rich sources of

LEVEL I: General professional activity (e.g., reading, teaching, consultation)

I
LEVEL II: In-depth review (e.g., in-c
in-depth reading, practice audit)
(All LEVEL II activities should
tioulc lead to an outcome)

I
I will modify
my practice

I will wait for information
before modifying my practice

I see no need to
modify my practice

FIG. 1. Model of self-directed continuing medical education (CME) curriculum.

SAMPLE: SELF-DIRECTED CME
CLINICAL ISSUE OR PROBLEM under review (print and underline keywords):

Si- FOLiC
/V T l)

ZcT
( fJ e u / Z A -c T u & g : d t P e c f s )

Circle code for CME method used (as many as appropriate):
A S A RESULT O F THIS C M E A C T IV IT Y (ch e c k ONLYcne):
y31 modify
[ ] I will wait for more [ ] I see no need to

W \\

rnY practice

Information before
modifying my practice

modify my practice

(

Dots'

Im TTL
mm yy

'T o ta l h o u r^

//,
FIG. 2. Record of self-directed CME taken from MOCOMP diary.
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new ideas and opportunities to up
date patient care practices. This
CME activity, whereby physicians
scan their professional environment
for new ideas, is referred to as level
I CME activity in our model. These
CME activities are too numerous to
be recorded by busy practitioners.
As important as they are, level I
activities rarely motivate specialists
to initiate a change in practice.
Some of the information derived by
scanning the environment, however,
captures the attention of the spe
cialist, who perceives an opportuni
ty to improve on the management
of a clinical problem.
CME resources (e.g., reading, dis
cussions, programs, rounds) are
now used in a more focussed man
ner to seek answers to the follow
ing three questions:
• What is the state-of-the-art
method of managing this problem?
• What is my current method of
managing this problem?
• What method of management
are my colleagues using?
This CME activity, termed level II
CME, differs from level I activity in
that it focuses on a specific clinical
problem and requires a more indepth use of CME resources. Level
II CME is goal oriented and always
comes to one of three possible
conclusions (or outcomes) regard
ing the management of the clinical
problem under review: (a) “ I have
decided to make a change in my
management of this clinical problem
as a consequence of this CME activ
ity” ; (b) “ I will wait for further
information before making the deci
sion to modify my practice” ; or (c)
“I see no need to change my prac
tice; I am satisfied with my current
approach to the management of this
clinical problem.”
The recording of self-directed
CME in the MOCOMP diary (Fig. 2)
has been restricted to level II CME
activity — those activities that ad
dress specific topics in sufficient

MOCOMP PROGRAM

depth for specialists to express the
potential impact on their practice.
MOCOMP Program members will
receive feedback of their CME activ
ities in the form of an annual CME
profile.

The MOCOMP Annual CME
Profile

A summary of diary entries, in
cluding attendance at conferences
registered in the MOCOMP Pro
gram will be sent to each specialist
annually along with aggregate data
computed from submissions by col
leagues in the same specialty and
practice setting. The main purpose
of providing an annual CME profile
is to assist specialists to appraise,
critically, the quality of their CME
activities. It is designed to encour
age specialists to review their CME
activities, discuss their results with
their colleagues and plan their CME
for the coming year. The profile will
consist of two sections.
Section A: Group and Type II CME

This section of the annual CME
profile will give specialists a sum
mary of the number of MOCOMP
credits earned, the mean credit rat
ing and the number of hours spent
attending rounds and conferences
as well as aggregate data obtained
from colleagues in the same special
ty and practice setting.

methods used and the outcome des
ignated to each topic recorded in
the MOCOMP diary during the year
(Table I).
A directory of keywords, CME
methods used and outcomes desig
nated to topics recorded during the
year by colleagues will also be in
cluded with the CME profile. The
topics entered into the diary should
be compared with the specialist’s
practice profile or case mix. All
specialists should be working to
ward obtaining data on their case
mix from computer records and
using these data to determine the
direction of their CME efforts.
The topics reviewed by the spe
cialist in the past year should be
compared with those reviewed by
colleagues in the same specialty and
practice setting. This exercise,
whereby we are kept informed of
the CME activities of our colleagues
(the topics they studied, the CME
methods used and the outcome des
ignated to each topic), is intended
to motivate the individual to keep
up to date.
A national specialty society may
use aggregate data obtained from
the annual CME profiles of its mem
bers to plan educational programs.
The data from the CME profiles of
members of a national specialty
society may serve as an important
method of needs assessment for a
national education program. For in
stance, the fact that members have
reviewed a specific topic during the
year and are waiting for more infor

mation before changing their prac
tice may be an indication for a
national or regional education ses
sion on that topic. The data from
the CME profiles will provide a
society with information on the
CME methods used by its members.
This information may be used to
plan future needs such as computer
learning programs and audiotapes.
Also, the data from CME profiles
may be used to monitor the re
sponse of society members to new
information. For instance, a society
may promote the recommendations
that result from a multicentred ran
domized trial. The response to
these recommendations can be
monitored by searching for the rele
vant keywords and identifying the
potential impact on practice (out
come codes) recorded in the CME
profiles of its members.

Summary

The Royal College MOCOMP
Pilot Project has taken several sig
nificant steps in its 1st year. A
credit system has been implemented
to facilitate recognition of CME of
the highest educational quality and
to encourage specialists to compare
their CME efforts with those of
their colleagues. The self-directed
CME curriculum currently followed
by the typical MOCOMP Program
member has been described. A diary
has been implemented for special
ists to record CME activities and

Section B: Self-directed CME

This section will provide a sum
mary of the number of individual
topics submitted by the specialist in
the year and the number of hours
spent in self-directed CME as well
as data, in aggregate form, submit
ted by colleagues.
The annual CME profile will in
clude, for the individual specialist, a
list of the keywords, the CME

Table I. Example of an Entry from an Annual Continuing Medical Education (CME) Profile
Item no.

CME code

Keywords

Outcome code

4*
5t

1,2,6
1,2,6

Folate, NTDs
PROM, antibiotics

1
2

*The role of folate in preventing fetal neural tube defects (NTDs) has been reviewed, using journal
reading, a literature search and preparing a seminar (CME codes 1, 2 and 6 respectively); the
outcome code (1) indicates the specialist’s intention to modify current practice as a consequence
of this review.
fThe role of antibiotics in premature rupture of the membranes (PROM) has been reviewed by the
same methods as those in item 4 (CME codes 1, 2 and 6); the outcome code (2) indicates the
specialist's intention to wait for more information before changing practice.
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their potential impact on practice.
Data will be fed back in the form of
an annual CME profile.
The MOCOMP Program is the
first attempt to motivate self-direct
ed CME through the use of a
diary and the first attempt to use
this instrument to encourage criti
cal appraisal of personal CME ha
bits. This unique component of

MOCOMP has created much atten
tion around the world where physi
cians are concerned about regula
tion of CME through examination.
The program is developing stan
dards for lifelong learning which,
when evaluated appropriately,
should be introduced into residency
training programs. Finally, a credi
ble program of research is develop

ing around the MOCOMP project to
answer questions regarding the re
lationship between CME and quality
of care and, in the future, to pro
vide information concerning the
relationship between performance in
residency training programs, CME
habits in practice and the quality
of care provided by practising
specialists. ■

book will provide endless pleasure for
all who have an interest in the human
frame, its failure and its repair. The
book will appeal to anyone involved in
medical care who is curious about its
origins or who has heard at college or
university names of the medical pio
neers. Who knows, you may even find
out what happened to Virchow!

Moreover, the book claims to be benefi
cial for residents in colorectal surgery,
pediatric surgery and vascular surgery.
It comprises a series of questions on
the content of each chapter of the main
textbook. Each question is followed by
a brief critique, and the correct answer
is given. The number of questions for
each chapter range from 12 (“The
management of acute trauma”) to 125
(“Cardiac surgery”).
The critiques are readable, compact,
well-written and clear, and the book is
probably helpful in emphasizing the
aspects of each chapter that the authors
feel to be of importance.
I found that the format is not condu
cive to proper study. Each critique and
answer is placed immediately after the
question. The temptation to skip to this
part before thinking over the question
and truly testing one’s knowledge is
almost overwhelming. It would be bet
ter if the questions were together and
the critiques were in a separate section,
similar to the format employed in the
SESAP syllabus.
It seems inherently improbable that
one compact volume could be helpful to
everybody from a medical student to a
subspecialist in one area of general
surgery although, clearly, there are
parts that may be helpful to each
particular level of training.
Overall, I found this to be an inter
esting companion for anybody who hap
pens to be in possession of Sabiston’s
textbook (14th edition). It is fun to dip

BOOK REVIEWS
continued from page 18

trove of information on a group of
remarkable people. The illustrations are
both intriguing and plentiful. They
show in the faces of both surgeons and
patients the Zeitgeist of their times.
The third section of the book is
devoted to a wide variety of special
subjects and covers the historical as
pects of almost everything from ampu
tations to orthopedic implants.
The fourth section is a station stop
at the turn of the century — a pause to
reflect on the state of the art at that
time, what had been achieved and what
was to come.
The book ends with reference to the
impetus wars have given to trauma
surgery, which arose from the sheer
necessity to keep soldiers alive and
capable of fighting again, or at least to
rehabilitate the veterans. Homer’s ob
servations on war injuries are well re
corded in the Iliad, and Roman Army
surgeons 2000 years ago were early
developers of pylons for immediate fit
ting to battlefield amputees.
David LeVay was a practising consul
tant orthopedic surgeon in London,
England, for over 30 years, after which
he spent a year working in Africa and
Australia. He has always been a writer
and at various times an editor and a
translator of French and German works.
He is also a gifted author, having
completed the monumental task of as
sembling historical facts and knowledge
on what is now orthopedic surgery. He
has chosen a very attractive way of
presenting his information as a blend of
history, anecdote and reference. This
32
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Charles Sorbie, MB, ChB, FRCS(Edin),
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Professor and head
Department o f Surgery
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Kingston, ON
K7L 3N6

SABISTON REVIEW OF SURGERY.
David C. Sabiston Jr. 291 pp. Illust.
W.B. Saunders Company, London;
Harcourt Brace Jovanovich, Inc., Phil
adelphia; HBJ-Holt-Saunders Distri
bution Services, Toronto. 1992.
$37.95. ISBN 0 -7 2 1 6 -3 5 3 4 -2

This paperback book is a companion to
the 14th edition of Textbook o f Sur
gery: The Biological Basis of Modern
Surgical Practice.
According to the preface, medical
students, surgical residents and practis
ing surgeons will benefit from reading
this book; it will be useful for revision
of basic surgical science in preparation
for the Board examinations, for ortho
pedic surgeons, neurosurgeons, otola
ryngologists, plastic surgeons, maxil
lofacial surgeons and neurologists.

continued on page 70
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T h e Value of Prostate-Specific Antigen
Levels in Pelvic Lymph Nodes
for Diagnosing Metastatic Spread
of Prostate Cancer
Daniel A. Shoskes, MD; John Trachtenberg, MD, FRCSC
Curative radical therapy for prostate cancer depends on accurate diagnosis of
metastatic spread to pelvic lymph nodes. The authors measured prostate-specific
antigen (PSA) levels in homogenized pelvic lymph nodes to determine the antigen’s
diagnostic value and its correlation with histologic findings. No PSA was detectable
in the lymph nodes of either women or of men without prostate cancer. A dilution of
prostate cancer tissue with nodal tissue showed that PSA is detectable in this assay
to a concentration of 1:100 000. In 38 patients who underwent pelvic lymph node
dissection for staging stage B prostate cancer the histologic findings were correlated
with PSA content. All nine patients with histologic evidence of metastatic disease
had measurable PSA in their nodes. Of the 29 patients with no histologic evidence
of metastatic disease, 23 had no detectable PSA in their nodes. The six patients with
negative histologic findings and positive findings for PSA had no progression of
disease at 18-month follow-up. The authors conclude that the measurement of PSA
in pelvic lymph nodes can add substantial information to that obtained by standard
histologic examination.
Le traitement radical du cancer de la prostate a visee curative depend du diagnostic
precis de l’envahissement metastatique des ganglions pelviens. Les auteurs ont
mesure les taux d’antigene prostatique specifique (APS) dans un homogeneisat de
ganglions lymphatiques pelviens, afin d’etablir l’interet de cet antigene pour le
diagnostic et sa correlation avec l’examen histologique. Aucun APS n’a ete decele
dans les ganglions lymphatiques de femmes ou dans ceux d’hommes qui n’avaient
pas le cancer de la prostate. La dilution de tissu prostatique cancereux et de tissu
ganglionnaire a montre que TAPS etait decelable par cette technique de dosage
jusqu’a conurrence de 1:100 000. Chez 38 patients soumis a une dissection des
ganglions pelviens pour la determination du stade B de revolution du cancer de la
prostate, les resultats histologiques ont ete mis en rapport avec la teneur en APS.
Les neuf patients qui presentaient des signes histologiques de metastases avaient
tous des taux mesurables d’APS ganglionnaire. Des 29 patients sans signes
histologiques d’envahissement metastatique, 23 n’avaient pas d’APS decelable dans
les ganglions. Les six patients ayant des resultats histologiques negatifs et un test
positif pour l’APS n’avaient pas montre devolution de la maladie apres 18 mois de
surveillance. Les auteurs concluent que le dosage de TAPS dans les ganglions
lymphatiques pelviens peut ajouter une information importante a l’examen
histologique standard.
From the Division o f Urology, The Toronto Hospital,
Toronto, Ont.
Accepted for publication Jan. 10, 1992
Reprint requests to: Dr. John Trachtenberg, Division o f Urology, The Toronto Hospital,
200 Elizabeth St., Toronto, ON M5C 2C4

treatment for clini
T hecallyoptimal
localized prostate cancer

remains controversial. Radical cura
tive therapy (radiotherapy or sur
gery) is based on the premise that
the tumour has not spread beyond
the confines of the prostate. The
standard diagnostic manoeuvre
prior to radical therapy is a bilateral
pelvic lymph node dissection, in
cluding the obturator and external
iliac nodes. Processing the nodes by
frozen section at the time of radical
prostatectomy is labour intensive,
delays surgery and is associated
with a 10% to 20% false-negative
rate.
Prostate-specific antigen (PSA)
is a serine protease that is speci
fic to the prostate and has enjoyed
widespread use as a serum marker
for detecting and for monitoring
prostate cancer.1-3 As well, it can
be used in an immunoperoxidase
stain to identify metastatic prostate
cancer in the lymph nodes45 and
in other tissues.6 The existence
of PSA in the pelvic lymph nodes
of healthy men is not known, and
there are no data available on the
ability to detect nodal spread of
prostate cancer by the measurement
of tissue PSA. To address these is
sues, we studied the tissue content
of PSA in normal lymph nodes and
in malignant lymph nodes in an
attempt to correlate histologic find
ings with the presence of the tu
mour marker.
CJS, VOL. 36, NO. 1, FEBRUARY 1993
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Materials and Methods
Controls
To determine the presence of
PSA in normal pelvic lymph nodes,
PSA was measured in the pelvic
nodes of 42 women and men (both
young and old) without prostate
cancer. The nodes from women and
men older than 40 years were ob
tained at the time of cystectomy for
transitional cell carcinoma; nodes
from men 40 years of age or youn
ger were obtained from cadaveric
organ donors. The serum PSA level
was normal in all men. No prostate
cancer was noted in the histologic
analysis of the prostates removed
during cystoprostatectomy.
Assay Sensitivity
To determine the maximum sen
sitivity of the assay to detect lymph
node PSA, normal lymph nodes
from female cadaveric organ donors
were serially diluted with malignant
prostatic tissue obtained from radi
cal prostatectomy specimens. The
lymph nodes were minced, homoge
nized and mixed with homogenized
prostate cancer tissue of known
PSA content. Serial dilutions were
continued to a concentration of 1:1
X 10-6 of prostate. Each assay was
adjusted to 2 mg of protein/mL of
assay. All PSA levels were deter
mined by Hybritech R reagents and
techniques (Hybritech Div. Eli Lilly
Inc., Canada, Toronto). All assays
were performed in triplicate.

made) level, total body bone scan
and abdominal and pelvic computed
tomography (CT). PSA was less
than 25 ng/mL (normal less than
2.25 ng/mL) in all cases. Before
prostatectomy, a modified pelvic
lymph node dissection was per
formed to include obturator and
external iliac nodes. All nodal tissue
was submitted for frozen section
histologic examination. In addition,
the highest node in the iliac dissec
tion was bisected and half was snap
frozen in liquid nitrogen, then
stored at —70°C for later analysis
for PSA. The other half was sent
for histologic examination. Patients
with positive lymph nodes on quick
histologic section did not undergo
radical prostatectomy.
Nodes for PSA determination

were thawed and homogenized,
then sonocated. After centrifuga
tion, the specimen was weighed,
then analysed for protein content.
All specimens were adjusted in con
centration to 2 mg of protein/mL,
then processed by the Hybritech R
PSA assay.

Results
Pure homogenates of prostate
cancer tissue had PSA levels great
er than 200 pg/L (Table I). Female
lymph nodes had no measurable
PSA. When the homogenate of fe
male lymph nodes was serially dilut
ed with the homogenate of prostate
cancer tissue, PSA was detectable
to a dilution of 1:100 000. Similar-

Table 1. S e n s itiv ity o f P ro s ta te -S p e c ific A n tig e n (P S A )*
Tissue

Dilution

PC
L ym p h n o d e 1
L ym p h n o d e 2
Lym ph node 3
PC 1
PC 2
PC 3
PC 1
PC 2
PC 3
PC 1
PC 2
PC 3
PC 1
PC 2
PC 3
PC 1
PC 2
PC 3
PC 1
PC 2
PC 3

PSA (Mg/L)

No d ilu tio n
No d ilu tio n
No d ilu tio n
N o d ilu tio n
1 :1 0
1 :1 0
1 :1 0
1 :1 0 0
1 :1 0 0
1 :1 0 0
1 :1 0 0 0
1 :1 0 0 0
1 :1 0 0 0
1 :1 0 0 0 0
1 :1 0 0 0 0
1 :1 0 0 0 0
1 :1 0 0 0 0 0
1 :1 0 0 0 0 0
1 :1 0 0 0 0 0
1:1 0 0 0 0 0 0
1:1 0 0 0 0 0 0
1:1 0 0 0 0 0 0

> 200
N o t d e te c te d
N o t d e te c te d
N o t d e te c te d
> 200
> 200
> 200
> 200
> 200
> 200
> 200
> 200
> 200
37.1 ± 1 .2
2 5 .2 ± 2 .2
2 0 .2 ± 2 .2
4 .2 ± 0 .4
5 .2 ± 0 .3
4 .7 ± 0 .4
N o t d e te c te d
N o t d e te c te d
N o t d e te c te d

'P ro s ta te ca n c e r (P C ) w a s s e ria lly d ilu te d w ith h o m o g e n iz e d fe m a le ly m p h -n o d e tis s u e . A ll
a ssays w e re a d ju s te d to 2 m g p ro te in /m L .

Study Group
Thirty-eight men with clinical
stage B7 prostate cancer having
negative findings on investigation
for metastatic disease consented to
radical prostatectomy. The investi
gations for metastatic disease con
sisted of measurement of the serum
prostatic acid phosphatase (enzy34
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Table II. P re s e n c e o f P SA in L y m p h N odes o f 4 2 P atie n ts W ith o u t P ro s ta te C ancer
Sex (age, yr)
Fem ale
Fem ale
M ale ( <
M ale ( <
M ale ( >
M ale ( >

40)
40)
40)
40)

No. of
patients
6
4
8
8
8
8

Location of
lymph node
P elvis
Abdom en
P elvis
A bd o m e n
P elvis
Abdom en

PSA
N ot
N ot
N ot
Not
Not
Not

d e te c te d
d e tecte d
d e tecte d
d e tecte d
d e tecte d
d e tecte d

PSA LEVELS IN PELVIC LYMPH NODES

ly, in all lymph node specimens
from women or men without pros
tate cancer, no PSA was detected
(Table II).
Of the 38 men with prostate
cancer, 8 had positive lymph nodes
on frozen section histologic exami
nation. All had PSA detected in
their lymph node homogenates (Ta
ble III). One further patient had
negative nodes on frozen section
but was later found to have positive
metastatic nodes on permanent sec
tion. This patient had detectable
PSA in the lymph nodes.
Of the 29 men with negative
lymph nodes on histologic examina
tion, 23 had no detectable lymph
node PSA. Six men, however, had

detectable lymph node PSA despite
a negative histologic diagnosis.
None of these patients subsequently
had recurrent or metastatic disease,
although the follow-up was short
(range from 5 to 18 months).

Discussion
By definition, for radical therapy
of prostate cancer to be curative,
the lesion must be localized to the
prostate. Preoperative assessment
of nodal spread is limited by the
efficacy of the imaging and bio
chemical modalities available. CT
can only detect substantially en
larged nodes, while pedal lymphan

Table III. Biochemical and Pathologic Comparison of PSA in Pelvic Lymph Nodes
Patient
no.
1

2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
* - = negative, + = positive

Histologic
findings*
—
-

+
-

+
+
-

+
-

+
-

+
-

+
-

+
+
—
-

Tissue PSA

Serum PSA (ng/mL)

Not detected
Not detected
Detected
Not detected
Detected
Not detected
Detected
Detected
Detected
Not detected
Detected
Detected
Not detected
Detected
Not detected
Not detected
Not detected
Detected
Not detected
Not detected
Detected
Not detected
Detected
Not detected
Detected
Not detected
Not detected
Not detected
Detected
Detected
Detected
Not detected
Not detected
Not detected
Not detected
Not detected
Not detected
Not detected

12
8
9
15
9
11
12
8
17
6
12
8
9
15
9
5
12
18
17
5
12
8
9
15
9
11
12
8
17
15
12
8
4
6
3
5
4
6

giography may miss obturator or
presacral nodes. Serum PSA values,
when markedly elevated, almost al
ways suggest locally aggressive or
metastatic disease, or both;8 howev
er, there is considerable overlap at
intermediate levels. Pelvic lymph
node dissection is the gold standard
for diagnosing stage D1 disease.
The reliance on quick-section inter
pretations at the time of surgery
may understate by as much as 10%
to 20%.
This preliminary study set out to
establish that the concentration of
PSA found in pelvic lymph nodes of
men with prostate cancer could be
used to determine the presence of
lymph node metastasis. The use of
a biochemical marker theoretically
could be more sensitive and specific
than histologic examination, partic
ularly with low volume of disease.
Because the presence of any nodal
disease portends a significantly
worse prognosis,9 this greater sensi
tivity could spare patients the mor
bidity of noncurative radical ther
apy. For those who believe that
lymph node metastasis is not a
contraindication to radical ther
apy,10 the diagnosis of D1 disease
still adds prognostic information
and aids in the treatment stratifica
tion. With the increased interest in
laparoscopic pelvic lymph node dis
section, PSA assay of the removed
nodal tissue mass may be easier
than standard histologic means
(Gerald W. Chodak, personal com
munication, 1992).
By using appropriate controls, we
demonstrated that PSA could not
be detected in normal lymph nodes
and that PSA could be measured in
very low concentrations in cancer
ous nodes, probably in the order of
1 cancer cell per 10 000 normal
cells. Put another way, this theoret
ically could detect one cancer cell in
less than 0.1 mg of tissue.
This study also demonstrated an
excellent correlation between the
CJS, VOL. 36, NO. 1, FEBRUARY 1993
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presence of PSA in pelvic nodes and
the presence histologically of metastases in pelvic nodes. All the men
with positive histologic findings had
PSA detected in their nodes. Six of
23 men with negative histologic
findings, however, were found to
have PSA in the pelvic nodes. It is
interesting to speculate whether
this result is in keeping with the
observation that metastatic disease
still develops in 20% to 35% of men
who undergo node dissection for
prostate cancer and have negative
findings on permanent sections.
Further follow-up of these patients
will determine whether this assay
has a 25% false-positive rate or
whether in fact it allows the identifi
cation of patients with unsuspected
low-volume metastatic disease.
Finally, although the current
PSA assay takes too long for practi
cal intraoperative use, the develop
ment of newer enzymatic assays
seeking an “all-or-nothing” effect
could eventually be faster and less
subjective than histologic analysis.
These solid-state assays have been
developed for the determination of
small concentrations of substances
in plasma, and the entire procedure
usually takes less than 15 minutes.
They require no special expertise or
processing and would be extremely
inexpensive to perform. The tests
are presently being developed com
mercially. The ideal situation, how
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ever, will probably combine the in
formation the two tests provide,
because tissue PSA may be able to
detect metastasis too small to see
with light histology, and very poor
ly differentiated tumours that do
not express PSA511 still could be
recognized by histologic appear
ance.

Conclusions
Measurement of PSA in nodal
tissue is a viable diagnostic tool
that correlates well with histologic
examination for metastatic prostate
cancer. PSA in nodes of women and
of men without prostate cancer was
undetectable, whereas all men with
positive nodes on histologic exami
nation had measurable PSA. Six
men with negative histologic find
ings had positive nodal PSA, sug
gesting either a 25% false-positive
rate or that this technique can
detect previously unmeasurable
low-volume metastatic disease. Res
olution of this will require larger
numbers with longer follow-up be
cause of the slow growth rate of the
disease.
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A Review of 1486 Transurethral

Resections of the Prostate in a Teaching
Hospital

Eric P. Estey, MD; David R. Mador, MD, FRCSC; Malcolm S. McPhee, MD, MSc, FACS, FRCSC
The authors reviewed retrospectively 1486 consecutive transurethral resections of
the prostate (TURP) gland performed in a teaching hospital between 1985 and
1987. The death rate was 0.8% in an institution where senior residents were the
primary resectionists in approximately 75% of TURPs. The results of this review are
compared with those of a 1974 study of 2223 patients. They indicated that TURP
was a reasonably well-tolerated surgical procedure in the training environment and
was associated with lower mortality and morbidity and a shorter hospital stay for the
patient than in the 1974 study. The authors believe that with proper supervision
and instruction, resident urologists can obtain satisfactory results while gaining
competence and experience in performing TURPs.

Les auteurs ont etudie de fa?on retrospective 1486 resections transuretrales de la
prostate (RTUP) consecutives pratiquees dans un hopital d’enseignement entre
1985 et 1987. Le taux de mortalite a ete de 0,8 %dans un etablissement ou les
residents seniors etaient les premiers intervenants dans 75 %des RTUP. Ces
resultats ont ete compares a ceux d’une etude realisee en 1974 chez 2 223 patients.
Ils indiquent que la RTUP est une intervention chirurgicale raisonnablement bien
toleree en milieu de formation, et qu’elle est reliee a une mortalite et a une
morbidity plus faibles et a un sejour hospitalier plus court que pour les patients de
1974. Les auteurs croient qu’avec une surveillance et des instructions adequates, un
resident en urologie peut obtenir des resultats satisfaisants tout en acquerant
competence et experience dans l’execution des RTUP.

50 years have passed since
O ver
transurethral resection of the
prostate (TURP) gland was devised
to relieve bladder outlet obstruction
for those with benign or malignant
disease. It has been estimated that
the probability of a 40-year-old man
undergoing a prostatectomy during

his lifetime is 29%, and 90% of
patients who undergo an operation
for bladder outlet obstruction will
have a TURP.12 The mortality from
TURP has declined steadily over the
past 30 years, with rates as low as
0.2% quoted in the American Uro
logical Association Cooperative
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Study in 1988.3 The literature con
tains numerous reviews indicating
that TURP is a reasonably safe
procedure; however, few surveys
have evaluated the safety of TURP
for neophyte resectionists.
The purpose of this review is to
evaluate the urologie care provided
in a teaching hospital to determine
if resident participation influences
patient morbidity or mortality. A
common surgical procedure, TURP,
is the basis of this evaluation.

Patients and Methods
Hospital charts of all 1486 con
secutive patients who underwent
TURP in one institution between
1985 and 1987 were reviewed.
Each record was examined with
respect to 25 variables. This review
deals with patient evaluation, resec
tion methods and early postopera
tive complications.
The evaluation was performed at
the Royal Alexandra Hospital, Ed
monton, a teaching institution affili
ated with the University of Alberta.
Senior urology residents obtain a
portion of their training at this
centre under the supervision of staff
urologists. Endoscopy is an impor
tant part of their training. The
urology resident is the primary resectionist in approximately 75% of
the TURPs performed at the hospi
tal. The resident receives superviCJS, VOL. 36, NO. 1, FEBRUARY 1993
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sion and instruction from the at
tending urologist during the opera
tion with periodic endoscopic as
sessment of the resection.
The resections were carried out
in the conventional fashion, resect
ing prostatic adenoma down to the
fibres of the surgical capsule. Re
sections were performed with inter
mittent irrigating resectoscopes,
using either 1.5% glycine solution
or distilled water as an irrigant. All
600;
534

patients with a positive urinary cul
ture, bacteriuria or indwelling Foley
catheters were given appropriate
antibiotics pre- and postoperatively.
Others were maintained on appro
priate antibiotics for several days
postoperatively. A Foley catheter,
with intermittent or continuous
bladder irrigation, was maintained
for at least 24 hours postoperative
ly. Postoperative hospital stay in
cluded the time from surgery to
discharge or patient death.
Major nonfatal complications
were noted. The overall mortality
included any death that occurred
while the patient was hospitalized,
even if it was not directly related to
the prostatectomy.

Findings
Patients
0 -4 5

4 6 -5 0 5 1 -6 0

6 1 -7 0

7 1 -8 0

8 1 - 9 0 91-10 0

Age, yr

FIG. 1. Age distribution of patients
who underwent transurethral resection
of prostate (TURP) between 1985 and
1987.

The average age was 63 years
(Fig. 1). Physical condition was
based on the American Society of
Anaesthesiologists (ASA) physical
status classification4 from 1 (no
systemic disease) to 5 (moribund
patients with little chance for sur
vival). The patients were fairly even
ly divided between class 1 and class
2 (644 patients [43.3%] and 751
[50.5%]). Only 91 patients (6.2%)
were class 3 or 4 (Fig. 2).
Laboratory Findings
The serum creatinine level was

T a b le 1.

determined before TURP. Table I
shows the distribution of patients
with normal and elevated serum
creatinine levels according to
whether 1.5% glycine or distilled
water was used as an irrigating
fluid. The group with elevated
serum creatinine levels and using
distilled water had a death rate of
3.8%.
Operative Findings
The operative technique and re
sults are noted in Table II. The
patients underwent TURP with in
termittent irrigating resectoscopes
using 1.5% glycine in 36% of cases
and distilled water in 64% of the
cases. Average time for the opera
tion (patient in theatre until transfer
to recovery room) was 60 minutes.
Anesthesia was fairly evenly distrib
uted between general and spinal.
The average decrease in the hemo
globin level was 14.2 g/L , and 9%
of the patients required at least one
unit of packed cells within 10 days
of operation. The average postoper
ative hospital stay was 5.75 days.
The average stay decreased during
the 3-year period of the study by 1
day.
Pathological Findings
The weight of prostatic tissue
resected ranged from 0.6 g to 160
g (Fig. 3). The average weight of
resected prostate was 24.3 g.
Pathological examination of the

Serum Creatinine Levels Before Transurethral Resection of the Prostate (TURP),
According to Type of Irrigant Used
W a te r

FIG. 2. American Society of A n e s 
thesiologists (ASA) classification of
physical condition. 1 = no systemic
disease, 2 = mild systemic disease, 3 =
moderate systemic disease, 4 = severe
systemic disease, 5 = moribund.
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C re a tin in e, ^ m o l/L

< 130
> 130
Total*

Glycine

P atien ts,
no. (%)

D eaths,
no. (% )

P atien ts ,
no. ( % )

D eaths,
no. (% )

830 (88.6)
106 (11.4)

5 (0.6)
4 (3.8)

445 (84.4)
82 (15.6)

3 (0.7)
0

936 (100)

9 (0.46)

527 (100)

3 (0.56)

*ln 23 patients the serum creatinine level was not measured before operation.

TRANSURETHRAL RESECTIONS OF THE PROSTATE

specimens revealed that 85% were
benign and 15% were malignant.

records and therefore are not in
cluded in this review.

Complications

Mortality

Major nonfatal complications oc
curred in 7.8% of the patients (Ta
ble III). Cardiovascular and throm
boembolic events complicated the
course of 1.1% of our patients.
Documented hyponatremia and
transurethral resection syndrome
were found in only 0.5%. Patients
who were readmitted for postopera
tive bleeding or repeat resection
were only accounted for if they
were readmitted to the Royal Alex
andra Hospital.
Minor complications were incon
sistently documented in the hospital

Twelve patients in this series died
— a death rate of 0.8%. The aver
age age of these patients was 79
years. Thirty-nine percent of those
who died were more than 70 years
old. The death rate for patients over
70 years of age was 1.7% compared
with 0.2% for those less than 70
years of age. The median ASA
classification was 3.
Preoperatively 57% of patients
had mild to moderate systemic dis
ease (ASA class 2 or 3). Of those
who died, 67% were in ASA physi
cal class 3 preoperatively. Four pa
tients (0.3% of the total) died after
elective admission for TURP. The
other eight who died were long
term admissions and were referred
to the urology service. There were
no intraoperative deaths. Eight pa
tients (0.5%) died within 30 days of
their prostatectomy. Of these, two
had intraoperative myocardial in
farction, two had pulmonary embo
lism and the remaining four died of

Table II. Operative Information
Irrigation fluid, % of patients
1.5% glycine
Distilled water
Anesthesia, % of patients
Spinal
General
Average operation time, min
Average decrease in
hemoglobin, g/L
Patients requiring blood
transfusions, %

36
64
55
45
60
14.2
9

respiratory or cardiac arrest more
than 10 days postoperatively. The
four patients who died without ob
vious precipitating factors all had
severe underlying systemic disease.
None of the patients who died had
urosepsis or electrolyte abnormali
ties. However, in patients with renal
dysfunction (an elevated serum cre
atinine level) in whom distilled
water was used as the irrigant, the
death rate was 3.8%.
Nine percent of the patients re
ceived blood transfusions for a low
hemoglobin level as well as opera
tive blood loss.
Residents were the primary resectionists for the surgery of 7 (58%)
of the 12 patients who died.

Discussion
The most remarkable finding in
this series with respect to the death
rate was the fact that 3.8% of
patients having an elevated serum
creatinine level and distilled water
used as the irrigating solution dur
ing surgery died. Distilled water as
an irrigating fluid has obvious bene
fits of low cost and optical superior
ity over other solutions. However,
because of the risks of hemolysis
and subsequent renal failure, many
urologists believe that distilled
water is contraindicated in TURP
despite its advantages.56 As shown
in this and other series, in patients
without renal impairment, the
choice of irrigating solution does
Table III. Nonfatal Complications, %
Complication
Thromboembolic events
Myocardial infarction
Transurethral resection
syndrome/hyponatremia
Repeat resection — within 1 yr
Bleeding* — < 60 d
Total

FIG. 3. Weight of prostate resected.

No. (% ) of
patients
5 (0.3)
12(0.8)
7 (0.5)
25(1.7)
67 (4.5)
116(7.8)

'Requiring readmission
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not appear to affect outcome; how
ever, care must be taken when
using distilled water in those with
reduced renal function. The appar
ent safety of distilled water as an
irrigating solution is probably ac
counted for by improved surgical
techniques limiting fluid absorption
and by the surgeon’s experience.
However, the use of distilled water
cannot be universally recommend
ed, especially when residents in the
early stages of their careers are
beginning to learn TURP, because
there may be a significant risk to
the patient.
To put this study into perspec
tive, we compared the findings with
those of a previous study by Melchi
or and associates in 1974.7 They
reported on the morbidity in a se
ries of 2223 consecutive patients
who underwent TURP.7 In their
study, as in this one, both staff and
resident urologists were included.
The comparisons are made in Table
IV. The two series have a similar
ratio of staff to resident as the
primary resectionist. The patients in
our series were slightly younger,
the group having a mean age of 63
years. In both series the mean
weight of specimen resected was
similar; however, the surgery was
performed, on average, 24 minutes

faster, and approximately 15%
fewer patients received blood trans
fusions at our institution.
The patients in our series were in
hospital approximately 1 day less.
This might reflect either an earlier
removal of the catheter or a change
in patient care over the 17 years
between the two studies. Presently,
it is the practice at our hospital to
remove the catheter the 1st day
postoperatively if bleeding is mini
mal. Furthermore, with hospitals
currently attempting to control
spending and the implementation of
continuing quality improvement
measures, the hospital stay postop
eratively for a patient undergoing
TURP is now approximately 3 days
in our institution.
The overall death rate in Melchi
or’s review was 1.3%. In this series,
the death rate within 30 days of
operation was lower at 0.5%. Most
of the deaths in both series oc
curred in elderly patients with mod
erately severe multisystem disease,
and the TURP probably contributed
little to their death.

results appear favourable in com
parison with other large reviews on
this very common surgical proce
dure. In this series, having senior
residents perform the procedure
does not have any adverse effect on
patient morbidity or mortality. With
proper supervision and instruction
from staff urologists, residents are
able to gain experience and techni
cal competency and maintain low
complication rates.
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Outpatient Laser Cone Biopsy
Under Local Anesthesia
Gavin C.E. Stuart, MD; Jill G. Nation, MD
The authors report on 60 patients who had abnormal findings on cervical cytologic
examination, necessitating conization of the cervix. The procedure was done in an
ambulatory setting, with a carbon-dioxide laser unit and local anesthesia. The
average operative time was 16.9 minutes. Fifty-one (85%) patients experienced no
complications, and there were no cases of excessive bleeding. In all patients, the
specimen was satisfactory for histologic review. Only 5% (three) of patients would
have preferred to have the procedure performed under general anesthesia.
Laser cone biopsy of the cervix can be performed in an outpatient setting, with
local anesthesia. Morbidity is minimal and there is potential for economic saving
when compared with conventional methods for biopsy of the cervix.

Les auteurs ont etudie 60 patientes qui avaient eu un examen cytologique anormal
du col uterin necessitant une conisation du col. L’intervention fut pratiquee en
milieu ambulatoire, sous anesthesie locale, a l’aide d’un laser au bioxyde de carbone.
Le temps operatoire moyen fut de 16,9 minutes. Cinquante-et-une patientes (85%)
n’eurent aucune complication et il n’y eut aucun cas de saignement excessif. On
obtint chez toutes les patientes un echantillon satisfaisant pour examen
histologique. Seulement trois patientes (5%) auraient prefere subir l’intervention
sous anesthesie generate.
La biopsie conoi'de du col au laser peut etre effectuee en milieu ambulatoire, sous
anesthesie locale. La morbidity est minime et il y a possibility d’une economic par
rapport aux methodes classiques de biopsie du col uterin.

ince 1976, laser vaporization of
cervical intraepithelial neoplas
tic lesions has been reported to be
of value in the management o f this
condition.1 The procedure has been
performed in both inpatient and
outpatient settings, with either local
or general anesthesia. However, excisional cone biopsy for diagnostic
purposes has generally been per
formed in an operating room under
local or general anesthesia with
either the scalpel or laser. The
purpose of this paper is to report
the use o f the laser in performing
excisional cone biopsies of the cer

S

vix under local anesthesia in an
outpatient setting in 60 patients.
The ability to carry out this proce
dure satisfactorily without the need
for hospital admission or general
anesthesia greatly reduces the mor
bidity usually associated with cone
biopsy and results in considerable
cost saving.

Patients and Methods
Sixty consecutive women, who
were referred to the Colposcopy
Clinic o f the Tom Baker Cancer
Centre, in Calgary, and who re
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29th Street NW,

quired a diagnostic cone biopsy o f
the cervix were the subjects o f this
report. The average age was 29.8
years (range from 22 to 43 years).
Twenty-four women had delivered
at least one infant previously and
the remainder were nulliparous.
All women had a history o f cervi
cal cellular abnormalities. Repeat
cytologic investigation was done be
fore colposcopic assessment, and
directed biopsy was done in all the
women. The indications for diag
nostic cone biopsy are listed in
Table I. Endocervical curettage was
not done routinely in all new pa
tients but did constitute part o f the
regular follow-up in those who had
previously received therapy for cer
vical intraepithelial neoplasia (CIN).
An unsatisfactory examination was
one in which the entire squamocolumnar junction could not be
seen or the area o f white epithelium
extended into the cervical canal.
The colposcopic diagnosis prior to
the cone biopsy is recorded in Table
II. The new patient with benign
atypia underwent cone biopsy be
cause the initial cytologic findings
were cells inconsistent with CIN
grade III. After adequate examina
tion, women in our clinic who are
found to have CIN grade I only are
not actively treated but are ob 
served in regular follow-up. The
five women with histologic evidence
o f CIN grade I underwent a cervical
conization because of a discrepancy
between cytologic and histologic
findings. Of the 60 women, 40 were
noted to have concomitant cytolog
ic or histologic changes consistent
with the presence o f human papillo
ma virus.
Informed consent for laser cone
biopsy was obtained from all the
CJS, VOL. 36, NO. 1, FEBRUARY 1993
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women. They attended the Ambula
tory Surgery Unit at the clinic 1
hour before their scheduled proce
dure. Lorazepam, 1 mg, was offered
as an anxiolytic medication. All pro
cedures were conducted in the
treatment area, with oxygen and
resuscitative equipment immediately
available. Pulse and blood pressure
w ere m onitored autom atically
throughout the procedure on a digi
tal display with pulse oximetry. All
procedures were performed by the
same gynecologist. An anesthesiolo
gist was not present. A nurse at
tended throughout to observe the
patient and to provide distraction
through conversation.
After repeat colposcopic exami
nation, the area to be excised was
outlined with a Xanar-20 carbondioxide laser (Xanar, Div. of Coher
ent Medical, Palo Alto, Calif.) at a
power density of 2420 w atts/cm 2.
This setting was chosen for a 1 mm
spot size with maximal energy out
put. Following this outline, the pa
tient was offered a paracervical
block (1% xylocaine without epi
nephrine), which was administered
with 5 mL of solution injected at
the base of each uterosacral liga
ment and then an additional 10 mL
injected circumferentially on the
cervix just distal to the line of
excision. After establishment of a
paracervical block, the line of exci
sion was extended to a depth of 10
to 15 mm to include the projected
squamocolumnar junction. A small,
20-cm skin hook was used to de

flect the specimen from the path of
the laser beam. Once the specimen
was mobilized in a cylindrical fash
ion, a long Allis clamp (Codman
Surgical Inc., Randolph, Mass.) was
applied to the cut edges of the
specimen, carefully avoiding trauma
to the surface epithelium. An Allis
clamp can be applied without crush
ing viable tissue, hence preserving
the histologic definition of the spec
imen. By placing this clamp under
traction and occasionally torsion, a
conical incision can be made across
the base of the specimen with the
laser beam. After removal of the
specimen, the base of the area was
treated with the laser at a power
density of 960 w atts/cm 2 to
achieve complete hemostasis. In five
women, excisional laser cone biopsy
was performed in combination with
ablation of visible disease beyond
the excised margins.
After the procedure, the women
were asked to remain in the unit for
at least 1 hour for observation of
any delayed vasovagal response or
other complication. All were con
tacted by telephone 1 week later as
part of the follow-up. The proce
dure was evaluated subjectively by
asking the women if they would
choose to have the procedure done
again under local anesthesia as op
posed to general anesthesia if it was
necessary. They were reviewed in
the clinic 1 month after the biopsy
to ensure adequate healing of the
cervix. Repeat cytologic and colpo
scopic assessment was conducted
after a 6-month interval.

Table 1. Indications for Diagnostic Cone
Biopsy
Indication
Positive endocervical
curettage
Unsatisfactory
examination
Microinvasive cancer
No lesion seen
Adenocarcinoma in
situ
Total

42

1(2)
60 (100)
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Nine patients (15%) declined the
offer of anxiolytic medication before
the procedure and received no pre
medication. Eighteen patients (30%)
did not wish to receive any local
anesthetic or paracervical block.
Three of the 60 patients had the
procedure completed by choice
without any premedication or local
anesthesia. They tolerated the pro
cedure well.
The procedure was completed in
all patients. Exact blood loss was
not recorded but was minimal with
the use of gauze swabs and the
application of ferric subsulfate
(Monsel’s) solution in all but two
women. These two required the
insertion of a Grafco vaginal tam
pon (Graham-Field Inc., Hauppauge, NY) as a vaginal pack, and
this was removed the morning after
the procedure. The time spent by
the patient in the procedure room
averaged 16.9 minutes (range from
10 to 40 minutes). The patient who
remained for 315 minutes did so
because of transportation difficul
ties rather than for medical reasons.
Fifty-one (85%) of the 60 women
experienced no significant complica
tions (Table III). Five women, all of
whom had a paracervical block ad
ministered, experienced cramping
pain and required oral analgesics

Referral
cytology

Directed
biopsy

Colposcopy

Benign atypia
CIN I
CIN II
CIN III
Negative

7
11
17
14
11

1
5
24
27
3

1
6
24
29
0

Total

60

60

60

Findings
22 (37)
2 (3)
1 (2)

Results

Table II. Pathological Findings in 60 Patients Before Laser Cone Biopsy

No. of patients (%)
34 (57)

Histologic review was completed
on all phosphate-buffered, form
alin-fixed specimens by staining
with hematoxylin and eosin.

CIN = cervical intraepithelial neoplasia

OUTPATIENT CONE BIOPSY

before being discharged. Three
women experienced a vasovagal re
sponse as evidenced by transient
bradycardia and hypotension. One
woman was admitted to hospital 4
days after the procedure with a
clinical diagnosis of pelvic inflam
matory disease and required intrave
nous antibiotic therapy. None of the
women experienced bleeding that
required a return visit to the clinic.
Retrospectively, when questioned,
three women (5%) stated that if
they had to undergo the procedure
again they would elect to have the
procedure performed under general
rather than local anesthesia.
The cervical cone biopsy was ade
quate for histologic review in all
patients. The average dimensions of
the specimen were 20 X 16 X 10
mm. The final pathological diagno
sis is reported in Table IV. No cases
of invasive cancer were detected in
this group.
Comments
In this paper we have addressed
the need to perform a cone biopsy
of the cervix under general anesthe
T a b le III. C o m p lic a tio n s o f L a s e r C one
B io p s y
C om plication

N o. of p a tie n ts (°/o)

N one
Pain
V a sova gal re s p o n s e
P e lvic in fla m m a to ry
disease

51 (8 5 )
5 (8 )
3 (5 )

T o ta l

6 0 (1 0 0 )

1 (2 )

T a b le IV. Final D ia g n o s is o f L a s e r C one
B io p s y
Final diagnosis
N o e v id e n ce o f
d y sp la sia
B en ig n a typ ia
CIN I
CIN II
CIN III
A d e n o c a rc in o m a in
situ
T otal

No. of p a tie n ts (% )

7 (1 2 )
2 (3 )
1 6 (2 7 )
4 (6 )
3 0 (5 0 )
1 (2 )
6 0 (1 0 0 )

sia in the hospital operating suite, a
situation which results in greater
patient morbidity and increased
cost, because of the need for an
anesthesiologist and an operatingroom facility, compared with the
use of local anesthesia in a clinic
setting.
It has been clearly documented2-4
that a cone biopsy .of the cervix can
be performed with the carbon-diox
ide laser with less morbidity than
with a conventional scalpel. Compli
cations that occur with reduced
frequency when the laser is used
include bleeding, both immediate
and delayed, cervical stenosis and
premature delivery. The ability to
perform this procedure in an out
patient setting has been reported
previously,5 but in the majority of
patients general anesthesia was
used. In 1987, Indman6 reported on
101 women who underwent laser
conization of the cervix in an office
setting with anaproxen sodium as
premedication and a paracervical
block using 0.5% bupivacaine hy
drochloride. Indman recommended
the use of vasopressin intraoperatively.
Our report further documents the
efficiency of this procedure in an
outpatient setting, with local anes
thesia and a modified technique.
Three of our patients had a vasova
gal response in the form of brady
cardia and hypotension. In the re
port by Indman6 transient hyperten
sion associated with the use of
bupivacaine and vasopressin was de
scribed in two patients. Although
the risk of cardiovascular complica
tions appears to be low, it is recom
mended that, if the procedure is to
be done in an ambulatory setting
without the presence of an anesthe
siologist, the pulse rate should be
monitored routinely and supplemen
tal oxygen and Trendelenberg posi
tioning should be available. In this
series, without the use of vasopres
sin or epinephrine, bleeding was not

a problem. Any loss of blood not
controlled by the use of the laser
beam at a diffused setting can usu
ally be controlled by the use of
topical ferric subsulfate solution.
Although the technique of diag
nostic conization of the cervix can
be accomplished in an ambulatory
setting with local anesthesia alone,
the technique must be acceptable to
the patient. Recognizing the limita
tions of retrospective questioning,
we found that only 5% of the
women would have elected to have
the procedure repeated under gen
eral anesthesia. We cannot com
ment on the role of premedication
with lorazepam because there is no
control group for comparison. It
would appear, however, that the
role of the nurse or other medical
attendant, as a distractor for the
patient, is essential and may be of
more value as an anxiolytic and
analgesic than the medication used.
Laser conization appears to be an
effective, well-tolerated technique
that can be used in the ambulatory
setting with only local anesthesia.
The economic advantages are likely
to be significant while delivering
appropriate patient care with mini
mal morbidity.
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Tablets 2.5, 5 ,1 0 , 20 mg

(enalaprilat)
1.25 mg/mL
Angiotensin Converting Enzyme Inhibitor

INDICATIONS AND CLINICAL USE
V AS O T E C ® is indica ted in the tre a tm e n t of
essential or renovascular hypertension; usually
ad m inistered in association w ith other drugs,
particularly thiazide diuretics. Consider the risk of
angioedem a (see WARNINGS). Normally used
when a diuretic or beta-blocker was ineffective or
associated w ith unacceptable adverse effects.
Can also be tried as initial agent where a diuretic
and/or beta-blocker is contraindicated or could
cause serious adverse effects.
Oral enalapril is also indicated in the treatment of
congestive heart failure, as adjunctive therapy in
patients not responding adequately to digitalis and
diuretics.
Use of ACE inhibitors during the second and
third trimesters of pregnancy can cause injury
or death of a developing fetus. When pregnancy
is detected, discontinue VASOTEC® as soon as
possible (see WARNINGS; Use in Pregnancy).
VASOTEC® I.V. (enalaprilat) is an active meta
bolite of enalapril; the onset of action after admin
istration occurs within 15 minutes, with the maximum
effect within 1 to 4 hours.
VASOTEC® I.V. is indicated for the treatment of
hypertension when oral therapy is not practical.
VASOTEC® I.V. has been studied with only one
other antihypertensive agent, furosemide, which
showed additive effects on blood pressure. Due to
insufficient experience in the treatment of acceler
ated or malignant hypertension, VASOTEC® I.V. is
n o t re com m e nde d in su c h s itu a tio n s (see
DOSAGE and ADMINISTRATION).

CONTRAINDICATIONS
H ypersensitivity to any com ponent; history of
an gione uro tic edema related to ACE inhibitor
therapy.

WARNINGS
Angioedema, with laryngeal edema and/or shock,
have been reported and may be fatal. In such
cases, discontinue drug prom ptly and observe
patient until swelling subsides. Swelling confined
to the face , lips, and m outh usually resolves
without treatment, although antihistamines may be
useful in relieving sym ptom s. However, where
there is involvement of the tongue, glottis and
larynx, likely to cause airway obstruction, prompt
administration of subcutaneous adrenaline (0.5 mL
1:1000) may be indicated. Patients with a history of
angioedema, unrelated to ACE inhibitor use, may
be at increased risk (see CONTRAINDICATIONS).
Symptomatic hypotension has occurred, usually
d u rin g in itia l the rap y or w hen the dose was
increased, and is more likely in patients who are
v o lu m e -d e p le te d . In p a tie n ts w ith s e v e re
congestive heart failure, excessive hypotension
m ay be associated w ith o lig u ria a n d /o r pro
gressive azotemia. For patients in whom the
excessive hypotension could result in severe or
fa ta l c o m p lic a tio n s , i.e . th o s e w ith s e v e re
c o n g e s tiv e heart fa ilu re , is c h e m ic h e a rt or
cerebrovascular disease - start therapy under
close medical supervision, usually in a hospital.
Such patients should be followed closely for the
potential fall in blood pressure during first two
weeks of therapy or when enalapril or a diuretic is
increased. If hypotension occurs, place patient in
supine position and if needed, a d m inister IV
infusion of normal saline. A transient hypotensive
response is not a contraindication to further doses
of enalapril or enalaprilat.
®Trademark Merck & Co., Inc.
Merck Frosst Canada Inc., R.U.

Neutropenia/agranulocytosis and bone marrow
depression have been caused by ACE inhibitors.
Current experience with enalapril shows incidence
to be rare. Consider periodic monitoring of white
blood cell counts in patients with collagen vascular
disease and renal disease.
Use of ACE inhibitors in pregnancy can cause
fetal and neonatal morbidity and mortality. When
pregnancy is detected, discontinue VASOTEC®
as soon as possible. Rarely, no alternatives to an
ACE inhibitor will be found and mothers should be
apprised to the potential hazards to the fetus.
Ultrasound should be performed to assess fetal
development, well-being and volume of amniotic
fluid. If oligohydramnios is observed, discontinue
VASOTEC® unless lifesaving for the mother.
A non-stress test and/or a biophysical profiling
may be appropriate however, if concerns persist, a
contraction stress testing should be considered.
Oligohydramnios may only appear after fetus has
sustained irreversible injury.
Closely observe infants exposed in utero to ACE
inhibitors for hypotension, oliguria and hyper
k a le m ia , and in itia te a p p ro p ria te co rre ctive
medical procedures.
Human Data: Exposure to ACE inhibitors during
second and third trimesters has been associated
w ith hypotension, neonatal skull hypoplasia,
anuria, reversible or irreversible renal failure and
death of the fetus. Oligohydramnios, associated
with fetal limb contractures, craniofacial defor
mation, and hypoplastic lung developm ent also
has been reported. Prematurity and patent ductus
arteriosus also reported but unknown if due to
ACE inhibitor use. It is not known whether expo
sure limited to the first trim ester can adversely
affect fetal outcome.

PRECAUTIONS
Impaired renal function: Renal function should
be assessed before initiating therapy with enalapril
or enalaprilat. Patients with renal insufficiency may
require reduced or less frequent doses, and their
renal function must be monitored appropriately (see
DOSAGE). Renal failure, which has been reported
mainly in patients with severe congestive heart failure
or underlying renal disease including renal artery
stenosis, is usually reversible when treated promptly.
Some hypertensive patients with no apparent
renal disease have developed increases in BUN
and c re atinine w hile on c o n c u rre n t d iu re tic /
enalapril therapy. Dosage reduction or discontin
uation of one or both drugs may be required.
Hyperkalemia: In clinical trials, hyperkalemia
(>5.7 mmol/L) was observed in approximately 1%
of hypertensive patients, and caused discontin
uation of therapy in 0.28% of such patients. Risk
factors for hyperkalemia development may include
renal insufficiency, diabetes mellitus, and con
comitant use of agents to treat hypokalemia (see
ADVERSE REACTIONS).
Valvular Stenosis: Theoretically, patients with
ao rtic stenosis, who do not develop as much
afterload reduction, might be at risk of decreased
coronary perfusion when treated with vasodilators.
Surgery/Anaesthesia: During major surgery or
anaesthesia with hypotensive agents, enalapril
blocks angiotensin II form atio n secondary to
compensatory renin release. Hypotension that
develops due to this mechanism can be corrected
by volume expansion.
Im paired liv er fu n ctio n : H epatitis, jaundice
(hepatocellular and/or cholestatic),elevation of
liver enzymes and/or serum bilirubin, which have
occurred in patients with or without pre-existing
liver abnorm alities, w ere usually reversed on
discontinuation of enalapril or enalaprilat. For any
unexplained symptoms, particularly within the first
months of treatment, a full set of liver function tests
and other necessary investigations are recom
mended. Consider discontinuation of enalapril or
e n a la p rila t w hen a p p ro p ria te . Use en alapril
or enalaprilat with particular caution in patients with
pre-existing liver abnormalities. Obtain baseline
liver function tests before in itia tin g drug and
monitor response and metabolic effects closely.
Cough: A dry, persistent cough has been report
ed, which usually disappears after withdrawal or
lowering the dose of enalapril or enalaprilat.
Nursing mothers: Enalapril and enalaprilat are
se c re te d in hum an m ilk in tra c e am ounts
therefore, nursing should be interrupted.
Pediatric use: This use is not recommended
because enalapril and enalaprilat have not been
studied in children.
Hemodialysis patients: Anaphylactoid reactions
have been reported with high-flux membranes (eg.

polyacrylonitrile [PAN]) and treated concomitantly
w ith an ACE in h ib ito r. If sym p tom s such as
nausea, abdominal cramps, burning, angioedema,
shortness of breath and severe hypotension
occur, stop dialysis immediately. The symptoms
are not relieved by antihistamines and the use of a
different type of dialysis membrane or class of
antihypertensive agent should be considered.
Drug Interactions
Hypotension - Patients on Diuretic Therapy:
P articularly when d iu re tics re cently initiated,
patients occasionally experience hypotension
after initiating therapy with enalapril or enalaprilat.
To minimize the hypotensive effects, discontinue
the diuretic or increase the salt intake prior to
starting the drug. If the diuretic cannot be dis
continued, patients should be placed under close
medical supervision for at least one hour after the
initial dose of enalaprilat (see WARNINGS).
Agents Increasing Serum Potassium: Since
enalapril and enalaprilat decrease aldosterone
production, elevation of serum potassium may
occu r. D iu re tic s su ch as s p iro n o la c to n e ,
triamterene or amiloride, or potassium supple
ments should be given cautiously for documented
hyp okalem ia o n ly and s h o u ld be m onitored
frequently. Potassium containing salt substitutes
should be used with caution.
Agents Causing Renin Release: Diuretics, for
example, augment the antihypertensive effect of
enalapril and enalaprilat.
A g e n ts A ffe c tin g S y m p a th e tic A c tiv ity :
Ganglionic blocking agents or adrenergic neuron
blocking agents, for example, may be used with
caution. B eta-adrene rgic blockers add some
further antihypertensive effect to enalapril.
L ith iu m S a lts : L ith iu m c le a ra n c e may be
reduced; therefore, monitor serum lithium levels
carefully if they are administered.

ADVERSE REACTIONS
VASOTEC®: In controlled clinical trials involving
2314 hypertensive patients and 363 heart failure
patients, the most severe adverse reactions were:
angioedema (0.2%), hypotension (2.3%) and renal
fa ilu re (5 ca se s). In h y p e rte n s iv e pa tie n ts,
hypotension occurred in 0.9% and syncope in
0.5%, with a discontinuation rate of 0.1%. In heart
failure patients, hypotension occurred in 4.4% and
syncope in 0.8%, with a discontinuation rate of
2.5%. The most frequent clinical adverse reactions
in controlled clinical trials were: headache (4.8%),
dizziness (4.6%) and fatigue (2.8%). Discontin
uation of therapy was required in 6.0% of the
2677 patients.

CARDIOVASCULAR
Hypotension
Chest Pain
Palpitations
Myocardial Infarction,
Acute
Myocardial Infarction,
Recurrent
GASTROINTESTINAL
Nausea
Vomiting
Dysphagia
Diarrhea
Abdominal pain
RENAL
Renal failure
Oliguria
Proteinuriat

Hypertension
%
(2314 Patients)

Heart Failure
%
(363 Patients)

0.9
0.9
0.6

4.4
1.7
0.3

0.2

0.6

—

0.3

1.4
0.8
0.1
1.4
0.7

1.1
1.7

0.1
1 case
0.1

—

3.0
1.4
0.6
—

DERMATOLOGIC
Rash
1.4
1.9
0.4
Pruritus
1.4
NERVOUS SYSTEM
Headache
5.2
2.2
Dizziness
4.3
6.6
Insomnia
0.5
0.3
__
Nervousness
0.6
__
Somnolence
0.6
—
Paresthesia
0.6
ALLERGIC
Cough
1.3
1.4
Angioedema
0.2
—
HEMATOLOGIC
__
Anemia
0.1
Leukopenia
1 case
—
MISCELLANEOUS
Muscle cramps
0.6
0.3
Dyspnea
0.6
1.1
—
Hyperhidrosis
0.7
Impotence
0.4
0.3
Fatigue
3.0
1.4
Taste disturbance
0.4
0.3
t Defined as >1g/24h or >0.5g/12h on two conse^
measurements, at least one month apart.

ABNORMAL LABORATORY FINDINGS
Hyperkalemia: (see PRECAUTIONS).
Creatinine, Blood Urea Nitrogen: Increases were
reported in about 20% of patients with renovascular
hypertension and about 0.2% of patients with
essential hypertension on enalapril alone. In
creases, which usually were reversible upon
discontinuation of enalapril or concomitant therapy,
were reported in 9.7% of heart failure patients who
were receiving diuretics and/or digitalis.
Hemoglobin and Hematocrit: Decreases (mean
approximately 0.34 g% and 1.0 vol%, respectively)
occurred frequently, but were rarely of clinical
importance. In clinical trials, less than 0.1% of
patients discontinued therapy due to anemia.
Hepatic: Elevations of liver enzymes and/or serum
bilirubin have occurred (see PRECAUTIONS).
ADVERSE REACTIONS REPORTED IN UN
CONTROLLED TRIALS AND/OR MARKETING
EXPERIENCE
With an incidence of 0.5 to 1%: Insomnia, im
potence, renal dysfunction, renal failure and
oliguria.
With an incidence < 0.5%:
Cardiovascular: M yocardial infarction or
cerebrovascular accident, possibly secondary to
excessive hypotension in high risk patients (see
WARNINGS); cardiac arrest; pulmonary em 
bolism; rhythm disturbances; angina pectoris.
Gastrointestinal: Anorexia; ileus; pancreatitis;
dyspepsia; constipation. Hemopoeitic: Neutro
penia; thrombocytopenia; bone marrow depres
sion. Hepatic: Liver function abnorm alities;
hepatitis; jaundice (hepatocellular and/or
cholestatic). Nervous System/Psychiatric: Vertigo;
depression; confusion; ataxia. Respiratory:
Bronchospasm/asthma; rhinorrhea. Other: Ery
thema multiforme; exfoliative dermatitis; StevensJohnson syndrome; toxic epidermal necrosis;
urticaria; photosensitivity; alopecia; flushing; tin
nitus; hearing impairment; glossitis; blurred vision.
A symptom complex has been reported which may
include fever, serositis, vasculitis, myalgia,
arthraigia/arthritis, a positive ANA, elevated
erythrocyte sedimentation rate, eosinophilia and
leukocytosis. Rash, photosensitivity or other
dermatologic manifestations may occur. These
symptoms have disappeared after discontinuation
of therapy.
LABORATORY TEST FINDINGS: Hyponatremia
VASOTEC® I.V.: Since enalapril is converted to
enalaprilat, those adverse reactions associated
with VASOTEC® tablets might also be expected to
occur with VASOTEC® I.V. The incidence of symp
tomatic hypotension is 3.4% with VASOTEC® I.V.
Other adverse experiences occurring in greater
than 1% of patients were headache (2.9%) and
nausea (1.1%). Adverse reactions occurring in 0.5
to 1.0% of patients in controlled clinical trials
include myocardial infarct, fatigue, dizziness,
fever, rash and constipation.

SYMPTOMS AND TREATMENT
OF OVERDOSAGE
Limited human data are available. The most likely
manifestation of overdosage would be hypo
tension, which can be treated by I.V. infusion of
norm al saline solution. E nalaprilat may be
rem oved from the general circulation by
hemodialysis.

DOSAGE AND ADMINISTRATION
VASOTEC®
FOR ORAL ADMINISTRATION ONLY
Dosage must be individualized. The absorption of
enalapril maleate is not affected by food.
HYPERTENSION
Initiation of enalapril requires consideration of
extent of blood pressure elevation, salt restriction
and recently used antihypertensive agents, the
dosage of which may need to be adjusted.
The recommended initial dose of enalapril maleate
in patients not on diuretics is 5 mg once a day.
Adjust dosage according to blood pressure
response; the usual range is 10 to 40 mg daily, in
a single dose or divided in two doses. Some
patients on once-daily dosage may have
diminished antihypertensive effect toward the end
of dosing interval and require an increase in
dosage, or twice daily administration. If blood
pressure is not controlled, a diuretic may be
added. Raising the daily dose above 40 mg is not
recommended because adverse reactions may be
increased.

Occasionally symptomatic hypotension may occur
following the initial dose, more likely in patients
currently taking a diuretic. Therefore, if possible,
discontinue the diuretic two to three days before
initiating enalapril therapy (see WARNINGS). If
the diuretic cannot be discontinued, use an initial
dose of 2.5 mg.
In the absence of sufficient experience in the
treatment of accelerated or malignant hyper
tension, enalapril is not recommended in such
situations.
Dosage in the Elderly (over 65 years): Start at
2.5 mg daily. Some elderly patients may be more
responsive than younger patients.
Dosage Adjustment in Renal Impairment: (see
PRECAUTIONS - Hemodialysis patients)
Guidelines for reducing doses in hypertensive
patients:

Renal Status

Normal renal
function
Mild impairment
Moderate to
severe impairment
Dialysis patients

Creatinine
Clearance
mL/min(mL/s)

>80 mL/min
(>1.33 mL/s)
<80 >30 mL/min
(<1.33 >0.50 mL/s)
<30 mL/min
(<0.50 mL/s)
—

Initial Dose
m g/day

5 mg
5 mg
2.5 mg
2.5 mg on
dialysis days*

* Enalaprilat is dialysable. Dosage on nondialysis days
should be adjusted depending on the blood pressure
response.

CONGESTIVE HEART FAILURE
Use in conjunction with a diuretic and digitalis.
Initiate therapy under close medical supervision,
usually in a hospital. Monitor blood pressure and
renal function before and during treatment with
enalapril, because severe hypotension, and more
rarely, consequent renal failure have been
reported (see WARNINGS and PRECAUTIONS).
When initiating enalapril consider the recent
diuretic therapy and possibility of severe salt/
volume depletion. Before beginning enalapril
reduce diuretic therapy if possible.
The recommended initial daily dose is 2.5 mg.
W hile managing sym ptom atic hypotension,
increase dose gradually, depending on individual
response, to the usual maintenance dose of 1020 mg daily, given in a single dose or divided in
two doses. This dose titration may be performed
over a two- to four-week period, or more rapidly if
indicated by residual signs and symptoms of heart
failure. The maximum daily dose is 40 mg.
VASOTEC® I.V. FOR INTRAVENOUS
ADMINISTRATION ONLY
VASOTEC® I.V. vials should be inspected visually
and should not be used if particulate matter or
discoloration is observed.
VASOTEC® I.V. may be administered in tra 
venously as supplied, or mixed with up to 50 mL of
one of the following diluents:
5% Dextrose Injection
0.9% Sodium Chloride Injection
0.9% Sodium Chloride Injection in 5% Dextrose
5% Dextrose in Lactated Ringer’s Injection
Diluted solutions should be used within 24 hours.
The dose is 1.25 mg every 6 hours administered
intravenously over at least 5 minutes. A clinical
response is usually seen within 15 minutes. Peak
effects after the first dose may not occur for up to
four hours after dosing. The peak effects of the
second and subsequent doses may exceed those
of the first.
No dosage regimen for VASOTEC® I.V. has been
clearly demonstrated to be more effective in
treating hypertension than 1.25 mg every 6 hours.
However, in controlled clinical studies in
hypertension, doses as high as 5 mg every
6 hours were well tolerated for up to 36 hours.
There has been inadequate experience with doses
greater than 20 mg per day.
In studies of patients with hypertension,
VASOTEC® I.V. has not been administered for
periods longer than 48 hours. In other studies,
patients have received VASOTEC® I.V. for as long
as 7 days.
The dose for patients being converted to
VASOTEC® I.V, from oral therapy for hypertension
with enalapril maleate is 1.25 mg every 6 hours
adm inistered intravenously over at least
5 minutes. For conversion from intravenous to oral
therapy, the recom m ended initial dose of
VASOTEC® tablets is 5 mg once a day with
subsequent dosage adjustments as necessary.

Patients on Diuretic Therapy
For patients on diuretic therapy, the recommended
starting dose for hypertension is 0.625 mg admin
istered intravenously over at least 5 minutes.
A clin ica l response is u su a lly seen w ithin
15 minutes. Peak effects after the first dose may
not occur for up to 4 hours after dosing, although
most of the effect is usually apparent within the
first hour. If after 1 hour there is an inadequate
clin ica l response, the 0.625 mg dose may
be repeated. Additional doses of 1.25 mg may be
administered at 6 hour intervals.
For conversion from intravenous to oral therapy,
the recommended initial dose of VASOTEC®
tablets for patients who have responded to
0.625 mg of enalaprilat every 6 hours is 2.5 mg
once a day with subsequent dosage adjustment
as necessary.
Dosage Adjustment in Renal Impairment
The usual dose of 1.25 mg of enalaprilat every
6 hours is recommended for pa tie nts with a
creatinine clearance >30 mL/min [>0.50 mL/s]
(serum creatinine up to approximately 3 mg/dL
[265.2 pm ol/Lj). For patients with creatinine
clearance <30 mL/min [<0.50 m L/s] (serum
creatinine >3 mg/dL [>265.2 pmol/Lj), the initial
dose is 0.625 mg (see WARNINGS).
If after 1 hour, there is an adequate clinical re
sponse, the 0.625 mg dose may be repeated.
Additional doses of 1.25 mg may be administered
at 6 hour intervals.
For dialysis patients, the initial dose should be
0.625 mg every 6 hours, (see PRECAUTIONS Hemodialysis patients).
For conversion from intravenous to oral therapy,
the recommended initial dose of VASOTEC® is
5 mg once a day for patients with creatinine
clearance >30 mL/min [>0.50 mL/s] and 2.5 mg
once daily for patients with creatinine clearance
<30 mL/min [<0.50 mL/s]. Dosage should then be
adjusted according to blood pressure response.

AVAILABILITY OF DOSAGE FORMS
Barrel-shaped, biconvex tablets, engraved with
code number on one side and VASOTEC on other.
VASOTEC® 2.5 mg - yellow, scored, engraved 14.
VASOTEC® 5 mg - white, scored, engraved 712.
VASOTEC® 10 mg - rust-red, engraved 713.
VASOTEC® 20 mg - peach, engraved 714.
All strengths available in bottles of 100 tablets.
VASOTEC® I.V. 1.25 mg per mL, is a clear,
colourless so lution and is su p p lie d in via ls
containing 2 mL.

PRODUCT MONOGRAPH
AVAILABLE ON REQUEST
(490iv-a,11,92)
References for 5527
1. SOLVD Investigators. Effect of enalapril on
survival in patients with reduced left ventricular
ejection fractions and congestive heart failure.
N Engl J Med Aug 1, 1991 ;325:293-302.
2. CONSENSUS Trial Study Group. Effect of
enalapril on mortality in severe congestive
heart failure: Results of the Cooperative North
S ca n d in a via n Enalapril S u rviva l S tudy
(CONSENSUS). N Engl J Med June 4, 1987;
316:1429-1435.
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Disseminated Leiomyomatosis
Peritonealis: Report of a Case
in a Postmenopausal Woman
Gia-Khanh Nguyen, MD
Disseminated leiomyomatosis peritonealis (DLP) is a rare condition that to date has
been reported only in premenopausal women. The author reports a case of DPL
occurring in a postmenopausal woman who had undergone total hysterectomy 30
years before and had received no hormonal therapy subsequently. The lesions were
multiple and consisted of smooth-muscle cells that proliferated from medium-sized
blood vessels. The author concludes that the patient’s lesions likely represent a
histologic variant of DLP.

La leiomyomatose peritoneale disseminee (LPD) est une affection rare qui n’a ete
signalee, a ce jour, que chez la femme en premenopause. L’auteur decrit un cas de
LPD survenant chez une femme en periode postmenopausique qui avait subi une
hysterectomie totale 30 ans plus tot et n’avait pas refu d’hormonotherapie
subsequente. Les lesions etaient multiples et etaient constitutes de cellules de
muscle lisse qui proliferaient a partir de vaisseaux sanguins de taille moyenne.
L’auteur conclut que les lesions retrouvees chez cette patiente represented
vraisemblablement une variante histologique de la LPD.

leiomyomatosis pe
D isseminated
ritonealis (DLP) is an infre

Case Report

quently reported lesion. About 30
cases have been documented.1"8 It
has been found exclusively in
women during their childbearing
years. Most cases were detected
incidentally at cesarean section.1-7
DLP lesions in women taking con
traceptive steroids and in women
who were not on contraceptive pills
have also been reported.5 One pa
tient with an ovarian granulosa-cell
tumour was found to have DLP at
laparotomy.8 1 report a case of DLP
incidentally found at laparotomy in
a postmenopausal woman.

A 63-year-old white woman, para
5 gravida 5, was admitted to the
University of Alberta Hospitals for
an elective cholecystectomy for
cholelithiasis. Her medical history
included a total abdominal hysterec
tomy performed at 30 years of age
for a benign endometrial lesion as
sociated with persistent vaginal
bleeding. No peritoneal lesions were
noted during that operation. She
had mild hypertension controlled by
hydrochlorothiazide and a low-salt
diet. She had not been on hormonal
therapy since her hysterectomy.
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Sciences Centre, University o f Alberta, Edmonton, Alta.
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At laparotomy, several subperitoneal round nodules of brown
ish tissue, ranging from 0.5 to 3 cm
in diameter, were found attached to
the parietal peritoneum and the
antimesenteric borders of both
small and large intestine. They cov
ered about 7% of the peritoneal
surface. A few small nodules were
present under the pelvic serosa.
Frozen-section examination of a
large peritoneal nodule gave a his
tologic diagnosis of neurofibroma.
The patient underwent an explora
tion of the common bile duct and a
cholecystectomy. Her postoperative
course was smooth, and she was
discharged from the hospital 10
days later. She is currently well
with no evidence of malignant dis
ease, 10 years after her cholecystec
tomy.

Pathological Examination
The largest fragment of peritone
al nodules was ovoid and measured
3 X 3 X 2 cm. It was firm, and its
cut surface was glassy white with
no hemorrhagic necrosis. Five tis
sue blocks, 1 mm3 of fresh tissue,
were fixed in 4% buffered glutaraldehyde and processed according to
the routine techniques for transmis
sion electron microscopic (EM)
study. Several tissue blocks were
fixed in formalin and processed for
light microscopic examination. Tis
sue sections 5 /am thick were
stained with hematoxylin and eosin,
Masson’s trichrome and reticulin
stains.

DISSEMINATED LEIOMYOMATOSIS PERITONEALIS

Light Microscopic Findings

FIG. 1. Peritoneal lesion shows prolif
eration of smooth-muscle cells radiat
ing from media of muscular blood
vessel (hematoxylin-eosin, original
magnification X 100).

The submitted lesions were subperitoneal round nodules consisting
of bundles of spindle-shaped cells
with a considerable amount of colla
gen tissue and numerous muscular
blood vessels of different size and
variable mural thickness. Many of
them appeared to be arteriolar in
type. Radiating from the media of
these vessels were spindle-shaped
smooth-muscle cells with cigar
shaped nuclei (Fig. 1). They encir
cled the vessels and spread away in
the mass lesion in an irregular
pattern. Less than one normal mi
totic figure was noted per 10 highpower fields. No nerve trunks were
identified. Reticulin fibres and thin
bundles of collagen fibres were seen
scattered between smooth-muscle
cells. The histologic findings sug

gested that the lesions represented
angiomyomatosis.

Ultrastructural Findings
Ultrathin sections of the lesion
confirmed a spindle-cell lesion that
was rich in blood vessels. The spin
dle-cell component consisted of ma
ture smooth-muscle cells with abun
dant intracytoplasmic bundles of
microfilaments with focal densities
(Fig. 2). Pinocytotic vesicles were
noted along the cell membrane,
which was often surrounded by in
complete basal lamina. These cells
appeared to be derived from the
media of adjacent small blood ves
sels. The supporting stroma con
tained delicate bundles of collagen
fibres and occasional fibroblasts
with irregular and indented nuclei
and abundant intracytoplasm ic

FIG. 2. Proliferated mature smooth-muscle cells show irregular and elongated nuclei, intracytoplasmic bundles of microfilaments
with focal densities (arrow), membranous pinocytotic vesicles (arrow heads) and incomplete basal lamina. Collagen fibres can be
seen in interstitial spaces (uranyl acetate and lead citrate stains, original magnification X 16 000).
CJS, VOL. 36, NO. 1, FEBRUARY 1993
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rough endoplasmic reticula. No
nerve axons or cells with digitating
cytoplasmic processes were identi
fied, nor were there cells with the
features of a myofibroblast. The EM
findings suggested a smooth-mus
cle lesion of vascular origin.

Discussion
The peritoneal lesions in this pa
tient were highly unusual. They
clearly arose from the media of the
subperitoneal arterioles. Their his
tologic features were in keeping
with those of an angiomyoma,
which has not been described in the
literature, although solitary angi
omyoma is a common tumour of
the subcutis, accounting for 25% to
50% of all superficial leiomyomas.9
Our patient’s peritoneal lesions
were different from those of infan
tile myofibromatosis (IM), peritone
al leiomyosarcoma and benign me
tastasizing leiomyoma of the uterus
in several aspects.
In patients with IM, the lesions
can be solitary or multicentric with
visceral involvement.10 In about
89% of patients with IM the condi
tion is diagnosed during the first 2
years of life. Histologically, the le
sions are composed of short curving
bundles of spindle-shaped cells and
collagen tissue extending in a fin
gerlike fashion into the surround
ing tissue with a hemangio
pericytoma-like pattern at the cen
tre.10 Histochemical and EM studies
suggest that the constituent cells
are myofibroblasts. The lesions in
IM have a tendency to regress, and
they may be hamartomatous in na
ture as suggested earlier by Shnitka, Asp and Horner,11 Bartlett, Otis
and Laasko12 and Beatty.13 Lei
omyosarcoma involving the perito
neum is characterized by nodules of
smooth-muscle cells with marked
cellular atypia and a high mitotic
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index.1 The benign metastasizing
leiomyoma generally presents as
one or more pulmonary nodules.
When leiomyosarcoma occurs in
the pelvis, the metastatic nodules
tend to locate near the round liga
ments of the uterus and iliac veins.1
Lesions of DLP are seen in
women during their childbearing
ages. They usually regress after
pregnancy but may persist.5 These
findings indicate that estrogen and
progesterone do play an important
role in the pathogenesis of DLP.
The experimental work of Fujii and
associates14 on guinea pigs also
supports this hypothesis. Micro
scopically, DLP is characterized by
numerous subperitoneal nodules of
spindle cells consisting of smoothmuscle cells, a mixture of smoothmuscle cells and myofibroblasts or
altered smooth-muscle cells and fi
broblasts. These cells are seen ar
ranged in fascicles orientated in
irregular or perpendicular patterns
similar to those of the common
uterine leiomyoma.1-8 No lesions re
ported were found arising from
smooth-muscle cells of the media of
blood vessels.13-8 However, in one
report, the lesions appeared to orig
inate from a muscular blood vessel.
The DLP lesions are most likely
formed by fibroblastic replacement
of subperitoneal decidua in preg
nant women.56 They seem to arise
from an abnormal metaplastic
change of submesothelial stem cells
in nonpregnant patients whose
ovarian hormonal levels can be nor
mal or elevated.45 It is most likely
that this patient's peritoneal lesions
represent a histologic variant of
DLP. The abundance of collagen
fibres might indicate that the le
sions formed a long time before
they were incidentally found at lap
arotomy for cholecystectomy. They
might have formed years or months
after the patient’s previous total
abdominal hysterectomy in 1948
and persisted.

I thank Dr. H. Kiltz of Athabasca, Alta.,
for clinical information on the patient
and Ms. S. Todd of the Department of
Pathology, University of Alberta for
preparing the manuscript.
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Spontaneous Rupture of the Spleen
in Patients With Infectious Mononucleosis
Jameel Ali, MD, FRCSC, FACS
The author describes two cases of spontaneous splenic rupture .occurring with
infectious mononucleosis in young, previously healthy patients. The reports
illustrate the variable clinical presentation — from sudden, fatal hemorrhage to
bleeding that stops spontaneously. Although conservative nonoperative treatment
may be successful in carefully selected cases, laparotomy with splenectomy appears
to be the safest therapeutic approach.
When a nonoperative approach is selected, the patient should be observed in a
critical-care facility with immediate access to an operating room. Normal activity
should not be resumed until the spleen has returned to its normal size as
demonstrated by computed tomography or ultrasonography.

L’auteur decrit deux cas de rupture spontanee de la rate survenant en cours de
mononucleose infectieuse chez des patients jeunes, prealablement en bonne sante.
Les deux cas illustrent l’etendue du tableau clinique allant de l’hemorragie soudaine
et fatale, au saignement qui s’arrete spontanement. Meme si un traitement
conservateur, non chirugical, peut suffire dans certains cas choisis, la laparotomie
avec splenectomie parait etre l’abord therapeutique le plus sur.
Si une approche non chirurgicale est choisie, le malade devrait etre garde dans un
service de soins intensifs ayant un acces immediat au bloc operatoire. Les activites
normales ne devraient etre reprises qu’une fois la rate revenue a sa taille normale,
verifiee par la tomographie par ordinateur ou l’echographie.

nfectious mononucleosis is a
common disorder, particularly
among young, previously healthy
individuals. Although splenomegaly
is reported in approximately half of
these patients,1'2 the disease usually
runs a benign course without un
toward long-term sequelae. Howev
er, it has been reported3 that 0.5%
of these patients, who present with
abdominal pain, suffer spontaneous
splenic rupture, which is associated
with a high death rate. Therefore,
physicians should be acutely aware
of the possibility of spontaneous
splenic rupture in infectious mono
nucleosis. Even when the diagnosis

I

is made there is controversy con
cerning the management and out
come.4'5
We present two cases of sponta
neous rupture of the spleen in pre
viously healthy young individuals,
in whom the presentation, manage
ment and outcome were quite differ
ent.

Case Reports
Case 1
An 18-year-old girl had been
healthy until she experienced a sore
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throat and mild fever with some
cervical lymphadenopathy. She was
seen by her family physician who
treated her with erythromycin for
what appeared to be pharyngitis
due to Streptococcus. She was ad
vised to stay in bed until the fever
subsided. Four days later, approxi
mately 12 hours before being ad
mitted to hospital, she experienced
increasing pain in the abdomen and
felt dizzy on getting out of bed.
There was no history of recent
trauma. She fainted during one epi
sode of dizziness. Approximately 6
hours later she was found to be
unresponsive, so she was admitted
to hospital. At Sunnybrook Health
Science Centre there was electrical
cardiac activity but no palpable
spontaneous peripheral pulse. Ex
ternal cardiopulmonary resuscita
tion was applied. Large-bore intra
venous lines were established with
administration of emergency blood.
The abdomen was quite distended.
At emergency laparotomy, there
was gross blood throughout the
peritoneal cavity. A bleeding spleen
was delivered into the wound and
quickly removed by clamping the
hilum of the spleen. Hemostasis
was then established and fluid infu
sion continued in the operating
room. At the termination of the
operation the patient’s vital signs
had stabilized. Her blood pressure
was 110/70 mm Hg and her heart
rate was 110 beats/min, but her
pupils remained fixed and dilated
and her core temperature was re
corded as 32°C. Upon closure of
the abdomen diffuse bleeding was
noted in the wound and the patient
CJS, VOL. 36, NO. 1, FEBRUARY 1993
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was given fresh frozen plasma and
platelets. She also received 10 units
of packed cells in the operating
room for resuscitation.
She was transferred to the inten
sive care unit where her neurologic
status did not improve. Signs of
disseminated intravascular coagula
tion developed with persistent pro
longation of the prothrombin (more
than 30 seconds) and partial throm
boplastin (150 seconds) times and a
depression of her platelet count.
She continued to have bright red
bloody drainage from her peritoneal
drains. In our opinion the hypocoagulable state resulted from the
hypothermia. Her hypocoagulability was relatively resistant to plate
lets, plasma, cryoprecipitate and
l-deamino-8-D-arginine vasopressin
(DDAVP). Subsequently, severe res
piratory failure, necessitating the
administration of 100% oxygen, and
high positive end-expiratory pres
sures (up to 20 cm H20) developed,
with demonstration of florid pulmo
nary edema consistent with acute
respiratory distress syndrome.
Acute renal failure gradually devel
oped, and, because of the continu
ing hemorrhage from her peritoneal
drains, the possibility of mechanical
bleeding in the abdomen was con
sidered. She was returned to the
operating room, and her abdomen
was re-explored. The ligatures in
the splenic hilum and other areas of
the abdomen were intact, and no
mechanical source of bleeding was
identified. After 72 hours of normothermia and correction of her coag
ulation defect there was still no
improvement in her neurologic sta
tus. Acute renal failure developed
with continuing deterioration of her
respiratory status. Primarily be
cause of her persistent deep coma
with no brain stem reflexes after
normothermia further aggressive
therapy was discontinued and the
patient died.
At autopsy there was still consid
50
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erable blood in the peritoneal cavi
ty. The enlarged spleen, which
weighed 350 g, was examined
grossly and histologically. There
was evidence of denudation of the
capsule in the area of the hilum
(Fig. 1). Histologic examination of
the spleen demonstrated findings
consistent with infectious mononu
cleosis. From a blood sample taken
at the time of admission the latex
agglutination test gave a positive
result for infectious mononucleosis.

Case 2
A 29-year-old man, who was oth
erwise healthy and athletic, present
ed to the emergency department of
Sunnybrook Health Science Centre
6 hours after experiencing abdomi
nal pain and faintness. He gave a
history of malaise and sore throat
for 7 days for which penicillin had
been prescribed. He denied any his
tory of trauma or unusual exertion.
His blood pressure was 110/70
mm Hg, his pulse rate was 70
beats/min and regular and his
chest was clear. Abdominal exami
nation revealed diffuse tenderness.
The hemoglobin level was 129 g /L
and the leukocyte count was 14.5
X 109/ L with a lymphocytosis
(lymphocyte count 7.2 X 109/L
[normal 1 to 4 X 109/L]). After 2 L
of fluids were administered over
approximately 6 hours his hemoglo
bin level was 109 g/L . The pre
sumptive diagnosis was a perforated
viscus, but upright chest films and
an upper gastrointestinal series
with Gastrografin contrast medium
gave negative results, and ul
trasonography demonstrated free
intraperitoneal fluid raising the pos
sibility of a lacerated spleen.
Because the patient was relatively
stable and his pain had occurred
approximately 6 hours previously,
he was taken to the critical care
unit where his blood pressure was
measured frequently and his cardiac

status was monitored. It was decid
ed to treat him conservatively for a
ruptured spleen. A latex agglutina
tion test gave a positive result for
infectious mononucleosis.
A smear of a peripheral blood
sample showed abnormal lympho
cytes consistent with infectious
mononucleosis. Computed tomogra
phy (CT) of the abdomen demon
strated a laceration through the
spleen, which appeared to have tri
pled in size compared with the size
of a normal spleen on CT scans
(Fig. 2). The patient remained sta
ble over the next 5 days with no
further deterioration in his vital
signs or drop in hemoglobin level.
He was then transferred out of the
critical care unit and slowly mobi
lized. Upon discharge from hospital
7 days after admission, he was
taking iron orally and had specific
instructions not to be involved in
any vigorous activity and to return
to the hospital immediately if ab
dominal pain or dizziness recurred.
At follow-up 8 weeks later his
hemoglobin level and leukocyte
count were normal (153 g/L and
4.9 X 109/ L respectively). Upon
repeat CT of the abdomen 12 weeks
after his admission the size of the
spleen had decreased to normal and
the laceration had healed. The pa
tient was advised to avoid vigorous
sports and body contact sports for
at least 3 months and to report any
abdominal pain immediately.

FIG. 1. Case 1. Gross appearance of
spleen showing denudation of capsule
and large splenic laceration.

SPLENIC RUPTURE IN INFECTIOUS MONONUCLEOSIS

Discussion
These two cases demonstrate
that spontaneous rupture of the
spleen can occur in association with
infectious mononucleosis and that
the course is variable and may in
clude a fatal outcome.
Several authors4 have cautioned
against conservative management
of a ruptured spleen associated with
infectious mononucleosis because
of a higher death rate than in
traumatic rupture of the spleen.
However, our case 2 demonstrates
that conservative management and
close observation can be successful.
The mechanism of splenic rup
ture in infectious mononucleosis is
not completely understood. Spleno
megaly appears to be a common
accompaniment of splenic rupture
in this disorder.1'2 Edema, increase
in cell size and lifting of the splenic
capsule would suggest that stretch
ing of the capsule may result in
spontaneous hemorrhage. Intense
inflammatory reaction and vasculitis
may also contribute. As seen in
both these cases the splenomegaly
can occur very rapidly in infectious
mononucleosis in contrast to other
causes of splenomegaly, and this

may predispose to splenic rupture.
However, a history of trauma usual
ly precedes splenic rupture in sple
nomegaly from other causes. It has
beeen claimed that splenic rupture
is unlikely during the first 2 weeks
of infectious mononucleosis.6 How
ever, our two cases have demon
strated that rupture can occur with
in 1 week. Although spontaneous
rupture of the spleen is rare, it is
the most common cause of death in
patients with infectious mononucle
osis.7
The timing of return to normal
activities remains unclear. As in our
case 2, it seems reasonable to re
strict activity until the spleen has
returned to normal size. Recom
mendations for return to sports
activities in athletes vary from 3
weeks to 6 months after clinical
resolution of the illness.3'8'9 A rea
sonable recommendation is that vig
orous activity should not be re
sumed until the spleen has returned
to normal size as determined by
imaging techniques.
Because of the usually benign
course and the ubiquitous nature of
infectious mononucleosis, compla
cency may exist among many physi
cians. However, splenic rupture in

FIG. 2. Case 2. Computed tomography scan of abdomen demonstrating spleno
megaly, large laceration of spleen and intraperitoneal blood.

infectious mononucleosis is a seri
ous complication, and precautions
should be taken once the diagnosis
is made to avoid vigorous sports
activity. The patient should be alert
ed to the possibility of spontaneous
rupture of the spleen. Any signifi
cant abdominal pain should prompt
further investigation and medical
supervision of care. Shoulder tip
pain or any signs of severe abdomi
nal pain require CT or ultrasonog
raphy for evaluation of the abdo
men. Splenomegaly, even in the
absence of a fall in hemoglobin,
calls for bed rest for the patient and
close observation. As with traumat
ic splenic rupture conservative man
agement requires close observation
in an intensive care setting, so that
emergency laparotomy can be car
ried out if there is any deterioration
of the patient’s condition.
All criteria for spontaneous sple
nic rupture in infectious mononu
cleosis as outlined by Rutkow7 were
met in our case 1. In case 2,
although the spleen could not be
evaluated histologically, all other
criteria were met.
It has been estimated that spon
taneous rupture of the spleen oc
curs in 0.5% of cases of infectious
mononucleosis,3 and the death rate
for splenic rupture has been report
ed to be as high as 30%.8 In
Rutkow’s report7 all patients sur
vived when splenic rupture was rec
ognized and treated early. This em
phasizes the need for rapid diagno
sis and treatment.
The argument for surgical re
moval is that the risks associated
with blood transfusion for ongoing
hemorrhage are of similar magni
tude to those of sepsis following
splenectomy and that the abnormal
spleen seen at operation may also
be more prone to rupture later.9
However, as seen in case 2, these
spleens do return to normal size. If
a period of observation and conser
vative management is considered,
CJS, VOL. 36, NO. 1, FEBRUARY 1993
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the patient should be under close
supervision until the spleen returns
to normal size.
A case o f sudden death due to
spontaneous splenic rupture in in
fectious mononucleosis, as in case
1, has also been reported previous
ly.10 This suggests that the magni
tude o f the hemorrhage from sple
nic rupture can vary from simple
small subcapsular hematomas to ex
sanguinating hemorrhage. Where
critical care facilities for close ob
servation and immediate surgery are
not available, splenectomy appears
to be the safest treatment.11
In case 2 nonoperative manage
ment was prompted by the fact that
the symptoms were present for at
least 6 hours before the patient
presented to the emergency depart
ment with stable vital signs. Had
this patient presented with hemody

namic instability or signs of contin
uing hemorrhage the decision to
operate would have been easier.
The patient was also fully informed
of the risk of nonoperative manage
ment as well as the risk of blood
transfusions. It was decided that if
blood transfusions became neces
sary to maintain hemodynamic sta
bility in this patient then operative
intervention would be the course of
action.
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SESAP VII Critique / Critique SESAP VII
Item 360
Pulmonary complications after operation are a leading cause of morbidity and mortality. The site of surgical
incision has a pronounced effect on the development of postoperative respiratory complications. Thoracic and
upper abdominal operations are associated with the highest risk.
Diaphragmatic function is markedly altered after upper abdominal operation. Abdominal pain, inflammation,
and local irritation are believed to be responsible for the decrease in lung volumes found postoperatively.
Intercostal nerve blockade is helpful in decreasing patient discomfort, but has not produced the expected
beneficial effect on lung volumes after midline incisions.
Patients with chronic obstructive pulmonary disease are at high risk for postoperative pulmonary
complications because of decreased maximum expiratory flow rates that make them unable to produce an
adequate cough. Without treatment, 60% of these patients develop a pulmonary complication. Preoperative
bronchodilators, antibiotics, and physiotherapy decrease the postoperative complication rate to 22%.
The lower limit of FEVj below which patients should not be given general anesthesia has not been clearly
defined. Patients at risk should be studied with preoperative pulmonary function tests. An FEV] less than 65% of
the predicted value indicates significant disease, and preoperative preparation is warranted prior to abdominal
operation. The decrease in vital capacity postoperatively is not related to the specific anesthetic agent used.

0
Reference
3 6 0 / 1 . Gass GD, Olsen GN: Preoperative pulmonary function testing to predict postoperative morbidity and
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Sulfhydryl-Containing Agents
in the Treatment of Gastric Bleeding
Induced by Nonsteroidal
Anti-inflammatory Drugs
Aws S. Salim, PhD(Surg), FRCS(Edin), FRCS(Glasg), FICS, FCICD
In a double-blind study involving 172 patients, the author investigated the effect of
sulfhydryl-containing agents (cysteine and methylmethionine sulfonium chloride
[MMSC]) on hematemesis resulting from erosive gastritis induced by nonsteroidal
anti-inflammatory drugs.
The 56 patients who received cysteine (200 mg orally four times a day) and the 59
patients who received MMSC (500 mg orally four times a day) were significantly
(p < 0.01) more hemodynamically stable, with no rebleeding, than the 57 patients
who made up a control group. Endoscopy carried out 48 hours after admission
demonstrated that gastric erosions were still present in a significantly (p < 0.01)
higher number of patients in the control group (20 [35%]) than in patients receiving
cysteine (6 [11%]) and in patients receiving MMSC (7 [12%]).
Eighteen patients (32%) in the control group required blood transfusion because
of continued bleeding or rebleeding compared with only 3 patients (5%) receiving
cysteine and 2 patients (3%) receiving MMSC (p < 0.01). Emergency surgery was
necessary in 13 patients (23%) in the control group and in 1 patient (2%) in the
group receiving cysteine who had rebleeding. Four patients in the control group
died postoperatively.
The results show that sulfhydryl-containing agents stimulate the healing of
erosive gastritis induced by nonsteroidal anti-inflammatory drugs and protect
against the complications of bleeding produced by the gastritis.

Dans cette etude a double insu impliquant 172 patients, on a etudie l’effet de
composes ayant des groupements sulfhydryles (cysteine et chlorure de
methylmethionine sulfonium [CMMS]) sur l’hematemese resultant de la gastrite
erosive provoquee par les anti-inflammatoires non steroidiens.
Les 56 patients qui regurent la cysteine (200 mg, quatre fois par jour, par voie
orale) et les 59 patients qui regurent le CMMS (500 mg, quatre fois par jour, par
voie orale) se sont averes significativement plus stables (p < 0,01) au plan
hemodynamique, puisqu'ils n’eurent aucune recidive hemorragique, que les 57
patients qui formaient le groupe temoin. L’endoscopie pratiquee 48 heures apres
l’entree a l’hopital a revele des erosions gastriques encore presentes chez un
nombre significativement plus eleve (p < 0,01) de patients du groupe temoin (20
[35 %]) que chez ceux qui avaient regu la cysteine (6 [11 %]) ou le CMMS (7 [12 %]).
Dix-huit patients (32 %) du groupe temoin necessiterent des transfusions a cause
d'une persistance ou d’une recidive des saignements, comparativement a seulement
3 patients (5 %) du groupe cysteine et 2 (3 %) du groupe CMMS (p < 0,01). line
intervention chirurgicale d’urgence fut requise chez 13 patients (23 %) du groupe
temoin et 1 patient (2 %) du goupe cysteine qui eprouverent une rechute
hemorragique. Quatre patients du groupe temoin sont decedes en postoperatoire.
Ces resultats demontrent que les composes possedant des groupements
sulfhydryles stimulent la guerison de la gastrite erosive provoquee par les
anti-inflammatoires non steroidiens et protegent des complications des saignements
causes par la gastrite.

ome nonsteroidal anti-inflam
matory drugs (NSAIDs), such
as acetylsalicylic acid or indomethacin, irritate the gastrointestinal
mucosa, causing bleeding or ulcer
ation, or both.1'2 The irritation
ranges in severity from a few small
acute ulcers to erosive gastritis, in
which the entire gastric mucosa is
inflamed and studded with erosions.
The latter condition may produce
life-threatening bleeding that re
quires surgical intervention. The
death rate associated with such in
tervention is at least 30%.3'4
Sulfhydryl-containing
agents,
such as DL-cysteine and methyl
m ethionine sulfonium chloride
(MMSC), have been shown, in the
rat,5 to convey gastric mucosal cytoprotection by sustaining the phy
sicochemical properties o f the mu
cosal barrier, thus affording protec
tion against injury from ischemia or
noxious substances. Sulfhydryls
bind the oxygen-derived free radi
cals that mediate tissue damage.6-7
These radicals were recently shown
to be directly implicated in gas
troduodenal ulceration, and scav
enging them protects against ulcer
ation by maintaining mucosal integ-
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rity in the face of deleterious
agents.8-10 Sulfhydryl-containing
agents make an essential contribu
tion to protein synthesis,11 and the
repair of tissue loss requires large
quantities of sulfur-containing
amino acids.11 The gastrointestinal
mucosa is highly anabolic and will
rapidly incorporate these amino
acids, which will then donate sulfur
for the sulfation of the acid muco
polysaccharides of gastrointestinal
mucin as well as for the synthesis
of mucosal and mesenchymal tis
sues.11 Furthermore, it has been
reported that sulfhydryls stimulate
the release of gastric mucin glyco
proteins in rats.7 Zalewsky and
Moody12 noted that mucus cells on
the surface and in gastric pits con
tained a highly sulfated mucin, and
Starkey, Snary and Allen13 demon
strated that the gel structure of
gastric mucin depends on disulfide
bridges. These actions suggest that
sulfhydryl-containing agents may
promote the repair of breaches of
the gastrointestinal mucosa and,
thus, maintain the integrity of this
mucosa and enhance its ability to
withstand forces tending to injure
it.
Since the possibility exists that
sulfhydryl-containing agents might
be beneficial in the treatment of
NSAIDs-induced upper gastrointes
tinal bleeding, the present study
was undertaken. It covered the peri
od October 1978 to December
1980.

Patients and Methods
Sulfhydryl-containing Agents

A 4% solution of DL-cysteine and
a 10% solution of MMSC (Sigma
Chemical Co., St. Louis, Mo.) were
prepared in double-distilled water
and placed in 300 mL dark glass
bottles. The double-distilled water
was given to the control patients.
54
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Study Design

The study was prospective, ran
domized, double blinded and con
trolled. It was conducted on con
secutive patients with rheumatoid
arthritis or osteoarthritis who pre
sented with hematemesis caused by
NSAIDs-induced gastric erosions.
Patients were randomized by draw
ing sealed envelopes.
Treatment was begun immediate
ly after the diagnosis was made. A
patient was judged suitable for the
study when all of the following
applied: hematemesis started within
2 hours of presentation; the patient
had received no treatment; there
were no clinical signs of shock or
any apparent hemodynamic distur
bance (pulse rate less than
100/min, systolic blood pressure
more than 100 mm Hg, hemoglobin
level more than 10 g/dL, packed
red cell volume in men more than
0.4 and in women more than 0.37).
Exclusion criteria included any of
the following: erosions extending
beyond the stomach; previous
upper gastrointestinal hemorrhage;
a history of dyspepsia; bleeding di
athesis or any hematologic disorder;
well-established causes for the de
velopment of stress-induced acute
gastric mucosal injury (trauma, sur
gery, burns, shock or sepsis); treat
ment with any gastrointestinal ulcer
healing agent during the 4 weeks
before presentation; hiatus hernia;
esophageal erosions or ulcers; coex
istent or previously noted gastric or
duodenal ulceration; a visible vessel,
a spurting vessel or a clot adherent
to a vessel seen during endoscopy;
previous anti-ulcer surgery; the use
during the month preceding the
bleeding episode of corticosteroids,
antineoplastic agents, antimalarial
agents, gold preparations, multiple
NSAIDs, anticholinergic agents,
phenothiazines or tetracyclines; the
presence of significant symptoms
from other gastrointestinal disor

ders that would make it difficult to
evaluate efficacy and safety of the
trial drugs (e.g., severe irritable
bowel syndrome); cardiorespiratory
problems; hepatic or renal disor
ders; pregnancy or alcoholism.
NSAIDs-induced erosive gastritis
was diagnosed when at endoscopic
examination, with the patient sedat
ed, most of the gastric mucosa
showed hemorrhagic inflammation
studded with erosions (breaches of
the mucosa regardless of their
shape, size, site or number).
When patients with hematemesis
were judged suitable for the study,
a complete history was obtained,
followed by physical examination.
After a complete fast the patients
were admitted to the hospital and
hydrated intravenously. Endoscopy
was undertaken within 6 hours of
admission. After erosive gastritis
was diagnosed, patients were ran
domized to one of the study groups
and allowed free fluids and milk
(the intravenous line was discon
nected soon after these were taken).
Standard hematologic and biochem
ical measurements were made, and
urinalysis was performed and re
peated daily until patients were dis
charged home or until complica
tions developed. Plain abdominal
radiography was always undertaken
to exclude visceral perforation. Pa
tients whose condition remained
stable with no further hematemesis
were examined by endoscopy again
48 hours after the start of treat
ment (preceded by a complete fast
for 3 hours) to study the integrity
of the gastric mucosa. These pa
tients were then allowed solid food,
and if that was well tolerated for 24
hours, the treatment was with
drawn, and they were discharged
home. Resumption of the NSAIDs
was not permitted until a week
later.
A central venous line was insert
ed when clinical signs of shock or
hemodynamic disturbance devel-
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oped, or when rebleeding occurred.
Restoration of the circulating blood
volume was attained by blood trans
fusion, and the effectiveness of re
suscitation was determined by clini
cal observations and monitoring of
central venous pressure.
The decision to abandon conser
vative management and to under
take emergency surgery — vago
tomy and antrectomy with underrunning of any obviously bleeding
points — was based on the follow
ing criteria: for patients older than
60 years — four units of blood
required within 24 hours or one
episode of rebleeding; for patients
60 years of age or younger — eight
units of blood required in 24 hours
or two episodes of rebleeding dur
ing the same admission.
The compliance of patients with
their regimen and any adverse reac
tions to this regimen that they
experienced were carefully moni
tored on special charts.
The end point for this study,
when the treatment code was bro
ken, was when patients were dis
charged home or when they re
quired insertion of a central venous
line.
Ethical Considerations
This investigation was approved
by the Ethical Committee on
Human Experimentation at the hos
pital, and every patient gave written
informed consent.
Study Groups
Two hundred and thirteen con
secutive patients who presented
with hematemesis caused by
NSAIDs-induced erosive gastritis
were randomized. In the first group,
patients were given 5 mL of doubledistilled water orally every 6 hours.
In the second group, patients were
given 5 mL of 4% cysteine (200 mg)
orally every 6 hours. In the third

group, patients were given 5 mL
of 10% MMSC (500 mg) orally
every 6 hours. All patients were
given the same volumes of solu
tions and they were treated for 3
days unless their condition deterio
rated.
Statistical Analysis
A sample size of 150 patients was
initially chosen, with 50 patients in
each group. On the basis of a
two-tailed Ltest, such a size will
detect a significant difference of
30% between active and placebo
therapy (p < 0.05) with a probabi
lity of 80% for the overall sample.
Because of the anticipated problems
of nonevaluability of some patients,
which could weaken any conclusion
drawn, the aim was to enter approx
imately 70 patients in each group.
The differences detectable within
any subgroup are considerably larg
er than 30%.
Results are expressed as percent
ages or the mean value. The x 2 test
with Yates’ correction was used to
determine statistical significance
(p < 0.05) of observed differences
in the percentage incidence between
the groups, and the Mann-Whitney
“U-statistic” test for nonparametric
data was used to establish the sta
tistical significance of observed dif
ferences in mean values among the
study groups.
Life-table analyses with MantelCox (log rank) and Breslow general
ized Wilcoxon’s statistics were used
to evaluate the statistical differ
ences in the results of treatment
between the groups. Pair-wise
comparisons were made between
groups with or without sulfhydrylcontaining agents. Cox proportion
al hazards models were then
used to investigate the effect of
these agents on the outcome of
treatment when account was taken
of the other patient factors as co
variants.

Exclusion o f Patients From Efficacy
Analysis
Patients were excluded from the
efficacy analysis on the basis of the
following rules, which were rigidly
applied: adverse reaction to the
therapeutic regimen; intolerance of
the therapeutic regimen; failure to
comply with the regimen; the use of
any form of medication, other than
the trial regimen, to avoid therapeu
tic activities of unknown origin.
The decision to exclude patients
from the efficacy analysis was un
dertaken before breaking the treat
ment code. Additional intention-totreat analyses were performed rein
cluding such patients and using
various theoretically possible out
comes to examine what influence
their exclusion had on the conclu
sions reached.

Results
Patient Characteristics
Seventy-two patients (45 women
and 27 men) with an age range of
28 to 74 years (mean 57 years)
were randomized to the control
group. Seventy patients (38 women
and 32 men) with an age range of
25 to 71 years (mean 55 years)
were randomized to the cysteine
group. Seventy-one patients (43
women and 28 men) with an age
range of 27 to 76 years (mean 59
years) were randomized to the
MMSC group. These patients were
randomized from a total of 391
patients seen during the study peri
od. Fifteen patients in the control
group, 14 patients in the cysteine
group and 12 patients in the MMSC
group were excluded (Table I). The
characteristics of the remaining pa
tients were similar with respect to
numbers, age range, sex ratio, num
ber of smokers and social drinkers
(Table II). None of the patients were
CJS, VOL. 36. NO. 1. FEBRUARY 1993
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heavy consumers of alcohol, but all
drank coffee every day. The daily
coffee intake and amount of smok
ing (all cigarettes) were comparable
among the groups. Thirteen women
in the control group, 15 women in
the cysteine group and 11 women
in the MMSC group had used the
contraceptive pill at some time in
their lives.
Comparison Between the Groups
No significant differences were
T a b le 1.

noted among the three groups with
respect to the indication for
NSAIDs, the type of NSAIDs used
or the duration of therapy (Table

ID.
Approximately 10% of patients in
each of the groups given sulfhydrylcontaining agents experienced ad
verse effects. These were mostly
headache, nausea, dyspepsia and
abdominal pain. They were suffi
ciently troublesome, however, to
lead to withdrawal of medication in
four patients receiving cysteine and

Patients in Study Groups and Reasons for Exclusion
Group

In c lu s io n /e x clu sio n

No. patients entered
No. available for
complete assessment
No. excluded
Excluded because of:
Drug intolerance
Adverse effects
Prohibited drugs used
Noncompliance

Control

C ysteine

MMSC*

72

70

71

57
15

56
14

59
12

0
0
3
12

3
4
1
6

2
2
2
6

'Methylmethionine sulfonium chloride

T a b le II.

Patient Characteristics
G roup

C h a ra c te ris tic s

Age, yr
Range
Mean
Sex
Men
Women
Smokers
Social drinkers,
< 14 units/wkf
Indication for NSAIDsf
Rheumatoid arthritis
Osteoarthritis
Duration of NSAIDs
therapy, mo
< 3
3-12
> 12
NSAIDs used
Diclofenac
Piroxicam
Mefenamic acid
Naproxen
Ibuprofen
Other

Control
( n = 57)

C ysteine
(n = 5 6 )

(n = 5 9 )

2 8 -7 1
56

2 7 -6 9
59

2 9 -7 5
57

22
35
27

24
32
24

23
36
30

22

25

27

32
25

35
21

30
29

41
9
7

47
5
4

44
8
7

22
11
10
7
6
1

19
14
9
8
4
2

24
16
11
4
4
0

tO ne unit = 284 mL of beer, 100 mL of wine or 40 mL of liquor
JNonsteroidal anti-inflammatory drugs
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in two patients receiving MMSC.
Three patients in the cysteine group
and two patients in the MMSC
group were intolerant of their regi
men (Table I). There were no obvi
ous treatment-related changes in
hematologic or biochemical values.
Clinical Progress
Thirty-nine patients (68%) in the
control group remained stable 48
hours after admission and had no
further hematemesis or signs of
continued blood loss. The number
of patients in the cysteine group
(53 [95%]) and MMSC group (57
[97%]) achieving the same outcome
was significantly (p < 0.01) higher.
The second endoscopic examination
demonstrated signs of hemorrhagic
inflammation in every stomach in
spected; however, erosions were
present in a significantly (p < 0.01)
higher number of controls relative
to the cysteine (6 [11%]) and MMSC
(7 [12%]) groups. The clinical prog
ress of these patients continued,
and they were all discharged home
after 3 days of hospitalization. It
follows that the number of patients
tolerating solid food and then
allowed home was significantly
(p < 0.01) larger in the cysteine
and MMSC groups than in the con
trol group (Table III).
Eighteen controls (32%) required
blood transfusion because of contin
ued blood loss (8 patients [14%]) or
an episode of rebleeding (10 pa
tients [18%]). Two patients (4%)
taking cysteine required blood be
cause of continued hemorrhage,
and another patient in the same
group (2%) required blood because
of an episode of rebleeding. In the
MMSC group, two patients (3%)
required blood transfusion for con
tinued bleeding. Emergency surgery
was necessary in six control pa
tients (11%) who continued to lose
blood, in seven control patients
(12%) who had an episode of re-
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bleeding and in the only patient in
the cysteine group (2%) who had
rebleeding. Four control patients
died postoperatively (one of cardiac
arrest and three of bronchopneumo
nia) giving an operative death rate
of 31% and an overall group death
rate of 7%.
A series of Cox proportional haz
ards models was fitted using, as
covariates, all factors other than
treatment with the sulfhydryl-containing agents to obtain a group of
patients and conditions that inde
pendently and significantly influ
enced recovery from the bleeding
episode. Treatments with cysteine
and MMSC were then added as
separate covariates. Age over 60
years, an episode of rebleeding dur
ing the same admission, transfusion
of blood, continued bleeding after
hospitalization and shock all had a
significantly (p < 0.001) detrimen
tal effect upon the recovery rate.
When these and all the other non
significant variables were allowed
for, treatment with cysteine or
MMSC continued to exert a signifi
cantly beneficial effect upon recov
ery from the hemorrhagic episode
(p < 0.01).
Intention-to-treat analyses were
performed to determine what might
have happened if all patients had
been evaluable. This required postu
lating that some patients would

have remained stable and experi
enced no rebleeding or continued
blood loss whereas others would
have had further rebleeding or con
tinued blood loss at various times.
When all the excluded patients
were assumed to have remained
stable after admission to the hospi
tal and had no further blood loss or
rebleeding or wlien they were as
sumed to have deteriorated, treat
ment with cysteine or MMSC con
tinued to afford a significant thera
peutic advantage (p < 0.01) in
terms of the numbers of patients
remaining stable and their complete
recovery from the bleeding episode.
This advantage, however, was lost
when only the patients excluded
from the control group were as
sumed to have remained stable and
to have made a full recovery where
as all those excluded from the other
groups were assumed to have dete
riorated because of rebleeding or
continued blood loss.

Discussion
NSAIDs can produce damaging
effects on the gastric and duodenal
mucosa, ranging from acute gastric
mucosal injury to perforation of
peptic ulceration.1-3 The incidence
of this injury is approximately 30%
and may increase to 51% in patients

Table III. C lin ic a l C o u rse o f P a tie n ts
Group, no. (% )
Clinical course
C o n d itio n sta b le a fte r 4 8 h
S econd endoscopy
H e m o rrh a g ic in fla m m a tio n
E ro sio n s
B lo o d tra n s fu s io n fo r:
C o n tin u e d b lo o d lo s s
R e b le e d in g
S u rg e ry fo r:
C o n tin u e d b lo o d lo s s
R e b le e d in g
R e turn to s o lid fo o d
a fte r 4 8 h
D is ch a rg e a fte r 3 d

Control
(n = 57)

Cysteine
(n = 56)

MMSC
(fl = 59)

3 9 (6 8 )

5 3 (9 5 )

57 (9 7 )

3 9 (6 8 )
2 0 (3 5 )

5 3 (9 5 )
6 (1 1 )

57 (9 7 )
7 (1 2 )

8 (1 4 )
1 0 (1 8 )

2 (4 )
1 (2 )

2 (3 )
0

6 (1 1 )
7 (1 2 )

0
1 (2 )

0
0

3 9 (6 8 )
3 9 (6 8 )

5 3 (9 5 )
5 3 (9 5 )

57 (9 7 )
57 (9 7 )

taking multiple NSAIDs.2 Inhibition
of cyclo-oxygenase by NSAIDs
leads to inhibition of prostaglandin
synthesis, an action that can initiate
the development of acute gastric
mucosal injury.14 Prevention of
prostaglandin synthesis depresses
gastric mucosal blood flow and bi
carbonate secretion, reduces mucus
production and causes atrophy of
the gastric epithelium.15 Thus, the
mucosal defensive properties are
impaired, allowing gastric acid to
attack and injure the mucosa.1516
This investigation demonstrates
that sulfhydryl-containing agents
stimulate the healing of acute gas
tric mucosal injury produced by
NSAIDs and protect against the
complications of the hemorrhagic
episode caused by such injury (Ta
ble III). Continued hemorrhage and
rebleeding are among the complica
tions and are particularly serious
because they may necessitate emer
gency surgery, which is associated
with a death rate of up to 30%. The
similarity in efficacy between cys
teine and MMSC and the fact that
the latter is converted via the transsulfuration pathway to cysteine11
suggest that the actions of the
sulfhydryl-containing agents used
were provided by cysteine.
Adverse effects, whether mild or
sufficiently troublesome to lead to
withdrawal, occurred in small num
bers of patients (Table I), and there
were no obvious treatment-related
changes in hematologic or biochem
ical values. These findings illustrate
the safety of cysteine and MMSC. It
would be an advantage if their daily
doses could be reduced without
compromising efficacy.
The compliance of patients with
the regimen was carefully moni
tored, and any violation led to ex
clusion of the patient (Table I).
Compliance was similar among the
groups, so the results cannot be
ascribed to differences in patient
compliance or to an unintended bias
CJS. VOL. 36, NO. 1, FEBRUARY 1993
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in favour of a particular group,
which may influence compliance.
Although sulfhydryl-containing
agents can be detected on the
breath, this was never raised by any
patient as a significant source of
inconvenience. Furthermore, it
could not be seen as a source of
bias in favour of any of the study
groups, since the primary parame
ters of assessment were objective
(Table III).

ulceration in the rat. J Pharm Phar
macol 1990; 42: 64-67
11. T urner FP, Brum VC, B ilodeau EG:
Incorporation of 355 L-methionine by
the rat with steroid ulceration. J Maine
Med Assoc 1977; 68: 227-243
12. Zalewsky CA, Moody FG: Mechanisms
of mucus release in exposed canine
gastric mucosa. Gastroenterology 1979:
77: 719-729
13. S tarkey BJ, S nary D, Allen A: Charac
terization of gastric mucoproteins isolat
ed by equilibrium density-gradient cen
trifugation in caesium chloride. Biochem

I am grateful to Dr. S.H. Alwash for the
opportunity to undertake this work at
the Medical City and to the nursing
staff for their help during the course of
the investigation. 1 am also grateful to
Mrs. Jutta Gaskill and to Mrs. Moira
Cairney for secretarial work.
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Lake Tahoe Annual Vascular
Conference
The course entitled “Strategies in Vas
cular Disease: Minimizing the Morbidity
in Diagnosis and Treatment” will be
offered at the Lake Tahoe Annual Vas
cular Conference to be held from Mar.
15 to 17. 1993. at the Resort at Squaw
Creek in Olympic Village, Squaw Val
ley. Calif. The conference is sponsored
by the Office of Continuing Medical
Education, UC Davis School of Medi
cine and Medical Center. The course is
designed for surgeons and radiologists
who deal with the complexities and
challenges of peripheral vascular dis
ease. For information contact: Office of
Continuing Medical Education, UC
Davis Medical Center, 2701 Stockton
Blvd., Sacramento, CA 95817; phone:
(916)734-5390

Symposium VIII on
Room Environment

Operating

This symposium will be held from May
3 to 5, 1993, at the Stouffer Harborplace Hotel in Baltimore. The sympo
sium is presented by the American
College of Surgeons in cooperation
with the American Society of Anesthesi
ologists and the Association of Operat
ing Room nurses. Five separate infor
mation sessions will be presented on
timely operating-room topics of ethical
conflicts in patient care, leadership,
environmental hazards, operating-room
efficiency and technology assessment.

J 1974; 141:633-639
14. Hogan D, T homas F, Isenberc J: A
single dose of cimetidine prevents As
pirin-induced gastric damage in man.
Dig Dis Sci 1986; 31 (suppl): 481S
15. Hawkey CJ, Ramptom DS: Prostagland
ins and the gastrointestinal mucosa: Are
they important in its function, disease,
or treatment? Gastroenterology 1985;
89:1162-1188
16. B ennett A. Collins P, T avares I:
Human gastric mucosal damage by anti
inflammatory drugs. Dig Dis Sci 1986;
31 (suppl): 483S

For more information contact: Ameri
can College of Surgeons, Committee on
Operating Room Environment, 55 E
Erie St., Chicago. IL 60611-2797;
phone: (312) 664-4050, ext. 250 or
361.

Progress in Gastrointestinal
Surgery
A course entitled "Progress in Gastroin
testinal Surgery” will be presented as
the major topic of the 57th Annual
Surgery Course, to be held from June
16 to 19, 1993, at the University of
Minnesota. The course is presented by
the Department of Surgery of the Uni
versity of Minnesota Medical School.
For more information contact: Office of
Continuing Medical Education, Univer
sity of Minnesota, Radisson Hotel Metrodome, Suite 107, 615 Washington
Ave. SE, Minneapolis, MN 55414;
phone: 1-800-776-8636; fax: (612)
626-7766

International Surgical Week
The 35th World Congress of Surgery of
the International Society of Surgery
with its integrated societies presents
International Surgical Week from Aug.
22 to 27, 1993, in Hong Kong. For
more information contact: Congress
Secretariat, 1SW Hong Kong, Depart
ment of Surgery, University of Hong
Kong, Queen Mary Hospital, Hong
Kong; phone: (852) 819-2235; fax:
(852)855-1897.
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Hematuria and Intravenous Pyelography
in Pediatric Blunt Renal Trauma
Paul F. Middlebrook, MD, FRCSC;* John F. Schillinger, MD, FRCSCt
Because the traditional protocol for investigating blunt renal trauma in children has
been questioned and because of societal awareness of health care costs, the authors
carried out a retrospective review of blunt renal trauma in 138 children over a
5-year period to establish criteria for urgent radiologic investigation of those with
suspected renal trauma. From their findings, they recommend that in the absence of
the suspected major injuries and hypotension a threshold count of 40 red blood cells
per high-power field is necessary before urgent intravenous pyelography should be
done.

Vu la remise en question du protocole traditionnel d'investigation des traumatismes
renaux fermes chez l’enfant et la conscientisation du public a l’augmentation des
frais de sante, les auteurs ont mene une etude retrospective portant sur 138 enfants
victimes de traumatismes renaux fermes au cours d’une periode 5 ans, afin d’etablir
les criteres commandant l’examen radiologique d’urgence de ceux soup^onnes de
traumatismes renaux. Des resultats obtenus, ils recommandent qu’en l’absence de
lesions importantes et d’hypotension, un seuil de 40 hematies par champ
microscopique a fort grossissement soit necessaire avant de pratiquer une
pyelographie intraveineuse d’urgence.

lthough hematuria is widely
recognized as an indicator of
potential urinary tract injury in
trauma, controversy persists over
the necessity of investigation in all
patients having hematuria after
blunt trauma and about the urgen
cy with which such investigation
should be performed. This contro
versy is further compounded by the
fact that current management for
most blunt renal injuries is conser
vative, so imaging results lead to
few changes in management. The
traditional method of investigating

A

these patients has been with intra
venous pyelography (IVP), although
enhanced computed tomography
(CT) is routinely used in many cen
tres.
The majority of patients with
blunt renal trauma have minor renal
involvement. Traditionally, children
have a greater propensity to pedicle
injuries with minimal hematuria.
Further, the incidence of congenital
anomalies in children is higher than
in adults, which may account for
renal injury with minor trauma.
Complicating this, is the incidence
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on routine analysis of microscopic
hematuria in children with no mor
bid condition. Hitherto, we have
investigated urgently all children
with significant abdominal trauma
who have hematuria. Recent arti
cles questioning this approach plus
a societal awareness of health care
costs led to a retrospective appraisal
of this approach.

Method
The standard management of
blunt trauma patients with either
gross or microscopic hematuria by
the urology service at the Chil
dren’s Hospital of Eastern Ontario,
Ottawa, has been urgent imaging
with IVP unless other suspected
injuries warrant alternative initial
procedures (e.g., CT). Patients with
normal findings on IVP have been
assumed to have minor renal contu
sions and have been managed with
bedrest in hospital until their urine
is clear. Major renal injuries have
been managed with bedrest for at
least 10 days and ambulation only
after the urine is clear and further
imaging indicates some resolution
of the local lesion. The records of
all patients with a diagnosis of renal
trauma (including contusion, lacera
tion, fracture and pedicle injury)
seen at our institution between Jan
uary 1986 and December 1990
were reviewed. For each patient, the
following data were collected: age,
sex, mechanism of injury, present
ing blood pressure, severity of he
maturia, result of initial imaging,
final diagnosis, associated injuries,
blood transfusion requirements and
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length of hospitalization. Note was
also made of adverse reactions to
the radiocontrast agent used in im
aging these patients. For purposes
of analysis, renal injuries diagnosed
as contusions (including those with
no identifiable lesion on imaging)
were classified as minor. Major inju
ries consisted of renal lacerations,
fractures and pedicle injuries. He
maturia was quantified as follows:
gross, greater than 40 red blood
cells per high-power field (rbc/hpf),
20 to 40 rbc/hpf and less than 20
rbc/hpf. A patient was considered
to be hypotensive if the first record
ed systolic blood pressure was
below 100 mm Hg. Associated inju
ries were considered major if they,
independently, would require hospi
talization beyond 24 hours. The
severity of renal injury was correlat
ed with the severity of hematuria,
the presence of hypotension, the
presence of associated major inju
ries, the mechanism of injury, the
duration of hospitalization and the
need for blood transfusion.

shock, underwent immediate lapa
rotomy. IVP successfully identified
all major renal injuries among the
children who underwent this inves
tigation.
A number of significant non-renal
abdominal injuries were also detect

ed (Table III), most of which were
identified by IVP. The exceptions
were three splenic contusions, one
hepatic contusion and one hema
toma in the gastrosplenic ligament.
These were identified by ul
trasonography or CT.

FIG. 1. Age range of 138 children with blunt renal trauma.

Findings
Table 1. Mechanisms of Injury

The records of 138 children (104
boys, 34 girls) were reviewed. No
child in the study had sustained
penetrating renal trauma. The chil
dren ranged in age from 2 to 17
years (Fig. 1), with a trend toward
the early to middle teenage years.
Falls and traffic accidents were the
most common mechanisms of injury
(Table I). Only 12 children sus
tained major renal injuries.
In itia l Im ag ing Investigations

IVP was the initial investigation
in 121 children, ultrasonography in
12 children and CT in 3 (Table II).
Two children did not undergo initial
diagnostic imaging: one had mini
mal microscopic hematuria: the oth
er, who was admitted in profound
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No. of patients
Mechanism
Fall
Traffic accident
Sports
Blow
Total

Minor renal
injury

Major renal
injury

Total

47
46
21
12

7
4
0
1

54
50
21
13

126

12

138

Table II. Results of Initial Diagnostic Investigation*
No. of patients
Result
Normal
Contusion
Laceration
Fracture
Pedicle injury
Total

Intravenous
pyelography

Ultrasonography

Computed
tomography

Total

80
32
6
3
0

7
4
1
0
0

0
2
1
0
0

87
38
8
3
0

121

12

3

136

*No imaging in two patients: one had minimal microscopic hematuria; the other was admitted in
profound shock with massive hemorrhage and underwent emergency laparotomy.

PEDIATRIC BLUNT RENAL TRAUMA

Severity of Hematuria
The severity of hematuria corre
lated with the presence of major
renal injuries (Table IV). For those
whose urinalysis results were re
corded, no child with fewer than 40
rbc/hpf in the urine had a major
renal injury. One had an isolated
major renal injury with micro
hematuria (> 40 rbc/hpf) alone.
This represents a positive predictive
value of 21% for gross hematuria
and 12% if all hematuria greater
than 40 rbc/hpf is considered. The
child admitted in profound shock
with massive intra-abdominal inju
ries who underwent immediate lapa
rotomy had no urine obtained for
analysis. This was the only patient
in the series who required laparoto
my.

child. One horseshoe kidney and
one ureterocele were also identified.
None of these patients sustained
major renal injuries.

major nonrenal injuries.) Thus, only
2 (17%) of the 12 patients sustain
ing major renal injury had hypoten
sion.

Hospital Stay

Other Considerations

The mean hospital stay for those
with minor renal injuries was 5.0
days (range of 0-to 14 days). The
longer hospitalizations were due to
associated nonrenal injuries. How
ever, the mean hospital stay for the
nine children with major renal inju
ries who were discharged was 18.5
days (range from 10 to 30 days).

Seven patients required blood
transfusion in the form of packed
red blood cells. Of these, five had
sustained major renal injuries. In
most of these cases, associated inju
ries were responsible for the blood
loss, but one patient had an isolated
major renal injury requiring trans
fusion. Four patients suffered com
plications directly related to their
renal injuries or to investigation for
these injuries. Although no patient
had a major reaction to radiocon
trast agents, two minor reactions
were recorded requiring antihista
mine therapy. One child had hyper
tension, which responded well to
medical therapy. Persistent hematu
ria was seen in one patient who
eventually required angioinfarction
of a renal segment to control the
bleeding. Both patients with compli
cations not related to radiocontrast
agents had major renal injuries.

Nonrenal Injuries
Forty-four major nonrenal inju
ries were sustained by 33 patients
(Table III). Six (18%) of the 33
patients had major renal injuries
compared with 12 (8.7%) of 138
patients in the total study popula
tion who had renal injuries.
Hypotension was seen in 12 pa
tients, only 2 of whom had major
renal injury. (Both had coexisting

Congenital Renal Anomalies
Congenital renal anomalies were
noted in four patients. Two had a
duplex collecting system, which had
previously been diagnosed in one

T a b le 111. M a jo r N o n re n a l In ju rie s in T ra u m a P a tie n ts W ith H e m a tu ria
N o. of in ju rie s

T o ta l no.

No. in p a tie n ts with
m a jo r re n a l injury

M a jo r b o n e fra c tu re
S p le n ic /h e p a tic la c e ra tio n
S p le n ic /h e p a tic c o n tu s io n
S ig n ific a n t head in ju ry
M a jo r th o ra c ic in ju ry

17
11
8
6
2

1
6
0
2
2

T otal

4 4 (in 3 3 p ts )

T yp e of injury

11 (in 6 p ts )

T a b le IV . H e m a tu ria in R enal T ra u m a P a tie n ts
N o. of p a tie n ts
D e g re e of
h e m a tu ria , rb c /h p f*
G ross
> 40
2 0 -4 0
< 20
2 + o n d ip s tic k
(n o m ic ro h e m a tu ria )
No u rine sa m p le a va ila b le
T otal
*R ed b lo o d c e lls p e r h ig h -p o w e r fie ld

M inor ren al
injury

M a jo r re n a l
injury

Total

38
41
21
25

10
1
0
0

48
42
21
25

1
0

0
1

1
1

126

12

138

Mortality
Three children died: two from a
closed head injury and one from
massive intra-abdominal and pelvic
hemorrhage (the child who required
emergency laparotomy for multiple
abdominal and pelvic injuries). All
three patients had sustained major
renal injuries, but these were not
considered directly responsible for
the deaths.

Discussion
Although the incidence of major
renal injuries in the pediatric litera
ture varies from 0%’ to 18%,2 our
incidence of 8.7% is consistent with
that of most series (5% to 10%).3~9
CJS, VOL. 36, NO. 1, FEBRUARY 1993
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Pedicle injuries are uncommon, and
although they were absent in our
series and that of others,7 they may
represent up to 2.5% of renal inju
ries, but they always occur with
major associated injuries.9
Congenital anomalies are tradi
tionally said to predispose the kid
ney to injury and are found in up to
17% of patients in blunt trauma
series.7 Our incidence of 2% differs
little from that expected in the
general population. The diagnosis
of renal injury with blunt abdominal
trauma has generated controversy
over the imaging modality used, the
indications for imaging and the ur
gency for performing imaging.
IVP is the traditional and most
widely available imaging technique.
In our series, only 22% of children
with abnormal findings on IVP had
major renal injury, but IVP missed
no major renal injury subsequently
found by other imaging techniques.
However, 5 (26%) of 19 children
with associated major nonrenal ab
dominal injuries had normal find
ings on IVP. This finding supports
the conclusion of Taylor, Eichelberger and Potter,8 who found that
73% of patients with traumatic he
maturia had significant other ab
dominal injuries that were missed
by IVP but were found by CT. They
concluded, and we concur, that en
hanced CT should be performed in
any patient with hematuria and evi
dence of other abdominal injury.
Ultrasonography with Doppler flow
or with nuclear renography may be
superior to IVP in defining renal or
other solid-organ injuries but is not
available consistently on an emer
gency basis in many centres, includ
ing our own.
The indications for renal imaging
with blunt trauma are controversial.
Some have reported the association
of major renal injury with micro
scopic or no hematuria.9 These in
stances are associated, however,
with other major injuries. Oth62
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ers3’410 have indicated that if mi
crohematuria with hypotension or
gross hematuria alone are the indi
cations for imaging, then 99% to
100% of all major renal injuries will
be identified.
In our series, 10 (91%) of 11
patients (one excluded because no
urinalysis was available) with major
renal injury had gross hematuria.
One, however, had microscopic he
maturia (greater than 40 rbc/hpf)
only and no other associated injury
or hypotension. The predictive fac
tors for major renal injury are far
from perfect. From several series3’4’10 the values reported were:
hypotension 17%, associated nonre
nal injuries 18%, gross hematuria
21% and hematuria greater than 40
rbc/hpf 8% (our series). If we had
applied the criterion of the thresh
old of hematuria being 40 rbc/hpf
or greater, all major renal trauma
would have been found by 90 imag
ing studies to detect 11 cases (Ta
ble IV). but 47 studies (34% of all
studies) would have been eliminated
(on an emergency basis at least).
From these studies and ours, we
conclude that urgent renal imaging
should be obtained in blunt abdomi
nal trauma if there is gross hema
turia or microscopic hematuria
greater than 40 rbc/hpf. In these
cases an IVP is adequate for diag
nostic imaging. If other major trau
ma or hypotension is present or
suspected, and either of these is
associated with gross or microscop
ic hematuria of any degree, then
contrast enhanced CT should be
done. These criteria should be suffi
cient to pick up all major renal
injuries including pedicle injuries.
It must be remembered that 4%
of primary school children have
microscopic hematuria on a single
urinalysis.11 Thus, children not
meeting the above criteria but with
less than 20 rbc/hpf should have a
future repeat urinalysis before fur
ther investigation. Those with a

count of 20 to 40 rbc/hpf should
be put on bedrest and undergo
non-urgent ultrasonography as a
precaution against the error in the
absolute precision of microscopic
urinalysis.
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T h e Clinical Significance of Acute
Hyperamylasemia After Blunt Trauma
Bernard R. Boulanger, MD, FRCSC;* David P. Milzman, MD;f Carl Rosati, MD, FRCSC;J
Aurelio Rodriguez, MD, FACS§
The clinical value of total serum amylase (TSA) levels measured after blunt trauma
remains controversial. To test the utility of this measurement, the authors surveyed
the routine admission TSA levels of 4316 adults who were victims of blunt trauma.
Most patients (58.2%) had been injured in motor vehicle accidents, and all were
admitted directly from the accident scene. Patients were divided into two groups
based on the admission TSA level: more than 125 U /L (abnormal) and 125 U /L or
less (normal). Of the 4316 patients, 3920 (90.8%) had a normal TSA level upon
admission. Hyperamylasemia was associated with a greater injury severity score
(ISS) and death rate, a lower admission Glasgow Coma Scale score and an increased
incidence of facial fracture, brain injury, pancreatic and hollow-viscus injuries and
hypotension (p < 0.01). However, the positive predictive value of an abnormal TSA
level for pancreatic and hollow-viscus injuries was 1.5% and 3.0% respectively. Also,
most patients with pancreatic (65%) and hollow-viscus (83%) injuries had a normal
TSA level. There was no relation between the anatomic grade of pancreatic injury
and the TSA level.
Acute hyperamylasemia after blunt trauma appears to be a poor predictor of
pancreatic and hollow-viscus injuries. Therefore, urgent TSA determinations should
not influence the clinical and radiologic evaluation of the blunt trauma victim.

L’interet clinique des niveaux d’amylase serique totale (AST) mesures apres un
traumatisme ferme demeure sujet a controverse. Dans le but de mesurer l'importance
de cette mesure, les auteurs ont mene une enquete sur les taux d’AST mesures de
fa$on systematique chez 4316 adultes, victimes de traumatismes fermes. La plupart
des patients (58,2 %) avaient ete blesses dans des accidents de la circulation et tous
sont arrives directement de la scene de l’accident. Les patients furent divises en deux
groupes selon leur niveau d’AST a l’arrivee : 125 U /L ou plus (anormal) ou moins
de 125 U /L (normal). Sur les 4316 patients, 3920 (90,8 %) avaient des taux d’AST
normaux. L’hyperamylasemie a ete relie a un indice de gravite des blessures (IGB) et
a une mortality plus eleves, a une cote plus faible sur l’echelle devaluation du coma
de Glasgow, et a une incidence plus elevee des fractures faciales, des lesions
cerebrates, des blessures du pancreas et des visceres creux, et d’hypotension (p <
0,01). Toutefois, les valeurs previsionnelles positives d’un AST anormal pour les
blessures du pancreas ou des visceres creux ont ete de 1,5 % et 3,0 %,
respectivement. De plus, la plupart des patients ayant des lesions pancreatiques
(65 %) ou des visceres creux (83 %) avaient des AST normaux. II n’y avait aucune
relation entre le grade anatomique des lesions pancreatiques et le niveau d’AST.
L’hyperamylasemie aigue post-traumatique semble un mauvais predicteur des
blessures du pancreas ou des visceres creux. En consequence, les dosages de LAST
en urgence ne doivent pas influencer revaluation clinique et radiologique des
victimes de traumatismes fermes.

he role of serum amylase in the
evaluation and management of
nontraumatic pancreatic disorders
is well established.12 Determination
of the total serum amylase (TSA)
level was first reported as useful in
the evaluation of the blunt trauma
victim in 1943.3 Since then there
have been conflicting reports on the
value of TSA in the acutely trauma
tized patient.4-7 Hyperamylasemia is
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associated with severe brain injury,
facial trauma and hypotension.8-10
The recent literature appears to
favour the hypothesis that acute
TSA is not clinically useful in the
blunt trauma victim.1112 However,
this hypothesis has not been tested
in a large group of blunt trauma
victims whose TSA levels have been
determined routinely.
Blunt pancreatic and hollow-viscus injuries are notoriously difficult
to detect nonoperatively, and clini
cians have sought reliable noninvasive diagnostic methods. Hyperamylasemia has been demonstrated in
61% to 90% of patients with blunt
pancreatic injuries and is known to
occur after bowel perforation and
ischemia.13"16 These data and the
lack of superior laboratory tests
have become the impetus for rou
tine determination of TSA levels in
the initial evaluation of the blunt
trauma victim with possible intra
abdominal injury. It is our hypothe
sis that acute hyperamylasemia is a
poor marker of pancreatic and hollow-viscus injury and that the inci
dence of acute hyperamylasemia
should not influence the clinical and
radiologic evaluation of the blunt
trauma victim.

Patients and Methods
The R Adams Cowley Shock
Trauma Center of the Maryland
Institute for Emergency Medical
Services Systems (M1EMSS) in Bal
timore is the clinical hub of Mary
land’s statewide emergency medical
services (EMS) system. Patients ad
mitted to the trauma centre are
managed with established institu
tional protocols by a trauma team
consisting of an attending trauma
tologist, a trauma surgery fellow
and three to four residents in sur
gery or emergency medicine.17 Ab
dominal injury is diagnosed or ex
cluded by diagnostic peritoneal la64
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vage, computed tomography (CT)
or repeated clinical examination.
Blood for TSA determination is
drawn routinely on admission to the
Shock Trauma Center. TSA is mea
sured by an enzymatic rate method
(Beckman Synchron CX4; Beckman
Instruments, Inc., Brea, Calif.) (nor
mal, 125 U /L or less).
Between July 1987 and June
1990, 4404 adult (more than 14
years old) blunt trauma victims
were admitted to the trauma centre
directly from the accident scene
(vital signs present). Of these, 4316
(98%) had TSA concentrations mea
sured within 90 minutes of admis
sion. Prospectively collected data
were obtained on these 4316 pa
tients from the MIEMSS-Dunham
clinical trauma registry.18 The study
population of 4316 patients was
divided into two groups: those with
a normal TSA level (125 U/L or
less) and those with an abnormal
TSA level (more than 125 U/L).
These groups were compared with
respect to age, sex, mechanism of
blunt injury, injury severity score
(ISS), admission Glasgow Coma
Scale (GCS) score, admission systol
ic blood pressure, results of ethanol
screening, the incidence of facial
and skull fractures and brain injury
and the incidence of pancreatic,
gastric, duodenal, small-bowel, co
lonic and rectal injuries. Ethanol
screens were recorded as positive or
negative. Brain injury was defined
as an intracranial traumatic lesion
demonstrated by CT. Hospital
charts were examined for patients
with a blunt pancreatic injury to
anatomically grade the injury ac
cording to the guidelines of Moore
and colleagues.19
The sensitivity, specificity, posi
tive predictive value and negative
predictive value for admission TSA
level as a test for pancreatic or
hollow-viscus injury were calculat
ed. Patient groups were compared
by Student’s f-test or x2 analysis, as

appropriate. All values are present
ed as means ± standard deviation.

Findings
The average age of the 4316
patients was 33.3 ± 15.8 years.
Males made up 69.6% of patients. A
majority of patients (2513 [58.2%])
had been involved in motor vehicle
accidents. The remainder were vic
tims of motorcycle accidents (320
[7.4%]), falls (610 [14.1%]), pedes
trian trauma (309 [7.2%]), bicycle
accidents (50 [1.2%]), blunt beat
ings (209 [4.8%]) and miscellaneous
mechanisms of injury (305 [7.1%]).
The mean ISS was 13.8 ± 12.4 and
the mean admission GCS score 13.8
± 2.7. Patients were transported
from the field by helicopter (2856
[66.2%]) or land ambulance (1460
[33.8%]). Hypotension (admission
systolic blood pressure less than 90
mm Hg) was present in 140 (3.2%)
patients. The in-hospital death rate
for these 4316 patients was 5.3%
(229 patients).
Of the study population, 3920
(90.8%) had an admission TSA con
centration in the normal range (125
U /L or less), and 396 patients
(9.2%) had abnormal TSA concen
trations (more than 125 U/L). Of
the 396 patients with abnormal
TSA levels, 309 (78.0%) had TSA
levels ranging from 126 to 200
U/L, 62 (15.7%) had levels ranging
from 201 to 300 U/L, and 25
(6.3%) had TSA levels greater than
300 U/L (Fig. 1).
When the 3920 patients with
normal TSA levels and 396 patients
with abnormal TSA levels were
compared (Tables I and II), signifi
cant differences were found be
tween the two groups for the fol
lowing factors: ISS, GCS score,
death rate and the frequency of
admission hypotension, facial frac
tures, and brain, pancreatic, and
hollow-viscus injuries (p < 0.01).
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blood pressure less than 90 mm Hg
and in 366 (8.8%) of 4176 patients
admitted with a systolic blood

An abnormal TSA concentration
was found in 30 (21.4%) of 140
patients admitted with a systolic
100
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FIG. 1. Total serum amylase (TSA) levels among 4316 adult blunt trauma victims
admitted directly from accident scene.
Table I. Comparison of Clinical Factors in Patients With Normal and Abnormal Total Serum
Amylase (TSA) Levels

Clinical factor
Mean age, yr (SD)
Males, %
Mean injury severity
score (SD)
Mean Glasgow Coma
Scale score (SD)
Ethanol screen,
% positive
Motor vehicle accident, %
Admission systolic
blood pressure,
< 90 mm Hg, %
Mortality, %

Normal (n = 3920)

Abnormal (n = 396)

Significance,
/rvalue

33.0(15.6)
69.8

35.9(16.5)
68.4

NS
NS

13.1 (11.9)

18.2(14.9)

< 0.001

13.9(2.6)

12.9(3.5)

< 0.001

31.4
57.8

35.3
62.1

NS
NS

2.8
4.6

7.6
12.4

< 0.001
< 0.001

SD = standard deviation

Table II. Comparison of Injuries in Patients With Normal and Abnormal TSA Levels
TSA, U/L
Injury
Brain injury
Facial fracture
Skull fracture
Pancreatic injury
Hollow-viscus injury

Normal, no. (%)
(rr = 3920)
495
245
351
11
59

(12.6)
(6.2)
(9.0)
(0.3)
(1.5)

Abnormal, no. (%)
(n = 396)

Significance,
p value

69(17.4)
49(12.4)
43(10.9)
6 (1.5)
12 (3.0)

< 0.01
< 0.01
NS
< 0.01
< 0.01

pressure greater than 90 mm Hg
(p < 0 . 001 ).
The 3006 males and 1310 fe
males in the study population had
similar incidences of abnormal TSA
concentrations (9.0% and 9.5% re
spectively). An abnormal TSA con
centration was equally prevalent
among patients with positive and
negative ethanol screens (10.2%
and 8.7%, respectively). Of the 25
patients with TSA levels greater
than 300 U /L, 10 had a positive
ethanol screen.
Of the 3920 patients with normal
TSA levels, 11 (0.3%) had pancreat
ic injuries and 59 (1.5%) a hollowviscus injury, and of the 396 pa
tients with abnormal TSA levels, 6
(1.5%) had pancreatic injuries and
12 (3.0%) a hollow-viscus injury
(Tables II to IV).
The highest TSA level among the
17 patients with pancreatic injuries
was 362 U /L. The 17 blunt pancre
atic injuries were graded according
to the system of Moore and col
leagues,19 and the injuries were
evaluated according to the TSA
levels (Table V).
No gastric or small-bowel injuries
were sustained by the 25 patients
with a TSA level greater than 300
U/L. One patient had a duodenal
injury, and another had colonic and
pancreatic injuries. The patient with
the highest recorded admission
TSA level (730 U/L) had no pan
creatic or hollow-viscus injury.
The TSA values for patients with
pancreatic, stomach, duodenal,
small-bowel and large-bowel inju
ries are shown in Fig. 2.
At the MIEMSS Shock Trauma
Center, the laboratory cost of a
TSA level assay is $1.50 US. There
fore, the cost of the routine TSA
measurements in these 4316 pa
tients was $6474.
The sensitivity, specificity, posi
tive predictive value and negative
predictive value for abnormal TSA
as a test for blunt pancreatic and
CJS, VOL. 36, NO. 1, FEBRUARY 1993
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hollow-viscus injury are shown in
Tables III and IV.

Discussion
Amylase, an enzyme that hydro

lyzes glycoside bonds, is a product
of two genes known as AMY 1
(salivary) and AMY 2 (pancreatic)
coded on chromosome number l . 20
The AMY 1 isoamylase, although
predominantly salivary in origin, is
also produced by the lacrimal

Table III. Evaluation of Abnormal TSA Level as a Test for Blunt Pancreatic Injury*
Pancreatic injury, no.
TSA level

Positive

Negative

Total

Normal
Abnormal

11
6

3909
390

3920
396

Total

17

4299

4316

'Sensitivity, 35.3%; positive predictive value, 1.5%; specificity, 91.3%; negative predictive value,
99.7%
Table IV. Evaluation of Abnormal TSA Level as a Test for Blunt Hollow-Viscus Injury*
Hollow-viscus injury, no.
TSA
Normal
Abnormal

Positive

Negative

Total

59
12

3861
384

3920
396

Total___________________________ 71__________________4245________________ 4316
'Sensitivity, 16.9%; positive predictive value, 3.0%; specificity, 91.0%; negative predictive value,
98.5%

glands, lungs, breasts and mullerian
tissues. The AMY 2 isoamylase is
produced only by the pancreas.21
Pancreatic isoamylase represents
approximately 33% of TSA in a
healthy human subject.22 Thus,
there are two main sources of
serum amylase: the pancreas and
salivary glands.
Any insult to tissues that contain
amylase may be associated with
hyperamylasemia. Interestingly, ma
lignant tumours of the lung, ovary,
colon and pancreas may have the
capacity to secrete amylase.23 In
1929, Elman, Avneson and Gra
ham24 reported the association be
tween pancreatic disease and hype
ramylasemia. Since their initial ob
servation, attention on the amylases
has focused on their use in the
diagnosis and management of pan
creatic diseases. Since the report of
Naffziger and McCorkle3 in 1943,
TSA determination has been used
to assess the possibility of pancreat
ic injury in the trauma victim, but
its usefulness in blunt trauma re
mains controversial.
In the multitraumatized patient,
hyperamylasemia may result from
circulatory shock, ingestion of
ethanol or narcotics, starch plasma
expanders and extra-abdominal in
jury.8102526 Olsen27 found that only
8% of patients with hyperamyla
semia and blunt abdominal trauma
had a pancreatic injury. In our
patients, the positive predictive
Table V. Relationship Between Grade of
Blunt Pancreatic Injury and Admission TSA
Level in 16 Patients*
Grade19
I
II
III
IV
V

FIG. 2. Distribution of TSA among patients with blunt pancreatic and hollow-viscus
injuries. Horizontal line indicates upper limit of normal (125 U /L ) for TSA. P =
pancreas, S = stomach, D = duodenum, SB = small bowel and LB = large bowel.
Numbers in brackets indicate number of patients with respective injury.
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TSA level, U/L
53,64,67,74,77,
95,96,98,170,178,
190,212
106,362
91
86
None

'One patient had an unknown grade of
pancreatic injury and a TSA level of 208
U/L.

ACUTE HYPERAMYLASEMIA AFTER BLUNT TRAUMA

value and sensitivity of hyperamylasemia as a test for pancreatic injury
were 1.5% and 35.3% respectively.
It is clear that an abnormal TSA
level is a poor marker of pancreatic
injury and that most patients with a
pancreatic injury will have a normal
TSA value. Reports of the efficacy
of pancreatic isoamylases and lipase
in evaluating the status of a blunt
trauma victim have also been disap
pointing.1112 The quest for a simple
blood test that will differentiate
pancreatic from extrapancreatic in
jury continues.
It is well accepted that the serum
amylase level does not correlate
with the severity of acute pancreati
tis.28 There are many reports of
severe pancreatic injuries in pa
tients with normal TSA levels. In a
series of 500 pancreatic injuries,
only 65% of patients with complete
pancreatic transection had elevated
TSA levels.14 In a study of endo
scopic retrograde cholangiopan
creatography in pancreatic trauma,
the degree of hyperamylasemia did
not correlate with ductal rupture.29
Table V19 relates the anatomic
grade of the pancreatic injuries in
our study to admission TSA levels.
There was no clear relationship be
tween the grade of pancreatic injury
and the TSA level. Therefore, the
admission TSA level is no measure
of the severity of a pancreatic inju
ry.
In both adults and children there
are increasing reports of the conser
vative management of radiologically
detected intra-abdominal injuries.
Surprisingly, pancreatic injuries
have been managed nonoperatively.30,31 Clinical, laboratory and radi
ologic criteria are required for the
proper institution of such conserva
tive protocols. Our study clearly
demonstrates that admission TSA
determination is not an appropriate
guide to the conservative manage
ment of patients with blunt pancre
atic injuries.

Nontraumatic intestinal perfora
tion and ischemia or infarction are
associated with elevated TSA lev
els.15 Pancreatic isoamylase is pre
dominant because salivary amylase
is degraded by gastric juice.22 Blunt
traumatic intestinal injuries have
been associated with high serum
amylase levels in 52% of cases.16
Fig. 2 displays the distribution of
TSA levels among patients with
hollow-viscus injuries. As is evident,
most hollow-viscus injuries (83.1%)
are associated with normal TSA
levels. The positive predictive value
and sensitivity of abnormal TSA
levels as a test for hollow-viscus
injury were 3.0% and 16.9% respec
tively. Therefore, difficulty in the
nonoperative diagnosis of blunt in
testinal injury is not diminished by
knowledge of the TSA levels.
Many factors may influence TSA
concentrations in healthy subjects.
Females have a higher mean TSA
level than males.32 In our trauma
population, 9.5% of females and
9.0% of males had an abnormal
TSA level. Mean TSA levels have
been shown to increase with ad
vancing age in both sexes.32 In one
study, TSA activity was very low in
infants, reached adult levels in
10-year-old children and remained
constant to the eighth decade,
when there was a 40% increase.33
The mechanism of age dependency
of TSA concentration is thought to
be an age-related decrease in renal
function. It is interesting that there
was no age difference between pa
tients in the normal and abnormal
TSA groups (Table I). However,
trauma populations are skewed to
young ages; thus, it is difficult to
draw conclusions about the possible
age dependency of TSA. There may
be a genetic determinant of TSA, as
observed by Tsianos and col
leagues34 in a study of residents of
the United Kingdom. Dubick and
associates35 reported elevated serum
amylase levels in cigarette smokers.

These studies shed light on the
complexity of amylase metabolism.
The relationship between brain
injury and hyperamylasemia further
confounds the clinical application of
TSA levels in the trauma victim. It
appears that severe brain injury,
specifically intracranial bleeding,
may activate pathways that increase
TSA levels.9 Vitale and colleagues8
reported that 38% of patients with
severe head injury had hyperamyla
semia. In our study, 69 (12.2%) of
564 patients with an intracranial
traumatic lesion on CT scan had
hyperamylasemia. This group in
cluded patients with mild to moder
ate head injury, which may explain
the lower incidence of hyperamyla
semia. Patients in the abnormal
TSA group had a significantly
greater incidence of brain injury (p
< 0.01) (Table II).
The pancreas is susceptible to
ischemic injury, resulting in hype
ramylasemia. Also, hyperamyla
semia has been correlated with the
degree of lactic acidosis and, sepa
rately, hypotension in the trauma
victim.10,36 In our study, patients
with an abnormal TSA level had
greater anatomic injury, as mea
sured by ISS and GCS scores and
an increased death rate (p < 0.001).
The incidence of hypotension on
admission was significantly higher
in the abnormal amylase group (p <
0.001). Blood lactate concentration
was not included in our study, but
our findings indirectly support the
association between lactic acidosis
and hyperamylasemia. Thus, elevat
ed TSA levels soon after a blunt
traumatic event is an indirect pre
dictor of the degree of anatomic
and physiologic insult.
Hyperamylasemia has been well
documented following oral or max
illofacial trauma. Isoamylase deter
minations confirmed the predomi
nance of salivary hyperamylasemia
in this subset of patients.37 In our
study population, 17% of patients
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with facial fractures had an abnor
mal TSA level. Facial fractures were
much more common in patients
with an abnormal TSA level (p <
0.01) (Table II). Our findings con
firm those of previous studies and
cast further doubt on the utility of
TSA estimation in the multiple trau
ma victim.
The association between alcohol
consumption and pancreatitis is
well described. Some have ques
tioned whether acute alcohol con
sumption or binges raise serum
amylase levels. Bloch, Weaver and
Bouwman20 reported that 30 of 58
clinically intoxicated individuals had
hyperamylasemia, which was most
frequently salivary in nature. In
contrast, only 1% of patients with
recent significant ethanol consump
tion had amylase elevations more
than twice the upper limit of nor
mal.38 Our findings do not support
a relationship between a positive
ethanol screen following trauma
and TSA, because the incidence of a
positive ethanol screen was similar
in patients with normal and abnor
mal TSA levels. Also, patients with
a positive ethanol screen were
equally as likely to have an abnor
mal TSA level as patients with a
negative ethanol screen. The inci
dence of ethanol consumption in
the blunt trauma victim appears to
have no influence on acute TSA.
Blunt pancreatic injury is an un
common lesion in blunt trauma. It
is theorized that this is due to the
well-protected retroperitoneal loca
tion of the pancreas and the high
immediate mortality with associated
intra-abdominal vascular injuries.39
Blunt trauma victims should be
assumed to have an intra-abdominal
injury until such injury is excluded
by either repeated clinical examina
tions, CT or diagnostic peritoneal
lavage. In this study, the incidence
of pancreatic injury (0.4%) among a
large group of patients (4316) at
risk for intra-abdominal injury
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would have been greater if we were
to select patients with intra-abdomi
nal injury or those undergoing lapa
rotomy. However, the purpose of
this study was to determine the
utility of TSA determination in all
trauma victims, not in a selected
subgroup with heightened suspi
cion of abdominal injury.
It is important to emphasize that
our study population consisted of
patients transported directly from
the accident scene. In Maryland’s
well-developed EMS system, prehos
pital response and transport times
are minimized. The majority
(66.2%) of patients are transferred
from the accident scene by Mary
land State Police helicopter. Thus,
an admission TSA level is obtained
on this group of patients very soon
after the traumatic event. A rising
TSA level after admission may indi
cate pancreatic injury.40 Similarly, a
patient transferred from a referring
hospital, hours to days after trau
ma, may have a high TSA level. Our
study did not evaluate the utility of
TSA levels under these circum
stances.
In the practice of surgery, utiliza
tion review and quality assessment
of diagnostic tests have become
increasingly important in efforts to
curb escalating health care costs.
For the 4316 patients in our study,
the cost of routine TSA measure
ment was approximately $6500
over a 3-year period. Also, when
faced with an elevated TSA level,
clinicians may be inclined to per
form expensive diagnostic proce
dures, delay enteral feedings and
prolong nasogastric suctioning and
hospital stay. With the demonstrat
ed poor positive predictive value of
TSA for pancreatic and hollow-viscus injury (1.5% and 3.0% respec
tively), enormous costs will be in
curred to rule out intra-abdominal
injuries. Clearly, early determina
tions of TSA in the trauma victim
are of low cost-benefit. As the cost

analysis of TSA has demonstrated,
closer scrutiny of diagnostic proce
dures and tests that are regarded as
routine in the evaluation of the
trauma victim is required.
In conclusion, acute TSA deter
minations should not influence the
clinical or radiologic evaluation of
adults who are victims of blunt
trauma.
We thank Linda Kesselring, Mary-Joan
McHugh and Kim Mitchell for their
expert assistance.
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BOOK REVIEWS
con tinu ed from page 32

into and to read the critiques. I did not
find it provided a true or penetrating
test of any depth or breadth of surgical
knowledge.
I believe this is a book that would be
better borrowed than bought.

C hristopher Heughan, MB, BChir, FRCSC
Division of Surgery
Memorial University of Newfoundland
St. John’s, NF
A1B3V6

SURGICAL REVASCULARIZATION
OF THE HEART: THE INTERNAL
THORACIC ARTERIES. Edited by
George E. Green and Ram N. Singh.
Illust. Igaku-Shoin Medical Publish
ers, Inc., New York. 1991. Price not
stated. ISBN 0-89-640-198-7
The internal thoracic arteries have be
come standard conduits in coronary
artery bypass surgery, due largely to
the persistence and proselytizing of Dr.
George Green, who pioneered the con
cept and who has edited this mono
graph.
This book’s greatest virtue is a long
chapter, written by Dr. Frank Sims, on
the histologic features of the internal
thoracic arteries, offering explanations
for its resistance to atherosclerosis, and
its excellent long-term patency. This
chapter is lucidly written and contains
excellent photomicrographs. It offers
insight to surgeons on the rationale for
the use of these vessels as bypass
conduits.
The remainder of the text is devoted
to issues that have been extensively
covered elsewhere. The opening chapter
is a concise history of coronary surgery
by a participant in its beginnings, Dr.
Donald Effler. Three chapters are devot
ed to the angiographic anatomy of
these vessels, postoperative assessment
of them and clinical results.
Eight chapters written by Dr. Green
outline his philosophies and techniques
of coronary bypass surgery, from mak
ing the incision and cannulating vessels
for cardiopulmonary bypass to a discus
sion of postoperative management and
complications. Since beginning these
70
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techniques, Dr. Green has used the
operating microscope in place of the
optical loupes favoured by most cardiac
surgeons, and he extols the virtue of
this instrument and his rationale for its
use. There are many operative photo
graphs detailing the differences in oper
ative fields at different magnifications.
Dr. Green devotes a chapter to refut
ing the notion that spasm of these
arteries can and does contribute to
postoperative cardiac dysfunction. He
has even reviewed the cineangiograms
of patients cited in case reports in the
literature to back up his views.
The final chapter is a discussion of
arterial conduits other than the internal
thoracic arteries, including splenic, radi
al, right gastroepiploic and inferior epi
gastric arteries.
This small book should be of interest
to many cardiac surgeons because of
the interesting material on the histopathology of the internal thoracic arteries.
The appeal of the remainder of the
book will be limited, though the surgi
cal technique of a fine and respected
pioneer in coronary artery bypass sur
gery will always be of interest. It is
conceivable that for housestaff it could
serve as a primer for coronary artery
surgery.

Elliot T. Gelfand, MD, FRCSC, FACS
Department of Surgery
3H2.11 W.C. Mackenzie
Health Sciences Centre
University of Alberta
Edmonton, AB
T6G 2B7

THE PRINCIPLES OF TRAUMA
SURGERY. Edited by Joseph A. Moylan. 343 pp. Illust. Gower Medical
Publishers, New York. 1992. $155.
ISBN 1-56375-013-9
This guide will attract anyone who is
faced with emergency treatment of the
multiply injured patient. Once one
starts reading any of the 20 chapters
that might be of particular interest, it is
difficult to put the text down before
reading it from cover to cover. In my

experience of reviewing trauma texts
over many years, this is one of the very
best.
Multiple American authorities cover
each of the subjects from the points of
view of prehospital, emergency depart
ment and trauma specialists. Topics are
covered thoroughly and concisely and
are emphasized clearly with highlighted
tables and illustrations. The subject
matter is presented definitively, and
where controversy exists, the schools of
thought are explained. The pathophysi
ology of the mechanics of injury, respi
ratory failure and ventilatory support
for both penetrating and blunt injury
are clearly presented. Specific injuries
to the face, neck, chest, abdomen and
extremities are dealt with individually,
and appropriate surgical exposure and
techniques are described. Various organ
injuries are classified by severity, and
each classification of injury is separate
ly described with regard to the most
appropriate treatment. Pediatric trau
ma, various forms of nutrition, burn
management and specific injuries to the
face and hands are dealt with in detail.
Each chapter is thoroughly referenced.
The organization of various levels of
hospital trauma category are explained.
This, I believe, is particularly important
in Canada, where such great distances
separate the major trauma centres. A
thorough knowledge of the resource
base of each hospital is extremely im
portant so that undue delay in organiz
ing transfer to a major trauma centre,
where indicated, is avoided. The princi
ples of advanced trauma life support
(ATLS) are well covered, and, more
importantly, the management beyond
ATLS in resuscitation and specific treat
ment is appropriately explained.
1 find it difficult to criticize this work
because it is comprehensive and well
done. However, some emphasis might
have been directed toward the assess
ment of neurosurgical injury, indicating
when further resuscitation is contraindi
cated. Similarly, the significance of cer
tain orthopedic injuries such as the
crushed, disrupted pelvis, which is fre
quently associated with blunt trauma to
the colon and small bowel, and mesen-

continued on page 80
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Laparoscopic Gastrointestinal
Anastomoses
Dawn L. Anderson, BSc(Med), MD; Patrick J. O’Regan, MB, BCh, BAO, FRCSC
In a preliminary study of laparoscopic gastrointestinal anastomosis, a gastric outlet
obstruction was created under laparoscopic control in six domestic pigs, weighing
an average of 25 kg. A simultaneous gastroenterostomy was formed with an
end-stapling device. All animals recovered clinically, and good anastomotic healing
was documented 1 week postoperatively. The authors suggest that an end-stapling
device could be one method of creating a gastrointestinal anastomosis for humans
that is safe and reliable, allows rapid recovery and decreases hospital stay.

Au cours d’une etude preliminaire portant sur l’anastomose gastro-intestinale
laparoscopique, une obstruction de la sortie gastrique a ete creee sous controle
laparoscopique chez six pores domestiques pesant, en moyenne, 25 kg.
Concomitamment, une gastroenterostomie a ete effectuee a l’aide d’une agrafeuse a
alimentation par le bout. Tous les animaux ont recupere cliniquement et le succes de
de l’anastomose a ete verifie 1 semaine apres l’operation. Les auteurs suggerent
qu’une agrafeuse a alimentation par le bout pourrait servir a creer une anastomose
gastro-intestinale chez l’humain de fa$on sure et fiable, tout en assurant une
guerison rapide et en diminuant le temps d’hospitalisation.

ince the report in 1989 on
laparoscopic cholecystectomy,1
the age of videoendoscopic general
surgery has been expanding at an
explosive rate. Laparoscopic chole
cystectomy and appendectomy are
common,2-4 and techniques for
other procedures are being rapidly
developed. In this paper we describe
a technique of laparoscopic gastroduodenostomy in domestic pigs
using an end-stapling device, and
we discuss possible human applica
tions.

S

Materials and Methods
Six domestic pigs weighing 25

kg each were used for this study.
Under general anesthesia and with
antibiotic coverage, a Veress needle
was used to create a pneumoperito
neum with a Storz 9.9-L high-flow
insufflator (Laparoflator 26012C;
Karl Storz, Tuttlingen, Germany). A
Storz ST-615C xenon light source,
ST 599C flash generator, ST 9050
Supercam laparoscopic camera and
a Sony Trinitron monitor (model
PVM 1943 MD; Sony Corp., Tokyo,
lapan) were used, all supplied on
loan for research purposes by R.
Laborie Surgical Ltd. (Brossard,
Que.), as were all of the laparoscop
ic instruments. A forward-viewing
laparoscope was inserted near the
umbilicus, and three additional
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working ports made up the total of
four punctures. Ampicillin and gen
tamicin were used perioperatively
for antibiotic prophylaxis.
A gastric outlet obstruction was
created by placement of a ligature
of 0 Prolene around the proximal
duodenum and tying it tight with a
Roeder loop knot. The duodenum
was chosen as the small-bowel seg
ment to use in the anastomosis,
because in the pig the duodenum is
long, has an easily mobilized por
tion and is of similar diameter and
wall thickness to human jejunum.
This type of procedure performed in
humans would most likely use the
jejunum. A segment of duodenum
distal to the obstruction was
brought up to the anterior wall of
the stomach where it was held by
corner stay sutures placed directly
through the abdominal wall. Open
ings were made in stomach and
duodenum with cautery and scis
sors. An Endopath, single-loading
end-stapling device (Figs. 1 and 2)
applied on loan by Ethicon, Peter
borough, Ont., was used to place
15 titanium staples individually
along the back and front walls of a
2-cm diameter anastomosis. The an
imals were kept on intravenous hy
dration for 24 hours. Their diet was
advanced over 3 days, and they
were killed 1 week postoperatively.
The site of gastroduodenostomy
was examined with the organs in
tact, the stomach was then opened
to allow inspection and measure
ment of the anastomosis. A probe
was also inserted through the pylo
rus to confirm that the laparoscopically created gastric outlet obstruc-

LAPAROSCOPIC GASTROINTESTINAL ANASTOMOSES

tion was complete. The appearance
was recorded photographically.

Results
In terms of visual and manual
examination, healing of the gas
troduodenal anastomosis was virtu
ally complete in all six animals at

the time of sacrifice (Fig. 3). The
anastomotic diameter was always
between 15 and 20 mm. In every
case the obstructing suture around
the proximal duodenum was intact,
confirming that the anastomosis
was the sole route of gastric empty
ing.
One animal, the second in the
series, showed signs of intermittent
obstruction, manifested by vomiting

after ingestion of large amounts of
food or water. It tolerated frequent
small liquid feeds, however. At au
topsy it was found that, although
the anastomosis itself was well
healed and widely patent, the loop
of duodenum used had been inad
vertently twisted 360° intraoperatively, causing the short afferent
limb to obstruct the efferent limb
whenever the stomach was very
distended.
Two animals appeared sick postoperatively, but the attending veter
inarian diagnosed the source of
their sepsis as pneumonia, and they
were given appropriate antibiotics.
In both animals, the diagnosis of
respiratory infection, not intra
abdominal infection, was confirmed
after sacrifice.

Discussion

FIG. 1. Endopath (Ethicon, Peterborough, Ont.) end-stapling device.

FIG. 2. Staple formation.

The benefits of laparoscopic over
traditional open general surgical
techniques have only been well doc
umented for a few procedures such
as cholecystectomy and appendec
tomy.5-7 However, extrapolation
from the observed decrease in post
operative pain, length of hospital
ization and rapidity of return to
work has led many surgeons to
explore the frontiers of this tech
nology. Many reports are found in
the literature of familiar common
operations with well-established in
dications being performed under la
paroscopic control, such as vago
tomy, Nissen fundoplication, feed
ing jejunostomy and others.8-11
There are many situations that re
quire bypassing a segment of the
gastrointestinal or biliary tract for
established benign or malignant ob
struction or for prophylaxis as with
a vagotomy. A substantial benefit of
decreased narcotic analgesics would
be more rapid recovery of gastroin
testinal function. For patients with
malignant disease and reduced lifeCJS, VOL. 36, NO. 1, FEBRUARY 1993
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span, the avoidance of a major
laparotomy, especially for a pallia
tive procedure, would certainly add
to their quality of life. Thus, laparo
scopic cholecystojejunostomy, with
use of the end-stapling device,
might be appropriate treatment in
certain cases of obstructive jaundice
due to carcinoma of the head of the
pancreas.

Conclusions
The ability to perform a safe,
reliable gastrointestinal anastomosis
under laparoscopic control would
allow a wide variety of patients the
same benefits in terms of rapid

recovery and decreased hospital
stay currently enjoyed by patients
who undergo laparoscopic cholecys
tectomy. The authors suggest that
an end-stapling device is one meth
od of creating a suitable anastomo
sis for humans. This technique
could also be used to supplement
other methods — to complete an
endoscopic anastomosis, as an ad
junct to other stapling devices or
for suturing. An appropriate mul
tifire instrument would reduce oper
ating time.
The authors gratefully acknowledge the
financial support for this project from
R. Laborie Surgical Ltd., Brossard,
Que.
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O p en Cholecystectomy: Its Morbidity and
Mortality as a Reference Standard
Robert M. Girard, MD; Michel Morin, MD
In a retrospective study of 10 471 cholecystectomies, performed between 1971 and
1990, the incidence and causes of death and morbidity of cholecystectomy were
analysed. There were 47 postoperative deaths (0.4%); 6 deaths occurred in 5841
patients less than 50 years old, 23 in 3898 patients between 50 and 70 years old and
18 in 732 patients more than 70 years old. Death rates in each group were,
respectively, 0.1%, 0.6% and 2.5% (p < 0.001). The death rate in 9339 patients who
had cholecystectomy alone was 0.3% and the death rate in 1132 patients who had a
concomitant common bile duct exploration (CEDE) was 1.6% (p < 0.001).
Cardiovascular complications were the main cause of death, and biliary, pulmonary
and wound complications were the most common. There were 614 complications in
529 patients; 176 of these patients were less than 50 years old, 252 were between
50 and 70 years old and 101 were more than 70 years old. Complication rates were,
respectively, 3.0%, 6.5% and 13.8% (p < 0.001). For patients with cholecystectomy
alone the morbidity was 3.6% and for patients who had a concomitant CBDE the
morbidity was 17% (p < 0.001). The mortality and morbidity of cholecystectomy
increase significantly with age and a concomitant CBDE. However, patients who
underwent cholecystectomy electively or for acute cholecystitis had comparable
mortality and morbidity.

Dans une etude retrospective portant sur 10 471 cholecystectomies effectuees entre
1971 et 1990, on a analyse la frequence et les causes de la mortalite et de la
morbidite. Quarante-sept deces postoperatoires ont ete enregistres (0,4 %); 6 deces
sont survenus chez 5841 patients de moins de 50 ans, 23 chez 3898 patients de 50 a
70 ans et 18 chez 732 patients de plus de 70 ans. La mortalite dans chaque groupe a
ete, respectivement, de 0,1 %, 0,6 % et 2,5 % (p < 0,001). La mortalite chez 9339
patients qui avaient subi une cholecystectomie simple a ete de 0,3 %, alors qu’elle
etait de 1,6 % chez 1132 patients qui avaient eu, concurremment, une exploration du
choledoque (EC) (p < 0,001). Les complications cardiovasculaires represented la
principale cause de deces, alors que les complications biliaires, pulmonaires et de
plaies ont ete les plus frequentes. II y a eu 614 complications chez 529 patients
(5 %); 176 patients avaient moins de 50 ans, 252 patients, entre 50 et 70 ans et 101,
plus de 70 ans. Les taux de morbidite respectifs etaient de 3,0 %, 6,5 % et 13,8 % (p
< 0,001). La morbidite chez les patients qui ont subi une cholecystectomie simple a
ete de 3,6 %, contre 17 % (p < 0,001) pour les patients qui ont eu une EC
concurrente. La mortalite et la morbidite reliees a la cholecystectomie augmentent
significativement avec 1’age et avec l’execution d’une EC concomitante. Toutefois, la
mortalite et la morbidite ont ete comparables, que les patients aient subi une
cholecystectomie non urgente ou pour une cholecystite aigue.
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holecystectomy has been the
standard therapy for patients
with symptomatic gallstone disease
for many decades and has proven to
be a safe and effective procedure.
The mortality and morbidity are
low.1-6 Long-term results are excel
lent, with most patients being
asymptomatic after surgery.5 De
spite the good results with tradi
tional cholecystectomy, the treat
ment o f gallstones has undergone
drastic changes in the past few
years. Several alternative nonsurgical options for the management o f
biliary lithiasis have been intro
duced,
including
extracorporeal
shockwave lithotripsy,6 chemical
dissolution7 and endoscopic and
percutaneous extraction.8 More re
cently, laparoscopic cholecystecto
my has emerged as a promising
surgical alternative to traditional
cholecystectomy,9 We carried out a
retrospective study o f traditional
cholecystectomy to analyse the inci
dence and causes o f mortality and
morbidity and to compare our expe
rience with that o f others.

C

Patients and Methods
The medical records o f 10 501
patients who underwent cholecys
tectomy between April 1971 and
April
1990
at
MaisonneuveRosemont Hospital were reviewed.
Excluded from the analysis were 30
patients who died after cholecystec
tomy but in whom the cause o f
death was unrelated to the proce
dure. Twenty-two o f these patients
died o f complications secondary to
CJS, VOL. 36, NO. 1, F E B R U A R Y 1993
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major surgery in which cholecystec
tomy was only incidental. The other
eight patients died of serious diseas
es up to 90 days after cholecystec
tomy performed for acute cholecys
titis, which complicated the course
of their disease.
Among the remaining 10 471 pa
tients, 6574 (63%) underwent cho
lecystectomy alone, 2765 (26%) un
derwent cholecystectomy with other
concomitant non-biliary procedures
(the most frequent being incidental
appendectomy, hernia repair, tubal
ligation and liver biopsy) and 1132
(11%) underwent cholecystectomy
with common bile duct exploration
(CBDE) for presumed choledocholithiasis.
Most of the operations were per
formed by a right subcostal inci
sion. Cholecystectomy was usually
performed from the porta hepatis to
the fundus (anterograde) after iden
tification of the anatomic structures
at the porta hepatis. If it was impos
sible or unsafe to perform antero
grade cholecystectomy, usually be
cause of acute cholecystitis, chole
cystectomy was then performed
from the fundus downward to the
porta hepatis (retrograde). Routine
operative cholangiography was per
formed when technically possible.

Cholecystitis was considered acute
when inflammation and edema of
the gallbladder were present at op
eration and confirmed histopathologically. Until 1976, the subhepatic space was drained in every case
with a soft Penrose drain. After
1976, a drain was used less fre
quently, and since 1985 it has been
used selectively in patients who had
a cholecystectomy for acute chole
cystitis or a cholecystectomy with
CBDE. When choledochotomy was
performed, the common duct was
closed over a T tube.
Differences were analysed by the
X 2 test. Differences were considered
statistically significant at p < 0.05.

Findings
Of the 10 471 patients, 7277
(69.5%) were female and 3194
(30.5%) were male. There were
5841 (55.8%) patients less than 50
years of age, 3898 (37.2%) between
50 and 70 years of age and 732
(7.0%) more than 70 years of age.
The youngest patient was 7 years
old and the oldest was 96 years old.
Routine intraoperative cystic duct
cholangiography was performed
when technically possible, in ap

Table I. Indications for Operation in Patients Who Died After Cholecystectomy
..
Indication

.

patients

Chronic cholecystitis
With cholelithiasis
With choledocholithiasis
Acute cholecystitis
With cholelithiasis
With choledocholithiasis

No. with associated disease
Acute pancreatitis Jaundice

36
22
14
11
7
4

7
3
4
2
2
0

8
0
8
5
1
4

proximately 90% of the patients.
Histopathological examination of
the gallbladder showed chronic cal
culous cholecystitis in 8484
(81.0%), chronic acalculous disease
in 296 (2.8%), acute calculous
cholecystitis in 1639 (15.7%) and
acute acalculous cholecystitis in 52
(0.5%).
Deaths
Forty-seven patients died, for an
overall mortality of 0.4%. Six (0.1%)
were younger than 50 years, 23
(0.6%) were between 50 and 70
years and 18 (2.5%) were older than
70 years. The difference between
each group is significant (p <
0.001). The indications for opera
tion in those who died are shown in
Table I. Twenty-two of them had
either associated acute pancreatitis
or jaundice, or both, at the time of
surgery. Four had acute suppura
tive cholangitis.
The surgical procedures per
formed for chronic and acute chole
cystitis and the death rates are
depicted in Table II. Among the
8780 patients with chronic disease,
36 died (0.4%), while among the
1691 patients with acute cholecysti
tis, 11 died (0.6%). This difference
is not significant, and patients with
acute cholecystitis had a death rate
comparable to that of patients who
underwent elective cholecystecto
my. The death rate in 9339 patients
who had cholecystectomy alone was
0.3%, whereas in 1132 patients who
had cholecystectomy with CBDE
the death rate was 1.6% (p <
0.001). Death rates according to

Table II. Surgical Treatment for Acute and Chronic Cholecystitis
Chronic cholecystitis
No. of
patients

No. of
deaths

Cholecystectomy
Cholecystectomy with CBDE

7841
939

Total

8780

Treatment
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Acute cholecystitis
%

No. ot
patients

No. of
deaths

%

22
14

0.3
1.5

1498
193

7
4

0.5
2.1

36

0.4

1691

11

0.6
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age and type of cholecystitis are
shown in Table III. The only signifi
cant difference found was in pa
tients with acute cholecystitis: in
patients between 50 and 70 years of
age the death rate was 0.4%, where
as in patients over 70 years of age
the death rate was 4.0% (p <
0.005). The most frequent cause of
postoperative hospital death was
cardiovascular complications (Table
IV), which accounted for 50% of the
deaths. Among the 23 patients who
died of cardiovascular complica
tions, 10 had myocardial infarction,
4 had cardiac insufficiency, 3 had
pulmonary embolism, 2 had mesen
teric thrombosis, 2 had cerebrovas
cular thrombosis, 1 had endocardi
tis and 1 had a dissecting thoracic
aneurysm. There were nine intra
abdominal extrahepatic deaths
caused by perforated duodenal ulcer
in three patients, abscess in three
patients and gastrointestinal bleed
ing in two patients. The other pa
tient died of a duodenal fistula with
peritonitis after an emergency pro
cedure for biliary ileus, during
which a cholecystectomy with re
pair of a cholecystoduodenal fistula
was also performed. Six of these
patients had cholecystectomy with
CBDE and had pancreatitis or jaun
dice, or both, at surgery.
Six patients died of hepatobiliary
complications, five of them after
cholecystectomy with CBDE. Three
deaths were attributed to septicemia
in patients with acute suppurative
cholangitis at operation, and two
deaths were caused by hepatic in

tients more than 70 years old had
complications (morbidity 9.2%) {p <
0.01). Among the 8742 patients
with chronic disease, 403 (4.6%)
had complications, whereas among
the 1680 patients with acute chole
cystitis, 126 (7.5%) had complica
tions. The incidence of complica
tions after cholecystectomy alone
was 3.6% (3.1% for chronic chole
cystitis and 6.1% for acute chole
cystitis) whereas after cholecystec
tomy with CBDE the incidence was
17% (16% for chronic cholecystitis
and 24% for acute cholecystitis)
(p < 0.001).
In the 529 patients, 614 compli
cations were seen, the most fre
quent being biliary, pulmonary and
wound complications. There were
169 wound complications among
which 126 were infected wounds.
Pulmonary complications were seen
in 140 patients. Among the 174
biliary complications, 75 were ex
ternal biliary fistulas, 64 were resid
ual stones and 5 were bile peritoni
tis. In addition, there were 30 in-

sufficiency. The other patient died
of a prolonged biliary fistula with
dehydration 4 months after a chole
cystectomy with CBDE. The other
causes of death were pulmonary
(four patients) and renal (one pa
tient) complications, infection from
a fulminant necrosis of the abdomi
nal wall (one patient) and undeter
mined causes (three patients).
Postoperative Complications
Postoperative complications were
found in 529 patients (5.1%). Of
these, 176 patients (3.0%) were less
than 50 years old, 252 patients
(6.5%) were between 50 and 70
years old and 101 patients (13.8%)
were more than 70 years of age.
The difference between each group
is significant (p < 0.001). In those
who underwent cholecystectomy
alone, 121 patients less than 50
years old had complications (mor
bidity 2.3%), 169 patients between
50 and 70 years old had complica
tions (morbidity 5.0%) and 47 pa

Table IV. Causes of Death
Procedure, no. of patients
Cholecystectomy

Cholecystectomy
with CBDE

Total

Cardiovascular
Intra-abdominal
(extra-hepatic)
Hepatobiliary
Pulmonary
Infectious
Renal
Undetermined

17

6

23

3
1
3
1
1
3

6
5
1
0
0
0

9
6
4
1
1
3

Total

29

18

47

Cause

Table III. Age-related Mortality and Type of Cholecystitis
Chronic cholecystitis

Acute cholecystitis

Age, yr

No. of
patients

No. of
deaths

%

No. of
patients

No. of
deaths

< 50
50-70
> 70

5089
3145
546

5
20
11

0.1
0.6
2.0

752
753
186

1
3
7

Total

8780

36

0.4

1691

11

%
0.1
0.4 “ I
4.0 J
0.6

*p < 0.005
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traoperative bile duct injuries
(0.3%); 24 occurred in 9339 pa
tients who had cholecystectomy
alone: 17 were considered minor
(small lacerations or punctiform
wounds) and 7 were considered
major (section or ligation). Eighteen
bile duct injuries occurred during
cholecystectomy for chronic chole
cystitis and 6 during cholecystecto
my for acute cholecystitis. There
were 6 cases of trauma to the
common or right hepatic duct, 12
in the area of the cystocholedochal
junction, 5 in the common bile duct
and 1 in a right accessory hepatic
duct. Except for one, all these trau
mas were recognized at the initial
operation and repaired. The only
unrecognized trauma was a partial
section of the common hepatic
duct, which led to a prolonged
postoperative biliary fistula and
later bile duct stenosis. This steno
sis was repaired 1 year later by a
Roux-en-Y hepaticojejunostomy.
Two other patients had reoperation
for drainage of a bile collection.
Two of the six bile duct injuries
that occurred during cholecystecto
my with CBDE were major and four
were minor. All were recognized
and repaired at initial operation
with no further problem.
The other complications that
should be mentioned were intra- or
postoperative hemorrhage in 20 pa
tients, postoperative intra-abdomi
nal abscesses in 21 patients and
cardiovascular nonlethal complica
tions in 26 patients.
Sixty-seven patients underwent a
second procedure for complications
1 to 45 days after cholecystectomy,
the most frequent being closure of
wound dehiscence, drainage of an
intra-abdominal abscess and control
of postoperative bleeding (Table V).

Discussion
In general, three factors are al
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leged to increase the death rate in
patients who undergo cholecystec
tomy: increasing age, the addition
of a concomitant CBDE and the
degree of inflammation of the gallbladder.1'3'4
A major risk factor is age. Of the
9339 patients who had cholecystec
tomy without CBDE, 5383 were
less than 50 years of age, and there
were four deaths in this group
(death rate 0.07%). In the group of
3431 patients between the ages of
50 and 70 years, there were 12
postoperative deaths (death rate
0.3%); in the group of 525 patients
over 70 years of age, there were
13 deaths (death rate 2.5%). Our
experience confirms that the death
rate increases significantly with age
(p < 0.001), due primarily to
associated medical conditions, parti
cularly cardiovascular problems.
The addition of a concomitant
CBDE also increases mortality. Al
though the death rate recorded for
9339 patients who had cholecystec
tomy alone was 0.3%, it increased
fivefold to 1.6% in 1132 patients
who had cholecystectomy with
CBDE (p < 0.001). Although the
addition of a CBDE is an important
factor influencing the death rate of
cholecystectomy, we believe that,
rather than the choledochotomy per
se, the main influencing factor is
that CBDE is most often necessary
in patients of advanced age with
associated medical conditions. In
addition, the increased likelihood of

sepsis in many patients with com
mon duct stones also influences the
death rate. Not only does the death
rate increase with the addition of a
CBDE, but also the causes of death
differ (Table IV). Whereas 17 (59%)
of the 29 deaths after cholecystec
tomy alone were caused by cardio
vascular complications, this was the
cause of death in only 6 (33%) of
the 18 deaths after cholecystectomy
with CBDE. In this last group, the
causes of death were more frequent
ly related to the intra-abdominal
condition at the time of surgery
(pancreatitis or cholangitis) and to
postoperative complications that de
veloped secondary to the associated
acute pancreatitis or cholangitis.
Many series have shown that the
presence of acute cholecystitis is an
important determinant of operative
mortality related to cholecystecto
my.1'3-4 But our experience as well
as that of Pickleman and Gonzalez2
cannot confirm that the presence of
acute cholecystitis increases the
death rate significantly. In our se
ries, as shown in Table II, the
degree of inflammation of the gall
bladder was not a significant deter
minant of operative mortality. Of
1691 patients with acute cholecysti
tis, 11 died (death rate 0.6%). Cho
lecystectomy without CBDE was
performed in 1498 of these 1691
patients and 7 died (death rate
0.5%). In contrast, 8780 patients
were operated on for chronic chole
cystitis and 36 died (death rate

Table V. Indications for Reoperation
After cholecystectomy
no. of patients

After cholecystectomy
with CBDE,
no. of patients

Total

Wound dehiscence
Intra-abdominal abscess
Intra-abdominal bleeding
Biliary fistula
Fixed Penrose drain
Small-bowel obstruction
Gastrointestinal bleeding
Hemobilia

19
13
7
3
3
2
1
1

7
5
3
3
0
0
0
0

26
18
10
6
3
2
1
1

Total

49

18

67

Indication
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0.4%). Cholecystectomy without
CBDE was performed in 7841 of
these 8780 patients and 22 died
(death rate 0.3%). Table III shows
that the difference in mortality for
patients with chronic or acute
cholecystitis is not affected by age.
Only patients more than 70 years
old with acute cholecystitis have an
increased death rate when com
pared with younger patients.
Acute pancreatitis or jaundice, or
both, may also be considered as
factors increasing mortality and
morbidity. Of the 29 patients who
died after cholecystectomy alone, 5
had pancreatitis at surgery. Of the
18 patients who died after cholecys
tectomy with CBDE, 4 had pan
creatitis and 12 had jaundice at
surgery. The high incidence of
jaundice in patients who died tends
to confirm the observation of others
that it increases the risk of chole
cystectomy with CBDE.10
There is much published data
proving the safety of cholecystecto
my. A study on biliary tract surgery
appeared in 1970 and summarized
the results of treatment in over
28 000 patients requiring cholecys
tectomy.1 The overall death rate
was 1.8%, with a rate of 1.5% for
elective cholecystectomy and 3.5%
for cholecystectomy for acute
cholecystitis. More recent studies,
however, have reported an operative
death rate of less than 1% (Table
VI2-6). These rates vary from 0% to
0.5% in elective cholecystectomy to
1.1% to 1.7% in urgent cholecystec
tomy.2-6 One of the largest series
reported showed that cholecystecto

my alone performed in 10 749 pa
tients was associated with an opera
tive death rate of 0.6% (0.4% for
chronic cholecystitis and 1.2% for
acute cholecystitis); furthermore, in
the last 1693 cholecystectomies
performed, there were only three
deaths for a mortality of 0.2%.4 In
addition, two series of patients who
underwent elective cholecystectomy
reported no deaths.3’5
Our overall death rate of 0.3% in
elective cholecystectomy does not
differ substantially from these se
ries. But in this series the overall
death rate of 0.5% for cholecystec
tomy in acute cholecystitis is much
lower than that reported in other
series.4'6 This difference possibly
can be explained by a more aggres
sive approach at the MaisonneuveRosemont Hospital where patients
with acute cholecystitis are operat
ed on as soon as the diagnosis is
made. Another explanation is that
the patients in this series were
younger than those in other series.
As to the death rate associated with
cholecystectomy with CBDE, recent
series reported a mortality between
0.7% and 4.4%,34 whereas in the
present series it was 1.6%.
As with mortality, the morbidity
of cholecystectomy also increased
with age and the addition of a
CBDE. From 2.3% in those less
than 50 years old it increased to
5.0% for those between 50 and 70
years old and 9.2% for those more
than 70 years old (p < 0.01).
Similarly, the addition of a concomi
tant CBDE increases the morbidity
of cholecystectomy from 3.6% to

T a b le V I. Operative M ortality After Cholecystectomy
S eries

Y ear

N o. of
p a tie n ts

Gallbladder Survey Committee1
Pickleman and Gonzalez2
Ganey and associates3
McSherry4
Gilliland and Traverso5
Heberer and associates6
Present series

1970
1986
1986
1989
1990
1990
1993

28 621
389
1 024
10 749
671
898
9 339

M o rtality, %

1.8
0.8
0.5
0.6

0.0
0.4
0.3

17.5% (p < 0.001). Contrary to the
mortality, which has decreased
since 1970, the morbidity has not
changed substantially. In the Ohio
report,1 the incidence of complica
tions was approximately 4%. In the
more recent series, the incidence
varied from 3.7% to 5.5%, being
higher after operation for acute
cholecystitis.24’5 Our overall mor
bidity of 3.6% (3.1% in chronic
cholecystitis and 6.1% in acute
cholecystitis) does not differ signifi
cantly from the rates in these series.
We encountered 30 intraopera
tive iatrogenic bile duct injuries
(0.3%). Twenty-four of these inju
ries occurred in the 9339 patients
who had cholecystectomy alone,
and 6 occurred in the 1132 patients
who had cholecystectomy with
CBDE. The incidence of bile duct
injury during cholecystectomy usu
ally reported in the literature varies
between 0.1% and 0.3% but most
often includes only major traum a.11
In this series, we considered minor
as well as major traumas. If only
major traumas (section or ligation)
had been included, the incidence
would be 0.07% for cholecystecto
my alone and 0.2% for cholecystec
tomy with CBDE.
In this review an attempt was
made to analyse the mortality and
morbidity in a large number of
patients who had undergone chole
cystectomy over the last two dec
ades. The findings confirm that
open cholecystectomy is a safe pro
cedure that can be performed with
low mortality and morbidity. Mor
tality and morbidity of cholecystec
tomy increase with advancing age
and with the addition of a concomi
tant CBDE. The presence of acute
cholecystitis at cholecystectomy
does not increase mortality or mor
bidity significantly. Cardiovascular
complications, especially myocardial
infarction, are the main causes of
death.
Because of its low mortality and
CJS, VOL. 36, NO. 1, FEBRUARY 1993
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morbidity, traditional cholecystecto
my is still the gold standard with
which the numerous new nonopera
tive techniques for gallstone man
agement as well as laparoscopic
cholecystectomy must be compared.
I thank Dr. Serge Dube for his statisti
cal assistance and Mrs. Anne DeNoncourt for her secretarial work.

References

1970; 119: 714-717
2. P ickleman J, Gonzalez RP: The improv
ing results of cholecystectomy. Arch
Surg 1986; 121: 930-934
3. G aney JB, Johnson PA, P rillaman PE
et al: Cholecystectomy: clinical experi
ence with a large series. Am J Surg
1986; 151: 352-357
4. M c Sherry CK: Cholecystectomy: the
gold standard. Am J Surg 1989; 158:
174-178
5. G illiland TM, T raverso LW: Modern
standards for comparison of cholecys
tectomy with alternative treatments for
symptomatic cholelithiasis with empha
sis on long-term relief of symptoms.
Surg Gynecol Obstet 1990; 170: 39-44
6. H eberer G, Sackmann M, K rAmlinc HJ

1. Gallbladder Survey Committee: 28,621
cholecystectomies in Ohio. Am J Surg

et al: The place of lithotripsy and sur
gery in the management of gallstone

disease. Adv Surg 1990; 23: 291-315
7. H ofmann AF: Medical dissolution of
gallstones by oral bile acid therapy. Am
J Surg 1989: 158: 198-204
8. Z immon DS: Alternatives to cholecystec
tomy and common duct exploration [E].
Am J Gastroenterol 1988; 83: 1272—
1273
9. The Southern Surgeons Club: A pro
spective analysis of 1518 laparoscopic
cholecystectomies. N Engl J Med 1991;
324:1073-1078
10. Pit t HA, Cameron JL, Postier RG et al:
Factors affecting mortality in biliary
tract surgery. Am J Surg 1981; 141:
66-72
11. A ndren -S andberg A, A linder G, B enc mark S: Accidental lesions of the com

mon bile duct at cholecystectomy. Preand per-operative factors of importance.
Ann Surg 1985; 201: 328-332

BOOK REVIEWS
continued from page 70

teric injury should have been stressed.
These injuries are very difficult to diag
nose because of associated abdominal
physical signs, poor specificity by ab
dominal lavage and poor definition by
plain radiography or computed tomog
raphy. Rectal injury is well emphasized;
however, in my experience it is a far
less common injury than the others.
At the Health Sciences Centre in
Winnipeg, we follow the guidelines of a
crash protocol in patients who have
class IV hemorrhage on arrival at the
hospital, have no blood pressure or
exhibit no electromyographic activity
or, finally, those who suffer cardiac
arrest within minutes of entering the
emergency department. In the young,
otherwise-healthy patient, this is usual
ly secondary to massive hemorrhage, so
we quickly determine the site of bleed
ing by insertion of right and left thora
costomy tubes, abdominal lavage and
pericardiocentesis, if indicated. Each
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cavity with massive bleeding is immedi
ately explored in the operating room.
The bleeding is controlled by compres
sion or clamping, and resuscitation by
other means is carried out in the operat
ing room. Review of such cases in our
experience has provided a 12% survival
rate in cardiac arrest and myocardial
activity categories and a 77% survival
rate in class IV deteriorating shock.
These principles are covered in the text
of this book, but they are buried in the
discussion of intra-abdominal injuries.
As far as the chest is concerned, the
author of that section recommends
emergency thoracotomy and determina
tion of the site of bleeding in the
operating room. I would suggest that
our principle of crash guidelines avoids
the misadventure of performing an ex
cellent surgical exercise and controlling
hemorrhage in the chest, while the
patient exsanguinates from intra
abdominal hemorrhage. Obviously, it is

unfair to criticize something that is
present, albeit hidden, in the text. How
ever, I believe these guidelines and the
principle of surgery as part of resuscita
tion should be emphasized. Otherwise
those patients balancing between death
at the accident scene and arrival in the
emergency department in extremis will
fall through the crack and die.
This text is a superb resource as a
reference and basic teaching vehicle for
those practising any form of trauma
surgery and those practising as emer
gency physicians. I would recommend it
for all hospital libraries, surgical pro
grams and as a personal reference text.

C.M. Burns, MD, FRCSC
Director, Trauma Services
Health Sciences Centre
820 Sherbrook St.
Winninpeg, MB
R3A 1R9
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Endoscopic Retrograde
Cholangiopancreatography
in the Management of Choledocholithiasis
With Laparoscopic Cholecystectomy
Andre Roy, MD, FRCSC; Vivian McAlister, MB, FRCSC, FRCSI; Ronald B. Passi, MD, FRCSC
With the advent of laparoscopic cholecystectomy, endoscopic retrograde
cholangiopancreatography (ERCP) has an increasing role in perioperative
management. To assess this role, the authors studied, retrospectively, 12 patients
who underwent ERCP out of a series of 475 who had laparoscopic cholecystectomy.
ERCP was indicated preoperatively for biliary colic in four patients, gallstone
pancreatitis in two and common bile duct stone on ultrasonography in one. ERCP
was performed postoperatively for jaundice in three patients, for cholangitis in one
and for a positive intraoperative laparoscopic cholangiogram in one.
Choledocholithiasis was diagnosed in six patients preoperatively and in three
postoperatively. Only one patient had an unsuspected residual bile duct stone
postoperatively. Of nine patients with stones, endoscopic sphincterotomy was
performed in eight and stones were cleared in all with no complications; a stone
passed spontaneously in the other patient. ERCP is indicated before laparoscopic
cholecystectomy in cases of jaundice, gallstone pancreatitis, cholangitis, abnormal
liver biochemistry suggesting cholestasis and ultrasonographic demonstration of
either a common bile duct stone or a common bile duct greater than 8 mm in
diameter. Operative laparoscopic cholangiography is indicated when the anatomy is
unclear or the bile duct appears dilated. If choledocholithiasis is founded, the
options include open or laparoscopic common bile duct exploration and intra- or
postoperative endoscopic sphincterotomy.

Avec l’avenement de la cholecystectomie laparoscopique, la
cholangiopancreatographie endoscopique retrograde (CPER) joue un role de plus en
plus important dans la demarche peroperatoire. Afin d’evaluer ce role, les auteurs
ont etudie, en retrospective, 12 patients qui avaient subi une CPER d’un groupe de
475 patients qui avaient subi une cholecystectomie laparoscopique. L’indication
preoperatoire de la CPER fut une colique biliaire chez quatre patients, une
pancreatite lithiasique chez deux et une choledocholithiase identifiee a l’echographie
chez un. Une CPER postoperatoire fut pratiquee pour ictere chez trois patients,
pour cholangite chez un et pour un cholangiogramme laparoscopique positif en
cours d’intervention chez un. Une choledocholithiase fut diagnostiquee en
preoperatoire chez six patients et en postoperatoire, chez trois. Un seul patient
presenta un calcul biliaire residuel insoupfonne apres l’intervention. Sur neuf
patients presentent des calculs, une sphincterotomie endoscopique fut pratiquee
chez huit patients et les calculs furent elimines dans tous les cas, sans
complications; un calcul fut elimine spontanement chez l’autre patient. Une CPER
preoperatoire est indiquee avant la cholecystectomie laparoscopique dans les cas
d’icteres, de pancreatite lithiasique ou de cholangite, quand les enzymes hepatiques
anormaux suggerent une cholestase ou que l’echographie demontre soit un calcul
dans le choledoque, soit un choledoque de diametre superieur a 8 mm. La
cholangiographie laparoscopique operatoire est indiquee quand l’anatomie demeure
obscure ou que le canal biliaire parait dilate. Quand une choledocholithiase est
confirmee, les options comprennent l’exploration ouverte ou laparoscopique du
choledoque et la sphincterotomie endoscopique intra ou postoperatoire.

ince the early reports of Dubois
and associates,1 Perissat, Collet
and Belliard2 and Reddick and Ols
en,3 laparoscopic cholecystectomy
has revolutionized the management
of gallstones by shortening hospital
stay to 2 days and allowing an
earlier return to normal activity, in
7 to 15 days. Laparoscopic chole
cystectomy has become the proce
dure of choice in managing symp
tomatic gallstones.4-6
With the advent of laparoscopic
cholecystectomy, there is an in
creasing role for endoscopic retro
grade cholangiopancreatography
(ERCP) perioperatively.7’8 In this pa
per, we review our experience with
ERCP and endoscopic sphincteroto
my (ES) in 12 patients who under
went laparoscopic cholecystectomy,
and we discuss the evolving role of
ERCP.

S

Patients and Methods
Between January and September
1991, 475 patients underwent lapa
roscopic cholecystectomy at Univer
sity Hospital, London, Ont., and
three referral hospitals. Among this
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group of patients, ERCP was per
formed pre- or postoperatively in
the 12 patients (10 women, 2 men).
The mean age of the patients was
43 years (range from 28 to 86
years). All patients were treated
initially as outpatients. Seven were
hospitalized for 24 hours after un
dergoing ES. Two other patients
were hospitalized for 4 days after
undergoing percutaneous transhepatic cholangiography (PTC).

Findings
Among the 12 patients (2.5% of
the study population) who needed
ERCP at some point in their investi
gation or treatment, ERCP dis
closed a stone (9 patients) and a
lesion (1 patient) in 83% of them
(10 of 12) and was successful in
clearing the bile duct of stones in
78% of patients (7 of 9). By combin
ing PTC with ERCP, the stone
clearance rate was 100% (nine of
nine). No complications related to
ERCP or ES occurred. Eight of nine
patients who had stones needed ES
for their extraction. In the ninth
patient a stone passed spontaneous
ly.
Preoperative ERCP

The indications for ERCP preoperatively were jaundice associated
with biliary colic and increased liver
enzymes (four), gallstone pancreati
tis (two) and common bile duct
(CBD) stones on ultrasonography
(one) (Table I).
Preoperative ERCP revealed CBD
stones in five patients and a normal
bile duct in two (Table I). Among
the five cases of choledocholithiasis, one was diagnosed by ERCP,
but cannulation with the sphincterotome was unsuccessful. PTC
was performed 3 days later and was
normal. The stone passed spontane
ously during the delay. One patient
82
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who had a normal ERCP underwent
a liver biopsy that showed drugrelated hepatitis. The second pa
tient with a normal ERCP under
went this investigation because of a
gallstone pancreatitis.
Postoperative ERCP

The indications for ERCP postop
eratively were jaundice with an in
creased alkaline phosphatase level
(three), cholangitis (one) and posi
tive laparoscopic cholangiography
(one) (Table I).
Postoperative ERCP revealed
choledocholithiasis in four patients
and CBD injury in one (Table I). In
one patient with choledocholithia
sis, cannulation with the sphincterotome was unsuccessful. PTC
with insertion of a no. 8 French
ring biliary catheter and ES by a
combined approach as previously
described9 were performed. The bile
duct injury was caused by a hemoclip misplaced while attempting to
control intraoperative bleeding. A
Roux-en-Y hepaticojejunostomy
bile duct reconstruction was per

formed 3 weeks later. Only one
patient had a residual stone that
was not identified from the clinical
history and preoperative work-up,
resulting in an incidence of 0.2% (1
in 475). The patient presented 8
months postoperatively and cholan
gitis was diagnosed.

Discussion
At present, like many others, we
favour a selective approach to the
perioperative assessment of patients
who undergo laparoscopic cholecys
tectomy.5-10"13 All patients should
undergo liver function testing (se
rum aspartase transaminase [AST],
serum alanine transaminase [ALT],
serum bilirubin and serum alkaline
phosphatase measurements) and ab
dominal ultrasonography in addi
tion to routine history-taking and
physical examination.14 Patients
with jaundice, cholangitis, gallstone
pancreatitis, biochemical abnormali
ties on liver function testing, a CBD
greater than 8 mm or ultrasono
graphic evidence of choledocholi-

Table I. Course of 12 Patients Who Underwent Laparoscopic
Cholecystectomy and Endoscopic Retrograde
Cholangiopancreatography (ERCP)
Patient
no.

Timing of
ERCP

1

Preop

2

Preop

3

Preop

4
5

Preop
Preop

6

Preop

7
8
9

Preop
Postop
Postop

10

Postop

11
12

Postop
Postop

Indication
tor ERCP
Jaundice,
high enzymes
CBD stone on
ultrasonography
Jaundice,
high enzymes
Pancreatitis
Jaundice,
high enzymes
Jaundice,
high enzymes
Pancreatitis
Cholangitis
Jaundice,
fever
Positive
cholangiogram
Jaundice
Jaundice

Diagnosis

Treatment

Normal

Liver biopsy

CBD stone

ES

CBD stone
Failed ES
Normal
CBD stone

PTC normal
ES

CBD stone

ES

CBD stone
CBD stone
CBD stone
Failed ES
CBD stone

ES
ES
PTC, ES

CBD stone
CBD injury

ES
Roux-en-Y
reconstruction

ES

CBD = common bile duct, ES = endoscopic sphincterotomy, PTC = percutaneous transhepatic
cholangiography

CHOLEDOCHOLITHIASIS

thiasis should undergo ERCP preoperatively (Table II).1415 If ERCP is
unsuccessful, the CBD can usually
be cannulated with the aid of PTC
and insertion of a biliary catheter.9
Intravenous cholangiography with
computed tomography is used com
monly for CBD assessment before
laparoscopic cholecystectomy. We
consider it neither routinely neces
sary nor justified. In a recent report
from Ireland,16 every patient who
had a choledocholithiasis shown on
a preoperative intravenous cholangiogram also had abnormal liver
function, justifying a preoperative
ERCP.
ERCP with sphincterotomy preoperatively is contrary to the find
ings of Neoptolemos, Carr-Locke
and Fossard17 and Neoptolemos,
Shaw and Carr-Locke18 in their
studies on CBD stones and standard
open cholecystectomy. However,
open CBD exploration would negate
the advantage to the patient of
laparoscopic over open cholecystec
tomy. It is therefore advantageous
to the patient to have ERCP preoperatively with ES instead of an open
bile duct exploration when there is
a CBD stone. When a diagnostic
ERCP is performed, a morbidity as
low as 0.8% and a mortality as low
as 0.05% can be attained. If ERCP
with ES is executed for choledo
cholithiasis, morbidity less than 5%
Table II. Indication for ERCP Related to
Laparoscopic Cholecystectomy
Preoperative ERCP
Jaundice
Gallstone pancreatitis
Abnormal liver function test results
(serum transaminases, bilirubin,
alkaline phosphastasej
Abdominal ultrasonography
common bile duct > 8 mm
common bile duct stone
Postoperative ERCP
Positive operative cholangiography
Jaundice
Biliary fistula/biloma
Abnormal liver function test results
(serum transaminases, bilirubin,
alkaline phosphatase)

and mortality less than 1% can be
achieved. Bleeding (1.4%), infec
tions (0.9%) and perforations (0.5%)
are the most serious complica
tions.19-20 Those numbers are com
parable to, if not better than, the
reported morbidity of 16% and mor
tality of 3.8% associated with open
CBD exploration.21
With selective preoperative
ERCP, operative cholangiography
through the gallbladder or cystic
duct is necessary only when the
dissection is complex, the anatomy
is distorted by inflammation, there
is a dilated bile duct or the preoper
ative ERCP is unsuccessful.14 When
an operative laparoscopic cholangiogram shows a CBD stone, a transcystic duct drain may be inserted
for draining the bile duct of an
impacted stone and for introducing
a guide wire if postoperative ERCP
and ES are not successful (10% to
20% of cases).22 The other options
are open or laparoscopic bile duct
exploration and intraoperative
ERCP.
With selective preoperative ERCP
and intraoperative laparoscopic cho
langiography, a 2% to 3% (0.9% to
6.3%) incidence of residual bile duct
stones is expected.7-23"25 Most re
tained stones will never cause prob
lems or will pass spontaneously into
the gut.26 Only 0.2% to 0.5% of
patients will eventually need treat
ment for a symptomatic residual
CBD stone.11-27-28
Routine laparoscopic cholangiog
raphy can be performed, with a
success rate of 70% to 95%.10 How
ever, routine operative cholangiog
raphy has never been proved to
have a positive risk-benefit ratio.
Disavantages include an increased
cost (estimated $299 US), radiation
exposure and problems related to
false-positive diagnoses.18-27-29 A
false-positive cholangiogram (10%
to 25%),30 leading to an unneces
sary negative CBD exploration
would increase the morbidity and

mortality of the procedure. Opera
tive cholangiography has not de
creased the incidence of bile duct
injury.31 Finally, it is difficult to
justify a test that benefits only
0.21% of the patients, those who
will eventually present with a symp
tomatic residual CBD stone.
Laparoscopic CBD exploration
performed via the cystic duct or a
choledochotomy has been reported
but does not appear as a practical
approach.5-28-32-33 It is a time-con
suming (up to 6 hours), complicat
ed, experimental procedure with a
low success rate.34 It should be
reserved for the experienced laparoscopist. Most surgeons cannot hope
to reach and maintain sufficient
skill to match the low morbidity,
the success rate and the efficacy of
ERCP and ES.19
Intraoperative ERCP has recently
emerged as a treatment for choledo
cholithiasis. It has been used previ
ously in the management of pancre
atic trauma discovered intraoperatively.35 It would be indicated when
an unsuspected stone is demon
strated intraoperatively. The safety
of this approach is unknown; one
case of pancreatitis with a pseudo
cyst has been reported.36
The perioperative management of
choledocholithiasis for patients un
dergoing laparoscopic cholecystec
tomy can now be added to the
pre-existing roles of ERCP. Various
indications for diagnostic as well as
therapeutic ERCP exist with laparo
scopic cholecystectomy as well as
with standard open cholecystecto
my (Table II).28-37

Conclusions
We consider that ERCP should
be performed preoperatively when
choledocholithiasis is suspected,
based on the patient’s history and
the findings on physical examina
tion, abdominal ultrasonography
CJS, VOL. 36. NO. 1. FEBRUARY 1993
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and biochemical investigations. We
do not advocate routine operative
cholangiography or laparoscopic
CBD exploration. Intraoperative
ERCP may have a limited role for
choledocholithiasis diagnosed by la
paroscopic cholangiography when
performed because of a dilated bile
duct discovered during surgery.
Prospective studies need to be done
to establish the best possible ap
proach to the management of pa
tients who undergo laparoscopic
cholecystectomy. It would have to
define the role of ERCP and opera
tive cholangiography as well as the
best sequence of execution based
on the morbidity and mortality of
the procedures.
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ORIGINAL ARTICLES

Anterior Cervical Corpectomy
for the Treatment of Complex
Cervical Lesions
Richard Hu, MD, FRCSC;* R. Geoffrey Wilber, MDt
Instability and stenosis of the cervical spine have been treated by posterior
decompression and anterior decompression with fusion. In this study the authors
evaluate the results obtained in 31 patients who underwent anterior cervical
corpectomy for compressive or unstable lesions of the cervical spine. Operative
level, preoperative and postoperative symptoms and physical findings were assessed.
Twenty-seven patients had preoperative neurologic symptoms and signs, including
alterations in sensation, motor findings and reflexes. The average follow-up was 12
months, average number of disc spaces excised was 2.5 and average number of
vertebral bodies excised was 1.6. With respect to relief of pain, results were good or
excellent in 27 patients. All patients but one had union of the bone graft. No
neurologic deterioration occurred. The authors believe that patients with
compressive lesions of the cervical spine can benefit from anterior cervical
corpectomy with fusion and that complications are minimal.
La stenose et l’instabilite de la colonne cervicale ont, jusqu’a maintenant, ete traitees
par decompression posterieure ou par decompression anterieure avec fusion. On a
evalue dans la presente etude, les resultats obtenus par corpectomie cervicale
anterieure chez 31 patients operes pour des lesions compressives ou instables de la
colonne cervicale. Le niveau operatoire, les symptomes pre et postoperatoires, ainsi
que les observations physiques ont ete evalues. Vingt-sept patients presentaient des
symptomes et signes neurologiques preoperatoires comprenant l’emoussement des
sensations et une diminution du tonus moteur et des reflexes. La surveillance
moyenne des suites therapeutiques est de 12 mois; on a excise en moyenne 2,5
espaces interdiscaux et 1,6 corps vertebral. En ce qui a trait au soulagement de la
douleur, on a obtenu de bons ou d’excellents resultats chez 27 patients. Sauf pour
un cas, il y a eu fusion du greffon osseux chez tous les malades. Aucune
deterioration neurologique n'a ete observee. Les auteurs croient que les patients
souffrant de lesions compressives de la colonne cervicale peuvent beneficier d’une
corpectomie cervicale anterieure avec fusion, tout en eprouvant un minimum de
complications.

tenosis of the cervical spinal
canal has been treated with a
variety of techniques. Controversy
exists as to whether an anterior or
posterior approach should be used

S

and whether stabilization is re
quired. Instability of the spine often
occurs after posterior surgical inter
vention,1-4 and as a result of degen
erative or traumatic conditions.
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Proponents of posterior decompres
sive methods such as laminectomy
and laminaplasty5’6 believe that mor
bidity is minimal and recovery of
neurologic function satisfactory.
Postoperative instability is not con
sidered serious provided the facet
joints have not been damaged. Pro
ponents of anterior decompression
and fusion report good results for
return of neurologic function and
stability.7-11 The goal of this paper
is to describe the technique and
results of anterior vertebral corpec
tomy for symptomatic cervical ste
nosis and instability.

Patients and Methods
A consecutive series of 31 pa
tients who underwent anterior cer
vical corpectomy at MetroHealth
Medical Centre, Cleveland, were re
viewed retrospectively. All patients
had surgery performed by one of
the authors (R.G.W.). Follow-up in
cluded a review of the outpatient
clinic notes and radiographs. Indica
tions for surgery included compres
sive conditions with myelopathic or
radicular symptoms, instability after
posterior decompressive surgery
and nonunion of segments previ
ously operated on.
Patients were assessed preoperatively by history taking and physical
examination. Particular attention
was paid to symptoms of pain in the
cervical spine, to motor deficits and
to signs of myelopathy, including
abnormal reflexes and weakness.
Radiologic assessment included anCJS, VOL. 36, NO. 1, F E B R U A R Y 1993
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teroposterior and lateral radio
graphs of the cervical spine (Fig. 1).
Magnetic resonance imaging (MRI)
followed by computed tomography
(CT) with intrathecal contrast medi
um was performed to confirm the
clinical diagnosis and help deter
mine proposed levels of decompres
sion and fusion (Fig. 2). The level
of decompression used was based
on the symptomatic radicular level
with confirmatory motor deficit dis
tal to the lesion and on the com
pressive levels on MRI and CT as
demonstrated by loss of subarach
noid cerebrospinal fluid surround
ing the spinal cord. Atrophy or
deformation of the cord was consid
ered a sign of substantial compres
sion.

Surgical Procedure
Patients were positioned supine
on the operating table with a small
roll beneath the shoulders to allow
slight extension of the cervical
spine. Somatosensory-evoked po-

FIG. 1. Lateral radiograph of cervical
spine demonstrating area of spondylo
sis with disc-space narrowing and os
teophytes.
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tentials were used intraoperatively
(Pathfinder; Nicolet, Inc.. Madison,
Wis.). Shoulder traction was main
tained with adhesive tape to allow
satisfactory intraoperative radiolog
ic visualization of the entire cervical
spine. The head was turned to the
contralateral side, allowing an an
terolateral approach to the cervical
spine. With the aid of self-retaining
cervical retractors, the longus colli
muscle was bluntly dissected from
the anterolateral aspect of the verte
bral bodies. Segmental vessels were
coagulated with diathermy. A later
al radiograph and a spinal needle in
the disc spaces allowed identifica
tion of upper and lower disc spaces
for proposed decompression. Rou
tine discectomies were then per
formed and decompression to the
posterior longitudinal ligament
(PLL) was done. Further decom
pression of vertebral bodies was
carried to a depth corresponding
with the disc space. A power burr
was used to remove the rest of the
vertebral body. Once the posterior
cortical surface was reached, the
burr was changed to a diamondtipped one to allow more gentle

removal of the posterior cortex of
the bodies. Angled and straight cu
rettes were used to pull forward
fragments that were adherent to the
PLL. Adequate posterolateral de
compression of the vertebral body
must be done by undermining the
vertebral body and the disc space
with the diamond-tipped burr or the
curettes.
Preparation of the end plates for
acceptance of bone graft was then
done with a keystone-type tech
nique.12 The superficial margin of
the trough for bone graft is narrow
er than the deeper portions, thus
allowing a shaped graft to lock into
place once inserted (Fig. 3). Bone
graft was obtained from the ipsilateral iliac crest if two or fewer
vertebral bodies were removed. If
more than two bodies were removed
a fibular strut graft was used. The
bone was harvested from the ipsilateral extremity. Post operatively, the
patients were maintained in a rigid
cervical thoracic orthosis if fewer
than three levels were fused. If
more than three levels were fused,
patients were placed into a Halovest
(Bremer Corp., Jacksonville, Fla.).

FIG. 2. Axial magnetic resonance image shows loss of cerebrospinal fluid anterior
to spinal cord and cord compression.

ANTERIOR CERVICAL CORPECTOMY

Patients with more than than
three levels of decompression were
kept in the intensive care unit with
endotracheal intubation for approxi
mately 36 to 48 hours because of
the potential for obstruction of the
airway secondary to edema in the
neck.
Follow-up
Postoperative follow-up and as
sessment were performed at 6
weeks, 3 months, 6 months and 1
year after surgery. Patients were
assessed for pain, sensory and
motor signs and myelopathic signs.
Pain and neurologic findings were

assigned a numeric grade. Pain was
graded from 0 to 3 as follows: 0, a
poor result, showing continuous
pain with no improvement from
preoperative levels; 1, a fair result,
some improvement; 2, a good re
sult, marked improvement with
minimal pain; and 3, excellent or no
pain. Postoperative neurologic sta
tus was graded similarly as follows:
0, no improvement; 1, minimal im
provement; 2, substantial improve
ment in motor findings; and 3,
normal motor strength.
Bony union was assessed from
flexion and extension lateral radio
graphs.

graft was used in 4 patients.
Twenty-seven patients had good
or excellent (grades 2 and 3) results
on assessment of pain relief. Four
patients had poor or fair results.
For patients with pre-existing neu
rologic findings, 16 had good
(grade 2) results and 11 had excel
lent (grade 3) results. There was a
slight negative correlation between
number of vertebral bodies excised
and neurologic result (r= 0.6).
All patients with iliac-crest grafts
had bony union. One of four pa
tients with a fibular strut graft had
nonunion (Fig. 4).

Complications
Results

FIG. 3. Diagram demonstrating key
stone shape of prepared trough with
fitted graft in place. PLL = posterior
longitudinal ligament.

FIG. 4. Nonunion of fibular graft treat
ed with posterior multilevel wiring and
fusion.

Thirty-one patients were re
viewed. The indications for surgery
included cervical stenosis or cord
compression (17 patients), non
union from previous surgery (6 pa
tients), an ossified PLL (5 patients)
and cervical kyphosis after pre
vious posterior decompression (3
patients). There were 19 men and
12 women in whom the average age
was 52.9 years (range from 23 to
77 years). Average time to follow
up was 12 months (range from 10
to 42 months). Preoperative neuro
logic findings included sensory defi
cit in 27 patients, motor weakness
in 24 patients and myelopathy in 17
patients. The average number of
discs excised was 2.5 with a mode
of 3. Four patients had one disc
excised, 11 patients had 2 discs
excised, 12 patients had 3 discs
excised and 4 patients had four
discs excised. An average of 1.6
vertebral bodies were excised with
the mode being one. Sixteen pa
tients had one vertebral body ex
cised, 11 patients had two vertebral
bodies excised and 4 patients had
three vertebral bodies excised.
An iliac-crest bone graft was used
in 27 patients and a fibular strut

Six patients had complications.
One patient required re-exploration.
After three-level anterior decom
pression there was improvement
from the preoperative levels, but
neurologic recovery plateaued with
continued weakness of the right
arm. CT with intrathecal contrast
medium demonstrated inadequate
decompression of the right pos
terolateral vertebral body. Re
exploration resulted in neurologic
improvement. One patient experi
enced nonunion of a fibular graft
and subsequently underwent pos
terior fusion with wiring of the
spinous process and bone grafting.
One patient had a sterile seroma of
the incision, and one had loosening
of the halo pin. Two patients had
persistent pain at the graft site.
There were no neurologic complica
tions and no other cases of nonun
ion.

Discussion
Cervical corpectomy is useful in
the treatment of complex compres
sive diseases of the cervical spine.
Alternatives include multilevel ante
rior cervical discectomy with or
CJS, VOL. 36, NO. 1, FEBRUARY 1993
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without fusion,27’10' 15 cervical lami
nectomy213 and cervical laminaplasty.56
Multilevel discectomy has been
shown to be useful; however, com
pleteness of decompression and the
limited visibility make this a more
technically demanding procedure. A
more complete decompression is
possible with corpectomy, and os
teophytes may be removed safely
without potential damage to the
spinal cord.8'9'12 With multilevel dis
cectomy, the number of interfaces
that are required for fusion in
crease, and this will increase the
incidence of nonunion. With cor
pectomy, only two surfaces are pre
sented for fusion with fewer
chances for nonunion. Laminecto
my as a treatment method for mul
tilevel stenosis should be discour
aged. Long-term results have prov
en that neurologic progression is
the rule rather than the exception
and that instability will occur pro
ducing cervical kyphosis.2-413 Bi
omechanical testing confirms the
instability of the spine after lami
nectomy.16 Laminaplasty is com
monly practised in the Far East
where multilevel ossified PLL is
common. It is considered that lami
naplasty will maintain biomechani
cal stability while enabling decom
pression of the central canal. This
approach may not be useful in
patients who have radicular symp
toms.
Postoperatively, 27 of the 31
patients in our study showed satis
factory neurologic improvement and
27 had satisfactory pain relief. The
number of vertebral bodies excised
seems to have a negative correlation
with neurologic results; that is, pa
tients with greater numbers of ver
tebral bodies excised will have the
poorer neurologic scores postopera
tively. This is not unexpected be
cause patients requiring decompres
sion of larger numbers of vertebral
bodies have more severe symptoms
88
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and findings preoperatively. No pa
tient in this series experienced neu
rologic deterioration.
The choice of graft material de
pends upon the number of levels
being decompressed. Autogenous
graft material is less prone to non
union than xenograft or allograft
material. With more than two verte
bral bodies being removed, iliaccrest graft is not straight enough to
provide a strong bicortical strut
that will fit within the trough creat
ed by corpectomy. Fibula will fit,
but the rate of nonunion is higher
with this type of grafting.17 One
patient experienced nonunion of his
fibular graft and required posterior
fusion, which resolved his symp
toms.17 Graft dislodgement did not
occur in this series but is a compli
cation of corpectomy.18 Patients
with more than three bodies ex
cised, with cervical lordosis or with
posterior instability following lami
nectomy are prone to dislodgement
and require halo immobilization
postoperatively.4 Airway obstruc
tion is life threatening, and our
patients with three-level corpectomy
or high cervical corpectomies re
main intubated in the intensive care
unit for 36 to 48 hours postopera
tively. Other complications in this
series have not been serious and
have been managed easily.

Conclusions
Cervical corpectomy is a safe and
effective treatment for complex
compressive lesions of the cervical
spinal cord. With appropriate pre
operative planning, intraoperative
technique and postoperative care
optimal results can be achieved.
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Carcinoma of the Prostate: Case Report
Padraig Warde, MB, MRCPI, FRCPC; Mary Gospodarowicz, MD, FRCPC
The authors report a case of carcinoma of the prostate with an unusual
presentation. The patient, an 80-year-old man, had swelling of the right buttock and
right side of the lower abdomen, diffuse bony pain and increasing weakness of both
lower limbs. He responded well to therapy. Aggressive management of previously
untreated carcinoma is warranted even in elderly patients with metastatic disease.

Les auteurs decrivent un cas de carcinome prostatique ayant presente un tableau
clinique inhabituel. Le patient, un homme de 80 ans, montrait une enflure de la
fesse droite et du cote droit de l’abdomen inferieur, une douleur osseuse diffuse et
une faiblesse croissante des membres inferieurs. II repondit bien a la therapie. Un
traitement agressif d’un cancer prealablement non traite est de mise, meme chez les
patients ages qui montrent un envahissement metastatique.

denocarcinoma of the prostate
is the second commonest cause
of cancer death in men in the
United States. There, in 1991, it
was estimated that 122 000 cases
of the disease would be diagnosed,
of which approximately 20% would
be metastatic.1 We report on a
patient with an unusual presenta
tion of metastatic adenocarcinoma
of the prostate and a gratifying
response to therapy.

A

Case Report

An 80-year-old man was first
seen in June 1986. He gave a 2-year
history of swelling of the right
buttock and right side of the lower
abdomen, a 3-month history of dif
fuse bony pain of increasing severi
ty and a 2-week history of increas

ing weakness of both lower limbs.
He was admitted to a community
hospital with acute urinary reten
tion and paraplegia.
At the time of admission his
performance status was estimated
at 40% on the Karnofsky scale. He
had a distended abdomen with a
large nontender mass in the right
iliac fossa, measuring 12 cm in
diameter. A second mass in the
right buttock measured approxi
mately 15 cm in diameter, and a
third mass in the medial left groin
measured 10 cm in diameter. He
had a urinary catheter in situ, and
on rectal examination anal tone was
normal. He had a moderately en
larged hard prostate, which was
clinically consistent with malignan
cy.
Neurologic examination of his
lower limbs showed virtually absent
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power in all muscle groups. Muscle
tone and sensation were decreased
bilaterally, plantar responses were
normal, but both ankle and knee
jerks were absent bilaterally.
Biochemical screening revealed a
10-fold elevation in the serum acid
phosphatase level. Computed to
mography (CT) of the pelvis and
abdomen (Fig. 1) showed a large
mass in the right side of the pelvis,
with destruction of the right iliac
bone. The mass, anterior to the iliac
wing, measured 11 cm in diameter;
the mass posteriorly measured 11.5
cm in diameter. A left pelvic sidewall mass and a third palpable mass
were present in the medial region of
the left thigh, extending from the
level of the mid-femur to the pubic
ramus.
Initially, the patient refused to
consent to any invasive investiga
tions, but he agreed to a biopsy of
the right buttock mass under local
anesthesia. This showed a moder
ately differentiated adenocarcinoma
consistent with a primary carcinoma
of the prostate (prostate-specificantigen staining was positive). Bilat
eral orchiectomy was recommended,
but the patient refused and was
started on stilbestrol, 1 mg three
times daily. He returned to the
referring hospital.
When seen again 6 weeks later
the patient had no pain and was
able to walk with some assistance.
Repeat CT showed a marked de
crease in the size of the previously
noted masses; however, some dis
ease was still present (Fig. 2). The
CJS, VOL. 36, NO. 1, F E BR U A R Y 1993
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FIG. 1. Computed tomography (CT) scan of pelvis at presentation.

serum acid phosphatase level had
returned to the normal range. The
urinary catheter was removed, and
stilbestrol was discontinued because
of concern regarding cardiovascular
complications. The patient contin
ued to refuse orchiectomy and was
started on 1 mg leuprolide daily.
The patient has been followed up
in the clinic at regular intervals for
5 years since diagnosis. On the last
follow-up examination he was fully
ambulant and pain free with a Karnofsky performance status of 90%.
Bladder control was normal. On
physical examination he had no
palpable masses, and digital rectal
examination revealed a soft, some
what enlarged prostate. Neurologically his lower limbs were normal. A
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FIG. 2. CT scan of pelvis 6 weeks after start of stilbestrol
therapy, showing marked improvement.

recent CT scan of the pelvis showed
an enlarged prostate but no other
abnormality. His acid phosphatase
level was normal, and his prostatespecific-antigen level was only mod
erately elevated. He continues to
have daily leuprolide injections and
to refuse orchiectomy.

perhaps a soft tissue sarcoma.
We emphasise that aggressive
management of previously un
treated carcinoma of the prostate is
warranted, even in elderly patients
with metastatic disease. The extent
of disease does not accurately pre
dict response to hormonal therapy;
indeed there are no absolute predic
tors of hormonal sensitivity.2

Discussion
Soft issue metastases as a pre
senting feature of metastatic carci
noma of the prostate are very un
usual. When we first examined this
patient it was our opinion that,
although he likely had metastatic
carcinoma of the prostate, he might
have another malignant tumour,
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T h e Spectrum of Surgery in Ethiopia
Antoine Loutfi, MD;* Joyce L. Pickering, MD, MSct
Ethiopia’s need for surgical services is assessed from on-site reviews of
operating-room records in various hospitals and compared with data from other
countries. Information on surgical manpower and total operations for the country
were obtained from the Ministry of Health of Ethiopia. In Ethiopia the ratio of
surgeons to population is very low (0.32 surgeons per 100 000 population) and
inadequate numbers of essential operations (e.g., cesarean section and
inguinal-hernia repair) are performed. The average age of the surgical patient is
young (37 years), and men are operated on twice as frequently as women.
Of the 9422 operations performed during 6 months in the central, regional and
rural hospitals surveyed, 7037 (75%) could be performed by a general practitioner or
a paramedic specially trained for the procedure and would not require a fully trained
general surgeon. The implications for surgical manpower training are discussed.

Les besoins ethiopiens en services chirurgicaux ont ete evalues par une etude sur
place des dossiers chirurgicaux de divers hopitaux et une comparaison avec les
donnees d’autres pays. L'information sur les effectifs chirurgicaux et sur le total des
interventions chirurgicales pratiquees dans ce pays ont ete obtenus du ministere de
la sante de l’Ethiopie. En Ethiopie, le rapport du nombre de chirurgiens a la
population est tres faible (0,32 par 100 000 de population) et un nombre insuffisant
d’operations essentielles (par exemple, cesarienne ou reparation de hernie
inguinale) est pratique. L’age moyen des operes est bas (37 ans) et les hommes sont
operes deux fois plus souvent que les femmes.
Des 9422 operations effectuees en 6 mois dans les hopitaux centraux, regionaux
et ruraux ayant fait l’objet de l’enquete, 7037 (75 %) auraient pu etre pratiquees par
un medecin generaliste ou par un infirmier paramedical forme specialement pour ces
interventions, sans avoir a recourir a un chirurgien general. On commente les
implications de ces resultats quant a la formation des effectifs chirurgicaux.

ublished data on surgery in
developing countries is scarce.
From observation it appears that
surgeons are few, that many people
die of treatable surgical conditions

P

and that the quality of surgical
service is often low.
To develop a rational approach to
improve this situation, it is impor
tant to have data on what surgery is
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currently performed and on the cur
rent state of surgical manpower.
This study was undertaken to iden
tify the number of surgeons and the
type and complexity of surgical
conditions commonly treated at the
different levels of the health system
in Ethiopia.

Methods
Information on the numbers of
surgeons, surgical beds and opera
tions performed throughout the
country was obtained from the Ethi
opian Comprehensive Health Ser
vices Directories for 1983-1984
and 1986-1987.12 Additional infor
mation on specific types of opera
tions (groin-hernia repair, cesarean
section and appendectomy) was
gathered from all the hospitals in
Addis Ababa and from three region
al hospitals (Jimma, Bahar Dar and
Gondar) for the period September
1988 to February 1989 inclusive.
From this information, we calculat
ed the annual rate of these opera
tions per 100 000 population.
The spectrum of surgery was
based on a review of the operatingroom log books and outpatient re
cords of minor operations for the
6-month period September 1988 to
February 1989 for the following
institutions: two central teaching
hospitals in Addis Ababa; the three
regional hospitals already men
tioned, all of which were located
more than 350 km from Addis
Ababa; two rural hospitals; and five
health centres.
CJS, VOL. 36, NO. 1, F E BR U A R Y 1993
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Although the rural and regional
hospitals and the health centres
were selected largely on the basis of
accessibility, from personal experi
ence they seem to be representative
of these types of health institutions
in Ethiopia. An important exception
is health institutions in areas of
active fighting due to the civil war.
These areas were not accessible to
the authors.
All operations were grouped into
four categories (A, B, C and D) in
ascending order of complexity, as
recommended by Watters and Bayley.3 These categories are defined as
follows.
• Group A — operations that
should be within the competence of
any qualified doctor or suitably
trained paramedic.
• Group B — operations that
could be performed by a doctor or
paramedic specially trained for the
procedure.
• Group C — operations that
normally could be performed by
someone with higher qualifications
and surgical training appropriate
for developing countries.
• Group D — operations that
require subspecialty training beyond
the scope of the average general
surgeon.
Sex and age of the surgical pa
tients were assessed for the two
central teaching hospitals.
To assess seasonal variations,
data were reviewed from one each
of the central, regional and rural
hospitals for an entire year, and
compared with the 6-month find
ings.

Findings
The population of Ethiopia was
approximately 42 million according
to the 1983-1984 census. With an
estimated growth rate of 2.9% per
year, the 1988-1989 population is
estimated to be 49 million.
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In 1986-1987 in Ethiopia there
were 170 surgeons, including all
general surgeons, orthopedic sur
geons, urologists, otorhinoiaryngologists and obstetrician-gynecolo
gists. Only 50 of these were Ethi
opians. In total 67 982 operations
were performed. The rate of opera
tions was 148 per 100 000 popula
tion, and there were nine surgical
beds per 100 000 population.
Table I compares the rates of
operations and surgeons per
100 000 population in Ethiopia
with those in other countries.4-6
In an attempt to contrast the
need for surgery with the surgery
performed in Ethiopia, populationbased data on cesarean sections,
groin-hernia repairs and appendec
tomies were compared with the
need for surgery in East African
countries as estimated by Nordberg7
(Table II578).
The seven hospitals and five
health centres from which data

were drawn ranged in size from 30
to 448 beds. The two central hospi
tals accounted for 873 beds (27.5%
of all beds in Addis Ababa), the
three regional hospitals for 625
beds (60.5% of all beds in the
regions studied) and the two rural
hospitals for 150 beds. All seven
hospitals had qualified general sur
geons, and all but one had a quali
fied gynecologist during the period
for which the operations were deter
mined. Expatriate surgeons repre
sented 50% of surgeons in teaching
hospitals and 100% of the surgeons
in the other hospitals.
Tables III to VI show the type
and number of operations per
formed at the three levels of hospi
tals in the various groups (A to D).
Table VII shows the number and
percentage of the different catego
ries of surgery performed in the
three levels of hospitals. Overall,
75% of the operations performed at
all hospitals fell into groups A and

Table I. Rates of Operations and Surgeons per 100 000 Population in Various Countries
Country
Ethiopia, 1983 - 1984
Pakistan, 19834
England and Wales, 1976s*
United States, 19786

Operations

Surgeons

163
124
1314
9200

0.32
0.36
1.8
38

'Includes general surgeons and general surgery cases only

Table II. Number of Cesarean Sections, Groin-Hernia Repairs and Appendectomies Performed in
Ethiopia and Other Countries Compared With the Need for These Operations in East Africa as
Estimated by Nordberg7'
Area/country
Addis Ababat
Regional
hospitals^
England and Wales5
Canada (1977)8
Nordberg7§
Need as estimated by
Nordberg7 for East
African countries

Cesarean
section
66
9.2

Groin-hernia
repair
8.7

Appendectomy
26

184
4-62

2.5
129.6
219
2-100

3
143.5
163

225

175

—

—

—

'Numbers per 100 000 population
tincludes all hospitals performing surgery
tJim ma, Bahar Dar and Gondar. Although these are regional hospitals, the town population was
used as the denominator to calculate the rates, because few patients actually come from outside
the town. If the regional population was used as the denominator, the rates would, of course, be
much lower.
§Data are from various East African countries, including Ethiopia.
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B, and these two groups accounted
for 64% of all general surgery
cases, 70% of urology cases, 59% of
orthopedic cases and 89% of obstet
ric and gynecologic cases. The
three levels of hospitals had similar
proportions of the different groups
of surgery.
When the operations were
grouped according to subspecialty,
operative obstetrics and gynecology
accounted for 44% of the total
operations, general surgery ac

counted for 34% of operations, or
thopedics accounted for 15% of
operations and urology accounted
for 7% of operations.
The 10 most commonly per
formed major operations were simi
lar in the three levels of hospitals
(Table VIII). A similar distribution
was also found for the most com
mon minor operations, with dilata
tion and curettage being the most
common.
General surgical emergencies ac

Table III. Number of Operations of Group A* Performed at the Three Levels of Hospitals in
Ethiopia
Level of hospital
Central

Regional

Simple biopsy
Wound repair
Foreign-body removal
Incision and drainage
of abscess
Chest-tube insertion
Miscellaneous (cutdown,
catheterization, dressing)

367
224
137

12
169
50

87
33

79
25

47

—

Total

895

335

Procedure

Rural
—

91
25
27
8
2
153

'Operations within the competence of any qualified doctor or suitably trained paramedic

Table IV. Number of Operations of Group B* Performed at the Three Levels of Hospitals in
Ethiopia
Level of hospital
Procedure
Skin grafting
Perianal surgery
Excision of lump
Groin-hernia repair
Appendectomy
Burr holes
Sigmoidoscopy
Circumcision
Scrotal operations
Amputation
Debridement/
sequestrectomy
Bouginage
Minor testicular
operations
Cystostomy
Fracture: closed
reduction
Dilatation and curettage
Cesarean section
Minor gynecologic
procedures
Total

Central

Regional

Rural

109
74
187
53
111
10
51
91
85
92

24
51
27
31
40
1

1
27
60
13
14

—

—
—

6
27
41

61
9
13

249
118

107
5

6

20
9

14
11

1
1

NAt
2654
301

63
314
116

39
90
30

81

90

26

4295

968

391

'Operations that could be performed by a doctor or paramedic specially trained for the procedure.
tNA = not available

counted for 31%, 43% and 52% of
all general surgical cases at the
central, regional and rural hospitals
respectively.
When sex was assessed, exclud
ing obstetric and gynecologic cases,
the male-to-female ratio was 2:1,
and the average age, excluding pe
diatric patients 12 years of age or
younger, was 38 years for males
and 34 years for females.
The average hospital stay on the
surgical wards was 14 days for the
two rural hospitals but over 20 days
for all others, and up to 51 days for
one of the regional hospitals.
Comparison of 6-month data ver
sus 1-year data in the selected hos
pitals showed no important differ
ences.
Of the 1650 patients with surgi
cal conditions who were seen at the
five health centres in 6 months,
90% had suffered trauma or had
general surgical emergencies. The
majority had lacerations, bites and
closed fractures that were managed
at the health centre. Patients with
acute abdominal and obstetrical
emergencies and elective conditions
were advised to go to the closest
hospital.

Discussion
A study such as this one, which
merely records what is done, does
not provide data on what operations
should or should not have been
performed. For this, populationbased information is needed. Also
we cannot comment on the out
come of these operations, clearly a
factor of major interest and worthy
of future study.
It seems clear that the operations
being performed in Ethiopia vary
little between teaching and rural
hospitals, with the exception of
proportionally more general surgi
cal emergencies (52% v. 31%) being
done in rural as opposed to teach
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ing hospitals. This difference may
be a reflection of the more limited
resources in peripheral hospitals,
where beds and supplies are used
for emergency conditions, and not
enough are left for elective cases.
Like Watters and Bayley,3 we
have found that the majority of
cases (75%) were not complex.
Without information on the com
plexity of individual cases, it is
difficult to comment on the appro
priateness of the relatively long av
erage stay for surgical patients.
However, personal experience in
central hospitals suggests that
much of it is unnecessary, and in a
significant proportion of patients is
due to long pre- and postoperative
stays for elective procedures.
That the unmet surgical needs in
most parts of East Africa are great
is not disputed. Nordberg7 estimat
ed that only 15% of needed opera
tions are carried out, and for some
areas this rate is much lower. We
found that the regional hospitals
performed only 4% of the needed
cesarean sections and 1.4% of the
needed hernia repairs. Many condi
tions requiring surgery affect men
and women during the most pro
ductive years of their life, when
they may be the primary breadwin
ners. This finding is supported by
the relatively young age of surgical
patients (38 years for men, 34 years
for women). The high ratio of men
to women on the surgical wards
suggests that women are probably
underserved.
Although most surgeons (71%) in
Ethiopia are expatriates and the aim
is to replace them with nationals, it
will take some time to replace them,
because the only training program
for surgeons in the country follows
a standard 4-year curriculum.8
Therefore, serious consideration
should be given to assessing and
improving the surgical skills of gen
eral practitioners, especially those
in rural areas. This could be done
94
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through a short training program in
which the practitioners can learn
how to manage the commonly en

countered surgical and obstetric
conditions seen in the rural hospital
or health centre. Specifically, they

Table V. Number of Operations of Group C ' Performed at the Three Levels of Hospitals in
Ethiopia
Level of hospital
Procedure

Central

Elective laparotomy
Colorectal operations
Colostomy
Gastroduodenal
operations
Gallbladder operations
Mastectomy
Thyroidectomy
Bronchoscopy
Tracheostomy
Incisional-hernia repair
Operation for
intestinal obstruction
Operation for
peritonitis
Intestinal fistula
Varicose-vein surgery
Prostatectomy
Kidney operations
Bladder operations
Cystoscopy
Hypospadias repair
Fracture fixation
Hysterectomy and other
major gynecologic
procedures

Regional

46
41
24

18
7
7

5
3
1

8

_

10
17
8
4
18

_

58

51

33

81
10
26
39
30
12
91
9
296

81
8
3
9
2
4

77
112
27
50
30
21
25

Total

Rural

_

1

_
_

1

_
_

5

32

_
_
_

1

_

1
1
9

128

291

110

40

1396

493

133

'Operations that normally could be performed by someone with higher qualifications and surgical
training appropriate for developing countries.
Table VI. Number of Operations of Group D* Performed at the Three Levels of Hospitals in
Ethiopia
Level of hospital
Procedure

Central

Regional

Rural

Plastic surgery
Orthopedicsf
General surgery):

121
122
51

19
13
19

5
12
1

Total

294

51

18

'Operations that require subspecialty training beyond the scope of the average general surgeon,
tlncludes operations such as tendon transfers, hip replacement and laminectomy.
^Includes thoracic, vascular, head-and-neck tumour surgery and anal atresia surgery.
Table VII. Total Number (%) of the Four Groups of Operation Performed at the Three Levels of
Hospitals in Ethiopia
Level of hospital
Group

Central

Regional

Rural

Total

A
B
C
D

895 (13)
4295 (62)
1396 (20)
294 (4)

335 (18)
968(52)
493 (27)
51 (3)

153 (22)
391 (56)
133(19)
18(3)

1383(15)
5654(60)
2022(21)
363 (4)

6880(100)

1847(100)

695(100)

9422(100)

Total
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need to be able to perform all
operations in groups A and B.
These trained practitioners should
be visited regularly by a fully
trained surgeon to help maintain
morale and quality control and to
provide continuing medical educa
tion.9
Ideally, these procedures should
be in the repertoire of finishing
interns. However, in Ethiopia the
relatively high ratio of students,
interns and residents to patients in
teaching hospitals means that op
portunities for students and interns
to perform the operations are limit
ed.
Three areas are of particular in
terest for further research. The
first, mentioned above, is the out

come of the operations performed.
The second is to know, before train
ing general practitioners further in
surgical skills, how many health
centres and hospitals in Ethiopia
actually have functioning equip
ment and staff that would allow
surgery to be performed. The third
area for research is health centres.
In Ethiopia in 1988 and 1989, there
were 156 health centres and 88
hospitals. Thus, more people have
access to health centres than hospi
tals. The referral system here is
essentially nonfunctional and it is
likely that, for reasons of logistics,
many who present to health centres
with acute surgical problems will
never get to a hospital. Thus, it is
important to know what surgical

Table VIII. T e n M o s t F re q u e n tly P e rfo rm e d M a jo r O p e ra tio n s b y L e ve l o f H o s p ita l In E th io p ia
Level of hospital
Frequency
1

Central

Regional

C esarean
s e c tio n
F ra cture
fix a tio n

F ra c tu re
fix a tio n
C esarean
s e c tio n

3

H y s te re c to m y

H y s te re c to m y

4
5

D e b rid e m e n t/
s e q u e s tre c to m y
P la s tic s u rg e ry

D e b rid e m e n t/
s e q u e s tre c to m y
O p e ra tio n fo r
p e rito n itis

6

G a llb la d d e r

7
8

A p p e n d e c to m y
A m p u ta tio n

R e lie f o f
in te s tin a l
o b s tru c tio n
A m p u ta tio n
A p p e n d e c to m y

9

O p e ra tio n fo r
p e rito n itis
G a s tro d u o d e n a l
o p e ra tio n s

G ro in -h e rn ia
re p a ir
P la s tic
su rg e ry

2

10

Rural
H y s te re c to m y
R e lie f o f
in te s tin a l
o b s tru c tio n
O p e ra tio n fo r
p e rito n itis
C esarean
s e c tio n
P la s tic su rg e ry
and te n d o n
tra n s fe rs
A p p e n d e c to m y

A m p u ta tio n
G ro in -h e rn ia
re p a ir
F ra c tu re
fix a tio n
D e b rid e m e n t/
s e q u e s tre c to m y

services health centres can and
should provide.
We thank the Ministry of Health of
Ethiopia, the members of the Depart
ment of Surgery, Addis Ababa Universi
ty, and the many staff at various hospi
tals whose cooperation helped us to
prepare this report.
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SPONSORS’ NEWS
NOUVELLES DES PARRAINS

Special Announcement

Canadian Association of General Surgeons

The Editorial Board of the Canadian Journal of
Surgery was delighted to learn of the news, an

1992-1993 Executive

nounced at the 78th Annual Clinical Congress of the
American College of Surgeons in New Orleans in
October 1992, that Dr. Lloyd D. MacLean has been
elected to the office of president elect of the Ameri
can College of Surgeons. Dr. MacLean will take
office as president of the College in October 1993,
during the Clinical Congress in San Francisco. This
honour is richly deserved by Dr. MacLean who has
served the American College of Surgeons throughout
his illustrious surgical career. He has been an
international representative of the Canadian surgical
community and is held in highest regard by many
national organizations, as recognized by election to
this prestigious office.

Lloyd D. MacLean, OC, MD, PhD,
FACS, FRCSC

The success of the Clinical Congress of the
American College of Surgeons is due primarily to its
highly organized and broadly ranging scientific pro
gram. The chairman of the Program Committee is
Dr. MacLean, in whose honour the 1991 Surgical
Forum was dedicated. The Editorial Board and
readers of the Journal applaud Dr. MacLean.
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President: Dr. Marvin J. Wexler
Past president: Dr. Frank W. Turner
President elect: Dr. Frederic G. Inglis
Secretary: Dr. Roger G. Keith
Treasurer: Dr. Marshall C. Hunting

1993 Annual Meeting

The 1993 annual meeting of the Canadian Associa
tion of General Surgeons (CAGS) will be held in
conjunction with the annual meeting of the Royal
College of Physicians and Surgeons of Canada in
Vancouver, in September. The preliminary program
under the chair of Dr. John Macfarlane is very
exciting. The first postgraduate course will be held
on the Thursday and will feature laparoscopic sur
gery. A second postgraduate course to be held on the
following Monday will be on surgical oncology with a
focus on colorectal cancer. The CAGS Lecture will be
presented by Mr. R.J. Heald from Basingstoke,
England. He will speak on rectal cancer. The Ghent
Lecture will be presented by Dr. Ernest Moore of
Denver. The Langer Lecture will be presented by
Professor Alfred Cuschieri from Dundee, Scotland,
who will speak on the place of laparoscopic surgery.
The 3 days of paper sessions will feature the CAGS
CME Day on Saturday and a combined paper/poster
session with the Canadian Association of Gastroen
terology on Sunday.

Other Forthcoming Meetings

The CAGS Research Conference will be held in
June 1993 in Banff, Alta. General surgery program
directors are reminded to encourage submission of
resident research abstracts in response to forthcom
ing announcements.
The 1993 spring meeting of the American College
of Surgeons will be held in Montreal from Apr. 25 to
28. This meeting has become a focus for general

SPONSORS’ NEWS

Over 700 CAGS members have enrolled in the
Royal College’s MOCOMP Pilot Program aimed at
developing a comprehensive strategy for motivating
specialists to continuously update their clinical prac
tice. This pilot project will end in 1 year, and the
formal program will be initiated by the Royal College
thereafter.

lumbia — Dr. Gary W. Kingston; University of
Calgary — Dr. Doug Johnson; University of Alberta
— Dr. Douglas May; University of Saskatchewan —
Dr. Richard Bigsby; University of Manitoba — Dr.
Donald Clark; University of Western Ontario — Dr.
Edward Davis; McMaster University — Dr. Adrian
Park; University of Toronto — Dr. George Azzie;
Queen’s University — Dr. John Drover; University of
Ottawa — Dr. Sully Garba; McGill University — Dr.
Andrew Hill; Universite de Montreal — Dr. Lucie
Bilodeau; Universite de Sherbrooke — Dr. JeanJacques Klopenstein; Universite Laval — Dr. Regent
St. George; Dalhousie University — Dr. Russell
Gowan; Memorial University — Dr. Barry Fleming.
General surgery program directors are reminded to
submit nominations for the 1993 CAGS Merck
Frosst Awards by the end of May 1993.

Core Training Program in Surgery

Canadian Orthopaedic A ssociation

The Royal College Specialty Committee in General
Surgery has approved the 2-year program for core
training in surgery and has developed guidelines to
integrate this within the full 5 years of general
surgery resident training. Most Canadian general
surgery programs are integrating the combined pro
grams with changes that have developed with the
replacement of rotating internship by a basic clinical
training year. Reduction in provincial funding for
postgraduate training is concurrent with these
changes in most provinces.

1992-1993 Executive

surgery and will feature four postgraduate courses,
on cancer management, ambulatory surgery, vascular
surgery and trauma. Dr. Jonathan Meakins will
present a named lecture entitled “Determinants of
sepsis in surgical patients.”

Royal College Maintenance of Competence
(MOCOMP) Program

CAGS Coat of Arms
The CAGS has approved the preparation of a
formal coat of arms for the Association. Gratitude is
directed to Dr. Bob Thorlakson for his leadership and
contributions to this project. The coat of arms will
subsequently be displayed in the new Royal College
headquarters and will be incorporated in the Associa
tion’s stationery and materials.

President: Dr. Maurice Duhaime
Past president: Dr. Marvin Tile
President elect: Dr. R. Mervyn Letts
Secretary: Dr. Robert F. Martin
Treasurer: Dr. Robert M. Hollinshead

Forthcoming Meetings
The Canadian Orthopaedic Association wishes to
announce the following forthcoming meetings for the
spring of 1993. Information on these programs may
be obtained by contacting the Canadian Orthopaedic
Association Secretariat in Montreal (phone: [514]
874-9003):
Apr. 14 to 16, 1993. The 6th Sainte-Justine Pediatr
ic-Orthopedic Review Course, Montreal, Que.
Apr. 23 and 24, 1993. The 24th Annual Meeting of
the Quebec Scoliosis Society, Montreal, Que.
June 10 to 18, 1993. The University of British
Columbia Orthopedic Update Course, Vancouver, BC.

Merck Frosst Awards
At the 1992 annual meeting, the CAGS Merck
Frosst Awards for Teaching Excellence were present
ed to the successful resident from each Canadian
university, general surgery program. The following
residents were honoured: University of British Co

Canadian S ociety for Vascular Surgery
1992-1993 Executive
President: Dr. Adrien Bouchard

CJS, VOL. 36. NO. 1, FEBRUARY 1993

97

SPONSORS’ NEWS

Past president: Dr. William G. Jamieson
President elect: Dr. Neil V. McPhail
Secretary: Dr. Kenneth A. Harris
Treasurer: Dr. Kenneth C. Grant
1993 Annual Meeting

The 15th annual meeting of the Canadian Society
for Vascular Surgery (CSVS) will be held in Vancou
ver, Sept. 10 to 12, 1993, in conjunction with the
annual meeting of the Royal College of Physicians
and Surgeons of Canada. To accommodate those
wishing to catch the Sunday flight “back east,” the
format of the meeting has been changed. Seminars
will begin Friday afternoon, concluding on Sunday
morning. This year the CSVS Lecture will be deliv
ered by Dr. Jonathan Towne from Milwaukee. The
topic of the Saturday afternoon symposium is “ Con
troversies in the Management of Cerebral Vascular
Disease.” This symposium will provide an update on
many of the recently completed or ongoing trials and
will include presentations by such distinguished
speakers as Dr. Thomas Riles from New York.
Abstract forms were distributed in the December
1992 issue of Annals o f the Royal College of
Physicians and Surgeons o f Canada. They are also
available from the Secretary of the Society. Surgeons
are encouraged to submit papers or case reports.
Cases should illustrate principles of vascular surgery
or describe unusual conditions or abnormalities and
include a review of the literature.
Dr. David Taylor and the local arrangement com
mittees are promising an excellent social program to
complement the scientific menu. We hope to have a
record turnout in Vancouver.
Course on Venous Thromboembolism

McMaster University will be conducting a course
entitled “Clinical Advances in Venous Thomboembolism — A Practical Approach” from May 14 to 16,
1993, at Niagara-on-the-Lake, Ont. Further informa
tion may be obtained from the Continuing Education
Office, McMaster University, Hamilton, Ont.; phone:
(416)521-7966 or (416) 389-4224.
Small Aneurysm Treatment Trial (SATT)

This study, randomizing patients with abdominal
aortic aneurysms measuring 4.5 to 5.4 cm in greatest
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diameter, continues to recruit patients from around
the world. The study is funded by the Medical
Research Council of Canada, with Dr. William Cole
of Ottawa as the principal investigator. Many centres
in Canada, the United States and Great Britain are
participating in this study, and it is hoped that
enrolment will reach over 400 patients in the next 2
years. The study design compares operative treat
ment and follow-up with ultrasonography of patients
with appropriate sized aneurysms. Follow-up is over
a 4-year period. The information gained should be
useful to all vascular surgeons making decisions
about treating infrarenal abdominal aortic aneu
rysms.

Membership

The CSVS accepts membership applications on
three different levels. Active members are surgeons
with an interest in vascular surgery who hold a
Certificate of Special Competence in Vascular Sur
gery or its equivalent. Associate members are those
with an interest in vascular surgery or vascular
diseases. Associate (candidate) members are those
enrolled in a vascular training program in Canada or
the United States.
Application forms may be obtained from the Office
of the Secretary of CSVS.

Luke Award

The Luke Award is given to the best paper
presented at the CSVS annual meeting. The selection
committee consists of the CSVS lecturer, the society
president and the chairman of the program commit
tee. The 1992 selection committee comprised Drs. T.
O'Donnell, W. Jamieson and A. Salvian. The 1992
prize was awarded to Dr. Joseph Sladen of Vancouver
for his paper entitled “Superficial femoral vein: a
useful alternative arterial conduit.”

Useful Addresses

The President of the CSVS is Dr. Adrien Bouchard
who can be reached at the Ottawa General Hospital,
501 Smyth Rd., Ottawa, ON K1H 8L6; phone: (613)
737-8539. The Secretary, Dr. Kenneth A. Harris,
can be reached at Victoria Hospital, 375 South St.,
London, ON N6A 4G5; phone: (519) 667-6780.

SPONSORS’ NEWS

Canadian Society of Cardiovascular and
Thoracic Surgeons

Canadian Society of Surgical Oncology
1992-1993 Executive

1992-1993 Executive

President: Dr. F. Neil McKenzie
Vice president: Dr. Elliot T. Gelfand
Secretary: Dr. W.R. Eric Jamieson
Treasurer: Dr. Edward F. Busse

President: Dr. Walley J. Temple
Past president: Dr. Henry R. Shibata
Secretary/treasurer: Dr. David R. McCready

2nd Annual Scientific Meeting
Meetings

The Canadian Society of Cardiovascular and Tho
racic Surgeons (CSCTS) meets annually with the
Royal College of Physicians and Surgeons of Canada.
Highlights of the 1992 meeting were a symposium
entitled “Further Directions in the Management of
Myocardial Infarction — Modern Interventional Ther
apies’’ and the Wilfred Bigelow Lecture, presented by
Dr. Hermes Grillo of Harvard Medical School and
entitled “Modern concepts in tracheal surgery.”
In 1993, the CSCTS will conduct joint symposia
— one symposium on transplantation with the
Canadian Thoracic Society and another symposium
on thoracoscopic surgery with the Canadian Society
of Endoscopic and Laparoscopic Surgery.
In July 1994, the Society will cosponsor, with the
International Scientific Committee for the Advance
ment of Cardiac Bioprostheses, the Vlth Internation
al Symposium on Cardiac Bioprostheses in Vancou
ver. The deadline for submission of abstracts for this
meeting is Dec. 1, 1993. The Canadian organizing
committee comprises Drs. Eric Jamieson (chairman),
Tirone David, Conrad Pelletier and Lawrence Burr.

Royal College Task Force

The Royal College of Physicians and Surgeons of
Canada is formulating a task force on training
requirements in cardiothoracic and thoracic surgery.
This task force will incorporate the nucleus members
of the specialty committees in thoracic and cardio
thoracic surgery. The CSCTS and membership will
have an opportunity to participate in the process.

The Canadian Society of Surgical Oncology
(CSSO) will hold its 2nd annual scientific meeting on
Saturday, Apr. 17, 1993 at the Queen Elizabeth
Hotel, Montreal. The meeting will take place in
conjunction with the National Cancer Institute of
Canada (NCIC) spring meeting from Apr. 17 to 20,
1993.
We encourage all interested members of the CAGS
to attend.
Further details about the meeting may be obtained
from: Dr. Walley J. Temple, President, CSSO, Tom
Baker Cancer Centre, 1331 - 29th St. NW, Calgary
AB T2N 4N2; phone: (403) 670-1914; fax: (403)
283-1651.

Membership

The CSSO, a young and developing Canadian
society, has joined the group of societies/associations sponsoring the Canadian Journal o f Surgery. A
mission of the Society is to stimulate the develop
ment of surgical participation in regional and nation
al clinical trials. There is a continuing need for
increasing involvement of surgical oncologists with
the programs of the NCIC. The Executive of the
CSSO welcomes membership applications from en
thusiastic surgeons with a dedicated interest in the
fields of surgical oncology. We also invite all mem
bers of the CAGS with a training in cancer and those
with a practice of at least 50% oncology from all
surgical disciplines to become members. For further
information contact Dr. Walley Temple in Calgary
(phone: (403) 670-1914).
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Instructions for Authors
The Canadian Journal o f Surgery will consider manuscripts of original articles, clinical research, surgical technique,
clinical reviews, history of surgery, a limited number of case reports, editorials and letters. Four copies of manuscripts, in
English or French, should be submitted to Dr. Roger G. Keith, Canadian Journal o f Surgery, Department of Surgery, Royal
University Hospital, 103 Hospital Dr., Saskatoon, SK S7N 4J9.
A covering letter, signed by all the authors, should state that the manuscript has not been published previously and is not
under consideration by any other journal. The authors should include a signed letter of permission from people identified in
the acknowledgements or identifiable in illustrative material as well as from the copyright holder of previously published
material (e.g., tables, illustrations and long quotations) that is being reproduced, with or without modification, in the
submitted article. The authors must disclose the source of any financial or material support, any commercial interest they
may have in the subject of the study and any affiliation or involvement with an organization that has a financial interest in
the research materials used or the topic.

Manuscript Preparation
The style of the submission should be compatible with “Uniform requirements for manuscripts submitted to biomedical
journals” (Can M ed Assoc J 1992; 146: 861-868).
The authors’ names should appear on the title page and the back of each set of illustrations. All acknowledgements should
be placed on a separate unnumbered page after the list of references.
To facilitate editing and electronic scanning, all pages (title page, abstract and key words [MeSH terms if possible], text,
references and figure legends) must be double-spaced, in 10-cpi, letter-quality type, without right justification or proportional
spacing.
For all manuscripts, authors should submit an original and three high-quality photocopies or additional printouts of the
text and tables, and four camera-ready copies of the figures.
In writing a case report it is not necessary to give a detailed patient history and results of physical examination in the
standard clinical format. Negative findings and normal results of laboratory tests need be included only if they are essential
for ruling out a possible diagnosis. It is enough to establish the reasons for the diagnosis and the management. The clinical
course should be described briefly and the significant observation or event described in sufficient detail to establish its
credibility. Reference to the literature should be confined to supporting the principal point being made about the event or
observation.
Abstracts are required for original, review and history articles and for case reports, but not for articles on surgical
technique and editorials. A structured abstract should be provided for original and review articles (see October 1992 issue,
pages 473 to 475). Abstracts for history articles and case reports should be brief, but detailed (from 60 to 150 words long).
References should be cited in numerical order of their appearance in the text. References cited in tables should be
numbered according to where the table is first cited in the text. The style for references should be that used in this issue of
the Journal.

Other Considerations
Colour figures can be reproduced only at the author’s expense. Authors should submit a positive transparency and three
colour prints of each figure.
If the manuscript has been prepared on a computer-based word-processing system, authors must specify the software
program used. We edit manuscripts with an IBM-compatible word-processing system and cannot edit from diskettes that are
not IBM-compatible. Authors should indicate if they are willing to send us a diskette when their manuscript has been
accepted.
The process of initial consideration, peer review and editorial decision making of the manuscript usually takes about 8
weeks. The original copy of a rejected manuscript will be returned to the authors; all other copies will be destroyed.
Accepted manuscripts will be edited not only to conform with Canadian Journal o f Surgery style and for correctness of
grammar, syntax and punctuation but also for clarity. The corresponding author will receive a copy of the edited manuscript
o r a galley proof before publication and is responsible for obtaining coauthors’ approval of the changes.
Authors will be expected to sign a document transferring copyright to the Canadian Journal o f Surgery. All accepted
manuscripts become the permanent property of the Canadian Medical Association and may not be published elsewhere, in
whole or in part, without written permission of the publisher. Reprints will be available for purchase and may be distributed
as the author desires. ■
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Directives aux auteurs
Le Journal canadien de chirurgie etudiera les manuscrits d’articles originaux, de recherche clinique, de technique
chirurgicale ou d’histoire de la chirurgie, un nombre restreint d’etudes de cas, des editoriaux et des lettres. Quatre
exemplaires des manuscrits, en frangais ou en anglais, doivent etre adresses au Dr Roger G. Keith, Journal canadien de
chirurgie, Departement de chirurgie, Hopital Royal University, 103 Hospital Dr, Saskatoon, SK S7N 4J9.
La lettre de presentation, signee par tous les auteurs, doit confirmer que le manuscrit n’a jamais ete publie et n ’a ete
soumis a aucun autre journal. Les auteurs divent y joindre une autorisation signee par les personnes citees sous la rubrique
des remerciements ou identifiable dans le materiel d’illustration ainsi que de tout detenteur de droits d'auteur de materiel deja
publie (p.ex., tableaux, illustrations et longues citations) et qui est reproduit, avec ou sans modification, dans l’article soumis.
Les auteurs doivent indiquer la source de toute aide financiere ou materielle, tout interet commercial qui les aurait motive en
ce qui concerne le sujet a l’etude ainsi que toute affiliation ou travail avec un organisme qui a un interet financier dans le
materiel de recherche utilise ou dans le sujet lui-meme.

Preparation du manuscrit
Le style doit se conformer aux «Exigences uniformes pour les manuscrits presentes aux revues biomedicales» (Can Med
Assoc J 1992; 146 : 871-878).
Les noms des auteurs doivent paraitre sur la page titre, de meme qu’a l’endos de chaque jeu d’illustrations. Les
remerciements doivent figurer sur un feuillet separe, non pagine, a la suite de la bibliographie.
Toutes les pages (page titre, resume et mots clefs [termes MeSH si possible], textes, references, tableaux et legendes de
figures) doivent etre dactylographies a double interligne, a 10 caracteres au pouce, sans justification a droite ni espacement
proportionnel, et imprime en «qualite lettre» afin de faciliter la revision et la lecture electronique.
Pour tout manuscrit, les auteurs doivent soumettre un original et trois photocopies de bonne qualite, ou trois impressions
su p p le m e n ta l de texte et des tableaux, et quatre copies des figures pretes a la reproduction photographique.
Pour les etudes de cas, il n’est par necessaire de rapporter une anamnese detaillee avec les resultats de l’examen physique
dans le format clinique normal. Les resultats negatifs ou normaux d’examens de laboratoire ne doivent etre mentionnes que
s’ils sont essentiels a l’exclusion d’un diagnostic possible. II suffit d’etablir les raisons qui ont contribue au diagnostic ou au
traitement. L’evolution clinique doit etre decrite succinctement et les observations ou evenements importants doivent etre
rapportes avec suffisamment de details pour en etablir la credibilite. La bibliographie doit se limiter au soutien du point que
Ton veut faire ressortir quant a l’evenement ou a l’observation.
Des resumes sont exiges pour les articles originaux, historique ou de revue ainsi que pour les etudes de cas; ils ne sont pas
requis pour les articles sur les techniques chirurgicales ou pour les editoriaux. Un resume structure doit etre fourni pour les
articles originaux et de revue (void le numero d’octobre 1992, pages 473 a 475). Les resumes pour les articles historiques et
les etudes de cas doivent etre brefs mais, detailles (de 60 a 150 mots).
La bibliographie doit etre etablie numeriquement, selon l’ordre d'apparition dans le texte. Les references citees dans les
tableaux doivent etre numerotees d’apres 1’ordre de la premiere mention du tableau dans le texte. Le style adopte pour la
bibliographie est celui qui est utilise dans ce numero du Journal.

Autres considerations
Les figures en couleur sont a la charge de l’auteur. II lui faudra fournir une diapositive et trois epreuves en couleur pour
chaque figure. Les auteurs sont pries de nous preciser, le cas echeant, le logiciel ayant servi a preparer le manuscrit. Nous
revisons les manuscrits avec un systeme de traitement de texte compatible avec le systeme IBM. Nous ne pouvons pas reviser
a partir de disquettes qui ne sont pas compatibles avec le systeme IBM. Les auteurs doivent nous indiquer s’ils sont disposes
a nous faire parvenir une disquette quand leur texte est acceptee.
Le processus relatif a l’etude preliminaire de l’article, a la revue critique et a la prise de decision de la redaction peut durer
a peu pres 8 semaines. La copie original de tout manuscrit refuse est retournee a ses auteurs et toutes les autres copies sont
detruites.
Tout manuscrit accepte est revise non seulement pour le rendre conforme au style du Journal canadien de chirurgie et
pour corriger les fautes de grammaire, de syntaxe et de ponctuation, mais aussi pour en assurer la clarte et la concision.
L’auteur de l’article recevra une copie revisee ou les epreuves en placard avant la publication et doit obtenir l’approbation des
coauteurs pour les changements apportes.
Avant la publication, tous les auteurs doivent signer un document par lequel les droits d’auteurs sont transferes au Journal
canadien de chirurgie. Tout manuscrit accepte devient propriety permanente de l’Association des medecins du Canada et ne
peut etre publie ailleurs, en entier ou en partie, sans la permission ecrite. Les tires a part sont disponibles sur demande et
peuvent etre distribues selon les desirs de 1’auteur.B
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CLASSIFIED ADVERTISING
ANNONCES CLASSEES
I he Canadian Journal o f Surgery is pleased to accept classified advertisements. The deadline is 1 month before issue date. Classified rates: $58
for the first 40 words or less, additional words 75 ? each (additional $23 for frame). Special Display under 100 words, 55 X 55 mm, $135. $17
charge (first insertion only) for CJS reply box numbers. Display rates available on request. VISA, MASTERCARD AND AMERICAN
EXPR ESS ACCEPTED.
Copy should be mailed to: Beverley Kirkpatrick, Manager, Classified Advertising, Canadian Journal o f Surgery, PO Box 8 650, Ottawa, ON
K1G 0G8. Tel: (613) 7 3 1 -9 3 3 1. Fax: (613) 523-0824.
Send all box number replies to: Box . . . . Canadian Journal o f Surgery, PO Box 8 6 50, Ottawa, ON K1G 0G8.
Le Journal canadien de ch irurg ie accepte volontiers les annonces classees. Celles-ci doivent etre recues au Journal au plus tard 1 mois avant la
date de parution. Tarifs des annonces classees 58 $ jusqu’a 40 mots et 75 c par mot supplem ental (23 $ pour encadrement au trait). Encadre
special jusqu’a 100 mots, 55 X 55 mm, 135 $. L ’emploi d’une bolte-reponse au Journal donne lieu a la perception d’un supplement de 17 $
(pour la premiere insertion seulement). Tarifs des encadres grand format disponibles sur demande. VISA, MASTERCARD ET AMERICAN
EXPR ESS ACCEPTES.
La texte des annonces doit etre adresse a : Beverley Kirkpatrick, Gestionnaire des annonces classees, Journal canadien de chirurgie, CP 8650,
Ottawa, ON K1G 0G8. T e l: (613) 731-9331. Fax : (613) 523-0824.
Veuillez faire parvenir les reponses aux numeros de boites a l’adresse suivante : Boite . . . , Journal canadien de chirurgie, CP 8650, Ottawa,
ON K1G 0G8.

GFT - GENERAL SURGEON: MB - The
Department of Surgery, Faculty of Medicine,
University of Manitoba and the Health Sci
ences Centre are seeking a contingent geo
graphical full-time general surgeon. Specific
responsibilities in gastrointestinal surgery.
Candidates must be eligible for registration
with the College of Physicians and Surgeons
of Manitoba. Certification in general surgery
by the Royal College of Physicians and
Surgeons of Canada is required. Additional
specific requirements include the following:
extensive clinical experience in gastrointes
tinal surgery including major hepatic and
pancreatic resections and laparoscopic sur
gery; skills and extensive experience in en
doscopic retrograde cholangiopancreatog
raphy and other G.l. endoscopy; and train
ing and experience in research with publica
tion success. Salary and academic rank will
be at the entry level in the department of
surgery. The University of Manitoba encour
ages applications from qualified women and
men, including members of visible minori
ties, aboriginal people, and persons with
disabilities. The university provides a
smoke-free environment, save for specially
designated areas. In accordance with Cana
dian immigration requirements, this adver
tisement is directed to Canadian citizens
and permanent residents. Closing date for
receipt of applications is Feb. 28, 1993.
Interested candidates should apply, enclos
ing a curriculum vitae in writing, to: Dr.
R.J.W. Blanchard, Professor and Head.
Department of Surgery, Health Sciences
Centre, GC 411 -8 2 0 Sherbrook St., W in
nipeg, MB R3A 1 R9.
-S93-137

SURGICAL ONCOLOGY FELLOWSHIP:
ON - The Division of General Surgery at the
University of Toronto is offering a 1-year
clinical fellowship available July 1, 1993.
The fellowship is intended for individuals
who have completed an accredited North
American university general surgical resi
dency and are eligible for certification. Pref
erence will be given to applicants eligible for
Canadian licensure. Applicants should sub
mit a current curriculum vitae with the
names of three referees to: Lome E. Rotstein, MD. Director, General Surgical On
cology Postgraduate Education, Toronto
General Hospital, Eaton Wing, 7th Floor,
2 00 Elizabeth St., Toronto, ON Canada
M 5G 2C 4.
-S92-131

SURGEONS-VASCULAR
AND ORTHOPEDIC
MSI currently has 311 outstanding
practice opportunities in solo, group,
clinic and HMO settings throughout
the U.S. These include coastal and
southeastern areas. We want to pres
ent these practices to you and be a
problem solver. There is no charge to
you for this service.
Call our
surgical specialists
(404) 6 5 3 -7 3 6 0 .
-S93-143

GENERAL SURGEON: ON - Well-estab
lished group practice is looking to replace a
retiring partner/surgeon to serve a communi
ty of 30 000 + located 25 minutes west of
London. Town population 10 0 0 0 + . Fully
computerized, modern clinic adjacent to a
fully accredited, well-equipped hospital using
116 acute care beds. Busy emergency de
partment. Preference will be given to orthopedics/gynecology. Essentials include la
paroscopy skills and fellowship status. Onein-three on-call schedule for this pleasant
community. Large referral base guaranteed.
Associate to full partnership attainable.
Please contact or send CV to: Steven Wong,
c/o Strathroy Medical Clinic, 376 Carrie
St., Strathroy, ON N7G 3E3; tel: (519)
245-0430.
-S92-128

FELLOWSHIP IN
ENDOUROLOGY AND ESWL
This 1-year postgraduate fellowship offers a
wide range of clinical experience in endourology including percutaneous surgery,
ureteroscopy, ESWL and laparoscopic sur
gery in urology. Aproximately 50% of the
fellow's time will be spent in the laboratory
participating in projects related to endourologic and shock wave lithotripsy re
search. Salary will commensurate with the
level of training.
Please reply with curriculum vitae to:
Dr. John Denstedt
Chief of Urology
St. Joseph's Health Centre
2 68 Grosvenor St.
London, ON
N6A 4V2
-S92-130

CLASSIFIED ADVERTISING Unlike a tabloid or newspaper that is read today and discarded tomorrow, an adver
tisement in the Classified Advertising section of CJS is read today and reread tomorrow.
CJS is the only Canadian publication exclusively for surgeons. No other Canadian surgical publication reaches over 6000
subscribers every 2 months, giving wide coverage for your advertising dollar.
Average issue readership of CJS (81%) is among the highest of any medical journal in Canada, the latest readership studies confirm the best and most cost efficient way to reach Canadian surgeons is through the pages of CJS.
LET CJS CLASSIFIED ADS WORK FOR YOU
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GENERAL PRACTITIONER/SURGEON: BC
— Souris Health District. Three physicians
require a general practitioner/surgeon. A sso
ciate w ould enter into active surgical/endoscopic practice. The com m unity o f 1700
residents has a modern, 30-acute-bed facility,
serving the district o f approxim ately 70 00
people. Located 30 minutes fro m Brandon
(population 40 000), a university centre. Con
tact: M r. J. Woodmass, Adm inistrator, or
Dr. D. Cram, Chief of Staff, PO Box 10 ,
Souris, M B ROK 2C 0; tel (204) 4 8 3 -2 1 2 1 .
-S93-145

B/C O R TH O P E D IC S U RG EO N S A N D
OTHER SPECIALTIES: NEW YORK, US Needed fo r a non-treatm ent disability evalua
tion centre in Buffalo, New York. For further
inform ation please reply w ith CV to : Sam H.
S tedm an, 6 2 0 Erie Blvd. W , Ste. 2 0 8 ,
Syracuse, NY, USA 1 3 2 0 4 : or tel (315)
4 7 5 -3 9 2 6 .
-S93-138

GENERAL SURGEON
Second general surgeon required for the town
of Milton in southern Ontario. This 103-bed
hospital serves a population of 35 000 with a
large catchment area; 16 general practitioners,
an internist, radiologist, obstetrician and one
other general surgeon comprise the active
medical staff. Several other surgical subspecial
ties available. State-of-the-art laparoscopic
equipment available. Milton is located within
easy access to two university medical centres
and provides great recreational opportunities.
Applications to:
Dr. L. Robinson
Chair, Manpower Committee
Milton District Hospital
30 Derry Rd. E
Milton, ON L9T 2X5
Tel (416) 878-2383
Fax (416) 878-0498.
—S93-146

RESEARCH FELLOWSHIP S PINE SUR
GERY - Orthopaedic Hospital Spine Center in
Los Angeles, California is offering a 1-year
spine research fellowship starting July 1,
1993. Fellowship training will include labora
to ry and clinical research w ith exposure to
clinical orthopedic surgery and academic con
ferences. Submit CV w ith references to:
Santi Rao, M D , Director, Orthopaedic Hos
pital Spine Center, 2 3 0 0 S Flower S t.,
S te. 2 0 0 , Los Angeles, CA 9 0 0 0 7 ; tel
(2 1 3 ) 741 -0 8 0 0 , fax (213) 7 4 7 -1 7 1 6 .
-S93-144

CLINICAL FELLOWSHIP
AVAILABLE
IN C A R D IO V A S C U LA R SURG ERY
B EG IN N IN G JULY 1, 1 9 9 3
There is an op p o rtu n ity fo r considerable
surgical experience w ith a busy adult cardi
ac surgical team (6 50 pum ps/year). Ideal
fo r surgeon aw aiting a position or betw een
residencies. Eligibility fo r O ntario general or
educational licence necessary. Salary ac
cording to experience or fee fo r service if
applicable.
Replies to:
Dr. Bernard S. Goldm an
Head, Cardiovascular Surgery
Sunnybrook H ealth S cience C entre
2 0 7 5 B ayview A ve., S te. H 4 1 0
Toronto, ON
M 4N 3M 5
Tel (4 1 6 ) 4 8 0 - 6 0 7 0
Fax (41 6) 4 8 0 - 6 0 7 2
-S 9 3 -136

CLINICAL FELLOWSHIP
IN KNEE AND
SHOULDER SURGERY
IN
SPORT MEDICINE
Applications are now being accepted fo r a 6-month sport medicine fellowship
starting July 1, 1993 emphasizing arthroscopic and open treatment o f knee and
shoulder injury and disease.
Applicants must be eligible for licensure in the province o f Alberta and
preferably will have completed their FRCSC in orthopedic surgery.
Address enquiries to:
Caroline Eagles, Program Secretary
Department o f Surgery, Room D6-012
Calgary General Hospital, BVC
841 Centre Avenue East
Calgary, Alberta
T2E 0A1

—S93-140

University of Ottawa • Faculty of Medicine

Universite d ’Ottawa • Faculte de medecine

Chair of Surgery

Chaire de chirurgie

The University of Ottawa invites applications for the position of chairperson
of the university department of surgery.

L’Universitd d’Ottawa accueille les candidatures k la direction de sa chaire
de chirurgie.

Applicants must be eligible to practise in Ontario and hold certification of the
Royal College of Physicians and Surgeons of Canada in surgery. The faculty
is seeking an individual with a track record of clinical and academic
excellence, leadership skills and potential to develop a strong research
program in surgery.

Les candidats et candidates doivent etre admissibles k exercer la profession
en Ontario et possbder I'agrdment k titre de specialiste du College royal des
medecins et chirurgiens du Canada, tout en faisant preuve de realisations
et d’experience en chirurgie Clinique et universitaire. Le poste comporte un
role de direction dans les milieux universitaire, hospitalier et communautaire
et la preference sera accordde a une personne competente qui s’est
engagde dans la voie de I'excellence universitaire en enseignement et en
recherche.

The department is responsible for directing both undergraduate teaching and
postgraduate programs in surgery in the Ottawa Civic Hospital and Ottawa
General Hospital and Children’s Hospital of Eastern Ontario. The successful
candidate will hold a joint appointment as chair of the university department
of surgery and head at one of the affiliated teaching hospitals.
The faculty is seeking an individual who will hold a full-time university
appointment. Salary and fringe benefits are commensurate with qualifica
tions and experience, and are in accordance with existing scales at the
University of Ottawa.
Priority will be given to Canadian citizens and permanent residents of Canada
in accordance with Canadian immigration requirements. Employment equity
is university policy.

Le departement a la responsabilite de fournir un enseignement de qualite
au niveau prddiplome et postdoctoral dans les hopitaux affilies offrant une
formation en chirurgie soit I'Hopital Civic d’Ottawa, I’Hopital General
d’Ottawa et I'Hopital pour enfants de I’Est de I’Ontario. La personne retenue
assumera une double affectation k la direction de la chaire de chirurgie de
I’universitb et a la direction de chirurgie dans un des hopitaux d’enseignement
mentionnes.
La faculte est a la recherche d ’une personne pour combler un poste a temps
complet. Le traitement et les avantages sont fonction de la formation et de
I'expbrience, conformement k I'dchelle en vigueur k I’Universite d'Ottawa.

A working knowledge of both English and French is desirable and a
commitment to support bilingualism within the faculty is essential.

En vertu des exigences canadiennes relatives a I’immigration, la priority est
accoutee aux personnes de citoyennete canadienne et de residence permanente au Canada. L'universitd a une politique d ’bgalite en matiere d'emploi.

Applicants are requested to forward their curriculum vitae and the names of
three referees prior to Apr. 15, 1993.

Une connaissance de I’anglais et du francais est desirable. Un engagement
a promouvoir le bilinguisme au sein de la faculte est essentiel.
Priere d'envoyer les demandes, accompagnees d’un curriculum vitae et du
nom de trois repondants, a I'adresse ci-dessous avant le 15 avr. 1993.

John F. Seely, MD
Dean, Faculty of Medicine
University of Ottawa
451 Smyth Rd.
Ottawa, ON
K1H 8M5

John F. Seely, MD
Doyen, Faculte de medecine
Universite d’Ottawa
451, chemin Smyth
Ottawa, ON
K1H 8M5
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THE MONTREAL GENERAL HOSPITAL
DIVISION OF PLASTIC SURGERY
A Search Committee has been
formed to
appoint a Plastic Surgeon-in-Chief at
The Montreal General Hospital
Candidates should possess a Quebec
medical licence,
certification by the Royal College of
Physicians and Surgeons of Canada
and demonstrated leadership
abilities as a
university plastic surgeon.
Interested candidates should contact:
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Dr. David S. Mulder
Surgeon-in-Chief
The Montreal General Hospital
1650 Cedar Avenue, Room D6-136
Montreal, PQ
H3G 1A4
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York-Finch General is a
303 bed community hospital
located at Highway 400 and
Finch Ave. West.

Orthopaedic
Surgeon
We are a fully accredited acute care facility
committed to a rapidly expanding community.
We are seeking an Orthopaedic Surgeon to
complement our Orthopaedic services.
Inquiries should be directed to Dr. M. Heller,
Chief of Surgery at (416) 748-7443.

Parke-Davis
Anusol-HC

11

York-Finch General Hospital
2111 Finch Ave. West
Downs view, Ontario
M3N IN I
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York-Finch General is a smoke free environment.
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Toradol
104

13,14, 15, 71
JCC, VOL. 36, N° 1, FEVRIER 1993

York-Finch General Hospital
For prescribing information see page 44 —

The Only
Injectable

ACE

Inhibitor
Gradual blood pressure reduction
• Prompt onset of action (usually within 15 minutes)
• Duration of action in most patients approximately 6 hours

Can be used to treat hypertension in many patients
with coexisting disorders including diabetes, asthma,
heart failure and angina
Favourable hemodynamic profile
Favourable tolerability profile
... as with VASOTEC
Frosst Std.) tablets

(enalapril maleate,

Easy to convert from I.V to oral and oral to I.V
Convenient to administer

VASOTEC
■ M fl
(enalaprilat)

For Many Patients With Elevated
Blood Pressure W hen Oral
Therapy Is Not Practical

NOT RECOMMENDED DURING PREGNANCY
BEFORE PRESCRIBING, PLEASE SEE PRESCRIBING INFORMATION
Tradem ark Merck & Co., Inc./Merck Frosst Canada Inc.. R.U. IP A A B I
RNT-93-CDN-6657-JA
------------

M

MERCK FROSST

FROSST
DIV. OF MERCK FROSST CANADA INC
KIRKLAND, QUEBEC

The benefits continue
long after Valtrac
has disappeared.
Introducing the Valtrac*
biofragmentable anastomosis ring,
a major breakthrough in bowel
anastomosis technology that’s both
surgeon friendly and patient friendly.
Already surgeons have proved Valtrac’s
procedural superiority over sutures and
staples in thousands o f patients. Valtrac
provides uniform application
regardless of location and
disparate bowel end sizes. It
also performs consistently in
end-to-end, end-to-side and
VALlTtAC side-to-side procedures.

And, finally, Valtrac closes under direct
visualization. So you know it’s closed.
Valtrac is patient friendly because it
biofragments and passes harmlessly and
painlessly out o f the body, leaving no foreign
matter to hinder postoperative imaging. It
provides the added benefit during healing
o f supplying intraluminal support, which
reduces the incidence o f stricture, stenosis
or obstruction1.
To attend a Valtrac clinic and get the full
Valtrac story, please call: (416)470-3600
and ask for the Valtrac line.

D<5

DAVIS+GECK

V

Cyanamid Canada Inc.
•Trademark of American Cyanam id Company lD a ta on file with Davis + Geek

